Acute Flaccid Myelitis

Neurological Disorder MONDO:0100115 Pathograph 21 Show in embeddings browser Myelitis Acute disease Central nervous system disorder

Acute flaccid myelitis (AFM) is a rare, acute, polio-like neurologic syndrome, mainly reported in children, with rapid flaccid limb weakness and spinal cord gray-matter involvement. Most cases follow a febrile or respiratory prodrome. The clinical syndrome localizes predominantly to lower motor neurons in the anterior horn of the spinal cord, can involve cranial, bulbar, axial, and respiratory muscles, and is strongly associated epidemiologically with non-polio enteroviruses, especially enterovirus D68.

Ask OpenScientist

Ask a research question about Acute Flaccid Myelitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
5
Pathophys.
11
Phenotypes
2
Hypotheses
3
Gaps
21
Pathograph
6
Medical Actions
4
Differentials
1
Datasets
2
Trials
2
Models
99
References
2
Deep Research
📘

Definitions

1
Clinical and radiologic AFM syndrome
AFM is defined clinically by acute flaccid limb weakness with objective evidence of spinal cord gray-matter involvement, typically by MRI, and/or supporting cerebrospinal-fluid inflammation after exclusion of mimics such as Guillain-Barre syndrome, spinal cord infarction, poliomyelitis, and transverse myelitis.
CASE_DEFINITION
Core AFM features
Core clinical characteristics
  • acute flaccid limb weakness Rapid onset limb weakness with lower motor neuron features.
  • spinal cord gray matter lesion MRI lesion centered in spinal cord gray matter, especially the anterior horns.
  • CSF pleocytosis Supportive inflammatory cerebrospinal-fluid finding in probable or definite AFM criteria.
Show evidence (1 reference)
PMID:31409689 SUPPORT Human Clinical
"Classification criteria for a confirmed AFM case are acute flaccid limb weakness and magnetic resonance imaging evidence of a predominantly gray matter lesion that spans at least one spinal segment"
This reproduces the surveillance definition for confirmed AFM and directly supports the two required core criteria.
Show evidence (2 references)
PMID:27422805 SUPPORT Human Clinical
"acute flaccid limb weakness with spinal cord gray matter lesions"
The US case review directly supports the core clinical-radiologic definition used here.
PMID:33357469 SUPPORT Human Clinical
"no single sensitive and specific test for AFM"
The Lancet review supports modeling AFM as a syndromic diagnosis requiring integrated clinical, MRI, CSF, and exclusionary evidence.

Mechanistic Hypotheses

2
EV-D68 Direct Neuroinvasion Model
ev_d68_direct_neuroinvasion_model CANONICAL
Evidence balance 2 support
In the best-supported model for epidemic AFM, EV-D68 respiratory infection is followed rarely by CNS access, receptor-mediated infection of spinal neural cells, and anterior-horn motor-neuron injury. Epidemiologic and human CSF evidence support the association, while mouse and organoid systems show that contemporary EV-D68 strains can infect neural tissue and cause paralytic myelitis. The model does not imply virologic confirmation in every patient.
Show evidence (2 references)
PMID:28231269 SUPPORT Model Organism
"Virus isolated from spinal cords of infected mice transmitted disease when injected into naïve mice, fulfilling Koch's postulates in this model."
Experimental transmission establishes direct causation in the mouse model, while the qualification "in this model" prevents overextension to humans.
PMID:33357469 SUPPORT Human Clinical
"the disease appears to be caused by non-polio enterovirus infection"
The clinical review identifies non-polio enterovirus infection as the leading human etiologic model.
Secondary Immune-Mediated Neural Injury Model
secondary_immune_mediated_injury_model EMERGING
Evidence balance 1 support
Direct neural infection may initiate AFM without being sufficient to cause the full motor-neuron injury. Persistent productive infection with little cytopathic effect in human spinal-cord organoids suggests that host immune responses or other secondary injury mechanisms may contribute to neuronal loss.
Show evidence (1 reference)
DOI:10.1128/mbio.01058-23 SUPPORT In Vitro
"EV-D68 infection is not the sole mediator of neuronal cell death in the spinal cord in those with AFM and that secondary injury from the immune response likely contributes to pathogenesis."
The human organoid study explicitly proposes secondary immune injury after observing prolonged productive infection without appreciable cytopathy.
?

Discussions and Knowledge Gaps

3
What proportion of human AFM is directly caused by EV-D68 neuroinvasion, and which tests can establish that cause in an individual patient?
KNOWLEDGE GAP OPEN afm_ev_d68_human_causation_boundary
Outbreak timing, respiratory detections, CSF antibodies, animal causation, and human-organoid infection form a coherent causal case. However, viral RNA is rarely detected in human CSF, case-control estimates are heterogeneous, and AFM is a syndrome with other infectious and noninfectious mimics. The graph therefore treats EV-D68 neuroinvasion as the canonical model for epidemic disease without assigning it to every case.
Posed 2026-07-20T00:00:00Z
Show evidence (2 references)
PMID:42066114 SUPPORT Human Clinical
"Across 98 studies, the pooled odds ratio (OR) was 1.39 (95% CI 1.14-1.69), with high heterogeneity (I2 = 98.9%; prediction interval 0.24-8.15)."
The high heterogeneity quantifies uncertainty in human association estimates.
PMID:31409689 SUPPORT Human Clinical
"supports the plausibility of a link between EV infection and AFM that warrants further investigation"
The CSF-antibody study explicitly frames its evidence as plausibility, not proof.
Why do large EV-D68 respiratory waves not consistently produce parallel AFM peaks, and what host or viral determinants govern the rare paralytic outcome?
KNOWLEDGE GAP OPEN afm_respiratory_wave_paralysis_mismatch
AFM counts remained low during the 2022 US EV-D68 circulation increase. Prospective linked respiratory, wastewater, genomic, host-immunologic, and neurologic surveillance is needed to distinguish viral genotype, prior immunity, ascertainment, and host susceptibility effects.
Posed 2026-07-20T00:00:00Z
Show evidence (1 reference)
PMID:38300829 SUPPORT Human Clinical
"It is unclear why EV-D68 circulation in 2022 was not associated with an increase in AFM cases"
The national surveillance report states the mismatch directly.
Which immune and developmental features must be added to organoid and mouse systems to reproduce human AFM motor-neuron loss and recovery?
HUMAN MODEL MISMATCH OPEN afm_organoid_mouse_translation_limit
Organoids show prolonged productive infection without appreciable cytopathy and lack a complete immune compartment. Mice are not native EV-D68 hosts and commonly require neonatal or modified conditions. These systems prove mechanistic capabilities but cannot determine the human balance between direct infection and immune-mediated injury.
Posed 2026-07-20T00:00:00Z
Show evidence (1 reference)
DOI:10.1128/mbio.01058-23 SUPPORT In Vitro
"Mice are not native hosts for EV-D68, and thus, existing mouse models use immunosuppressed or neonatal mice, mouse-adapted viruses, or intracranial inoculations."
The organoid paper directly states key limitations of animal translation.

Pathophysiology

5
Non-polio Enterovirus Respiratory Infection
AFM most often occurs after a respiratory or febrile illness. EV-D68 is the leading epidemic-associated virus. Only a very small fraction of respiratory infections are followed by AFM, and the route and determinants that permit subsequent CNS access in children remain unresolved.
response to virus GO:0009615 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to virus (GO:0009615). GO:0009615 is a biological process from the Gene Ontology. ↑ INCREASED
respiratory system UBERON:0001004 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in respiratory system (UBERON:0001004). UBERON:0001004 is an anatomical location from the Uberon multi-species anatomy ontology. central nervous system UBERON:0001017 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in central nervous system (UBERON:0001017). UBERON:0001017 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:33357469 SUPPORT Human Clinical
"the disease appears to be caused by non-polio enterovirus infection"
This clinical synthesis supports the enterovirus model while appropriately using probabilistic wording.
PMID:31409689 SUPPORT Human Clinical
"The cause of AFM remains elusive. An infectious agent is only rarely detected in cerebrospinal fluid (CSF)."
Direct human etiologic confirmation is uncommon and the graph therefore does not represent neuroinvasion as proven in every case.
MFSD6- and ICAM5-Mediated EV-D68 Neural Cell Entry
MFSD6 is a directly demonstrated EV-D68 entry receptor in respiratory and neural primary cells. ICAM5 is a proposed neuron-specific receptor and is retained as complementary, lower-tier evidence rather than treated as a universal AFM receptor mechanism.
MFSD6 hgnc:24711 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves MFSD6 (hgnc:24711). hgnc:24711 is a gene from the HUGO Gene Nomenclature Committee. ICAM5 hgnc:5348 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves ICAM5 (hgnc:5348). hgnc:5348 is a gene from the HUGO Gene Nomenclature Committee.
symbiont entry into host cell GO:0046718 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased symbiont entry into host cell (GO:0046718). GO:0046718 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:40132641 SUPPORT In Vitro
"Knockout of MFSD6 expression abrogated EV-D68 infection in cell lines and primary cells corresponding to respiratory and neural cells."
Genetic loss-of-function and primary-cell experiments directly support MFSD6-dependent entry.
PMID:41467840 SUPPORT Other
"ICAM-5) as a neuron-specific receptor that provides a molecular explanation for neurotropism in AFM."
A receptor-usage review supports ICAM5 as a neuron-specific alternative, but this is weaker evidence than the MFSD6 perturbation experiments.
Spinal Neural Cell Tropism and Infection
Contemporary EV-D68 strains productively infect human spinal-cord organoids. Tropism differs by strain across neurons, cycling astrocytes, and oligodendrocyte precursor cells, indicating that neural susceptibility is neither uniform nor explained by motor neurons alone.
motor neuron CL:0000100 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves motor neuron (CL:0000100). CL:0000100 is a cell type from the Cell Ontology. astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology. oligodendrocyte precursor cell CL:0002453 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte precursor cell (CL:0002453). CL:0002453 is a cell type from the Cell Ontology.
spinal cord UBERON:0002240 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in spinal cord (UBERON:0002240). UBERON:0002240 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
DOI:10.1128/mbio.01058-23 SUPPORT In Vitro
"productively infected with contemporary strains, but not a historic strain, of EV-D68"
Productive infection in human spinal-cord organoids establishes direct human-cell neural tropism and a strain effect.
"distinct viral tropism and host transcriptional responses"
Single-cell profiling supports strain- and cell-type-specific tropism.
Spinal Gray Matter Inflammation and Motor Neuron Injury
AFM injury is centered on spinal gray matter and anterior-horn motor neurons. Cranial motor nuclei can also be involved, accounting for facial, bulbar, and respiratory manifestations that cannot be attributed to spinal anterior horns alone.
anterior horn motor neuron CL:2000048 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves anterior horn motor neuron (CL:2000048). CL:2000048 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
ventral horn of spinal cord UBERON:0002257 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ventral horn of spinal cord (UBERON:0002257). UBERON:0002257 is an anatomical location from the Uberon multi-species anatomy ontology. brainstem UBERON:0002298 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brainstem (UBERON:0002298). UBERON:0002298 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"The primary site of injury in AFM is the anterior horn cells of the spinal cord"
The clinical review identifies the principal anatomic lesion.
Segmental and Cranial Lower Motor Neuron Dysfunction
Dysfunction of segmental anterior-horn and cranial motor systems produces rapid flaccid weakness, depressed reflexes, asymmetry, and, when brainstem or respiratory motor pools are affected, facial, bulbar, or ventilatory impairment.
motor neuron CL:0000100 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves motor neuron (CL:0000100). CL:0000100 is a cell type from the Cell Ontology.
ventral horn of spinal cord UBERON:0002257 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in ventral horn of spinal cord (UBERON:0002257). UBERON:0002257 is an anatomical location from the Uberon multi-species anatomy ontology. brainstem UBERON:0002298 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brainstem (UBERON:0002298). UBERON:0002298 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
This defines the motor distribution beyond limb weakness.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Acute Flaccid Myelitis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

11
Head and Neck 1
Facial weakness Weakness of facial musculature HP:0030319 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Facial weakness, annotated with Weakness of facial musculature (HP:0030319). HP:0030319 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
The review lists facial muscle involvement in the broader set of AFM muscle groups that can be affected.
Limbs 2
Acute limb weakness Limb muscle weakness HP:0003690 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is acute limb weakness, annotated with Limb muscle weakness (HP:0003690). HP:0003690 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"acute-onset flaccid limb weakness"
The review identifies acute flaccid limb weakness as a defining feature.
Asymmetric limb weakness FREQUENT Limb muscle weakness HP:0003690 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is asymmetric limb weakness, annotated with Limb muscle weakness (HP:0003690). HP:0003690 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34747551 SUPPORT Human Clinical
"asymmetric limb weakness (58% vs. 0%, p < 0.001)"
Fifty-eight percent of the AFM cohort had asymmetric weakness, supporting the frequent band and its value against GBS.
Musculoskeletal 1
Respiratory insufficiency due to muscle weakness OCCASIONAL HP:0002747 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Respiratory insufficiency due to muscle weakness (HP:0002747). HP:0002747 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39657203 SUPPORT Human Clinical
"Eight patients (21.6%) had respiratory failure during the index hospitalization."
Eight of 37 children had respiratory failure, directly supporting the occasional frequency band in this cohort.
Nervous System 3
Acute flaccid paralysis HP:0003470 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is acute flaccid paralysis, annotated with Paralysis (HP:0003470). HP:0003470 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"acute flaccid paralysis"
Acute flaccid paralysis is part of the core clinical description of AFM.
Areflexia HP:0001284 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Areflexia (HP:0001284). HP:0001284 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39163469 SUPPORT Human Clinical
"decreased or absent reflexes"
The StatPearls clinical summary supports decreased or absent reflexes as a classic AFM finding.
Cranial nerve palsy Cranial nerve paralysis HP:0006824 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cranial nerve palsy, annotated with Cranial nerve paralysis (HP:0006824). HP:0006824 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31014167 SUPPORT Human Clinical
"with cranial neuropathy"
The EV-D68-associated AFM review describes cranial neuropathy among common presenting features.
Other 4
Prodromal respiratory tract infection HP:0011947 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is acute prodromal respiratory tract infection, annotated with Respiratory tract infection (HP:0011947), qualified as temporality acute. HP:0011947 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:39163469 SUPPORT Human Clinical
"upper respiratory tract infection"
The clinical summary identifies a preceding upper respiratory infection; no frequency band is assigned because the available quantitative endpoint pooled respiratory and gastrointestinal prodromes.
Spinal cord gray matter lesion VERY_FREQUENT Spinal cord lesion HP:0100561 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is spinal cord gray matter lesion, annotated with Spinal cord lesion (HP:0100561). HP:0100561 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26720027 SUPPORT Human Clinical
"Fifty-six patients had T2 hyperintensity of spinal gray matter on magnetic resonance imaging"
Fifty-six of 59 cases had the MRI abnormality, supporting the very-frequent band.
CSF pleocytosis FREQUENT HP:0012229 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is CSF pleocytosis (HP:0012229). HP:0012229 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26720027 SUPPORT Human Clinical
"43 patients had cerebrospinal fluid pleocytosis"
Forty-three of 59 cases had CSF pleocytosis, supporting the frequent band.
Bulbar palsy HP:0001283 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bulbar palsy (HP:0001283). HP:0001283 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
The review lists bulbar involvement in the broader set of AFM muscle groups that can be affected.
🗃️

External Assertions

1
Orphanet acute flaccid myelitis record
Orphanet structured disease record ORPHA:623801
Orphanet's ORPHA:623801 structured record for acute flaccid myelitis provides the rare-disease identifier, exact MONDO cross-reference, narrower ICD-10 mapping, MeSH and UMLS cross-references, broad onset categories, and international incidence annotations used to cross-check this entry.
Show evidence (2 references)
ORPHA:623801 SUPPORT Other
"MONDO:0100115 | Exact"
Orphanet maps ORPHA:623801 exactly to the MONDO disease identifier used by this entry.
ORPHA:623801 SUPPORT Other
"ICD-10:G04.8 | Narrower"
The Orphanet cross-reference table records a narrower ICD-10 mapping for AFM.
💊

Medical Actions

6
Acute supportive care
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Acute management is primarily supportive and includes close monitoring for bulbar and respiratory muscle involvement, intensive-care support when needed, pain control, prevention of complications, and multidisciplinary neurologic and infectious-disease evaluation.
Target Phenotypes: Respiratory insufficiency due to muscle weakness HP:0002747 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Respiratory insufficiency due to muscle weakness (HP:0002747). HP:0002747 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33357469 SUPPORT Human Clinical
"guide diagnosis, management, and rehabilitation"
The Lancet review supports management and rehabilitation as central AFM care domains.
Mechanical ventilatory support
Action: mechanical ventilationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is mechanical ventilation (NCIT:C70909). NCIT:C70909 is a clinical intervention from the NCI Thesaurus. Ontology label: Mechanical Ventilation NCIT:C70909
Respiratory muscle weakness or bulbar dysfunction can require intubation, invasive mechanical ventilation, or other airway and respiratory support.
Target Phenotypes: Respiratory insufficiency due to muscle weakness HP:0002747 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Respiratory insufficiency due to muscle weakness (HP:0002747). HP:0002747 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39163469 SUPPORT Human Clinical
"requires intubation and mechanical ventilation"
The current clinical summary supports ventilatory support for severe AFM respiratory insufficiency.
Physical therapy and rehabilitation
Action: physical therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is physical therapy (NCIT:C15302). NCIT:C15302 is a clinical intervention from the NCI Thesaurus. Ontology label: Physical Therapy NCIT:C15302
Long-term care relies on early, intensive, and individualized rehabilitation, including physical therapy, occupational therapy, bracing, orthopedic monitoring, and functional support for residual motor deficits.
Target Phenotypes: Limb muscle weakness HP:0003690 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Limb muscle weakness (HP:0003690). HP:0003690 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:33357469 SUPPORT Human Clinical
"unique long-term rehabilitation needs"
The Lancet review directly supports rehabilitation as a core AFM management need.
Transcutaneous spinal cord stimulation with gait training
Action: spinal cord stimulationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is spinal cord stimulation (NCIT:C21023). NCIT:C21023 is a clinical intervention from the NCI Thesaurus. Ontology label: Spinal Cord Stimulation NCIT:C21023
Transcutaneous spinal cord stimulation paired with gait training has early pediatric case-series evidence for feasibility and walking-function improvement after AFM-related incomplete spinal cord injury. This is an investigational rehabilitation adjunct rather than established standard care.
Target Phenotypes: Limb muscle weakness HP:0003690 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Limb muscle weakness (HP:0003690). HP:0003690 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
DOI:10.3390/children11091116 SUPPORT Human Clinical
"safe and clinically feasible intervention"
A four-child case series supports feasibility and possible walking benefit but remains preliminary evidence.
Reconstructive surgery for persistent paralysis
Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Selected patients with persistent severe upper-extremity paralysis after AFM may undergo reconstructive procedures such as nerve transfer, muscle-tendon transfer, or free muscle transfer. Evidence remains observational and procedure selection depends on residual donor-nerve and synergistic-muscle function.
Target Phenotypes: Upper limb muscle weakness HP:0003484 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Upper limb muscle weakness (HP:0003484). HP:0003484 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
DOI:10.2106/JBJS.OA.23.00143 SUPPORT Human Clinical
"nerve transfer, muscle-tendon transfer, or free muscle transfer"
This retrospective cohort supports reconstructive surgery as a selected intervention for persistent AFM upper-extremity paralysis.
Immunomodulatory acute therapies
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Intravenous immunoglobulin, corticosteroids, and plasma exchange have been used empirically in AFM, especially early in the syndrome when mimics remain possible. Available clinical evidence does not establish that these therapies reverse AFM motor neuron injury, so this entry models them as empiric and uncertain rather than proven disease-modifying treatment. Preclinical EV-D68 AFM-model data further caution against assuming benefit from corticosteroids.
Show evidence (2 references)
PMID:26621554 SUPPORT Human Clinical
"intravenous immunoglobulin, corticosteroids, or plasma exchange"
The case series documents real-world use of immune therapies but also persistent deficits, so it supports exposure rather than proven efficacy.
PMID:28968718 SUPPORT Model Organism
"Dexamethasone treatment worsened motor impairment, increased mortality, and increased viral loads."
Mouse-model evidence specifically cautions that corticosteroid exposure may worsen EV-D68 paralytic myelitis biology, although it is not direct human treatment evidence.
🌍

Environmental Factors

1
EV-D68 respiratory circulation and wastewater seasonality
EV-D68 circulation is the main environmental infectious exposure context for AFM surveillance. Wastewater monitoring can detect EV-D68 seasonality and regional timing before or alongside clinical respiratory diagnoses, which may help public-health preparedness even though AFM remains rare relative to EV-D68 infection.
Show evidence (2 references)
PMID:41853773 SUPPORT Other
"Enterovirus D68 (EV-D68) can cause severe respiratory illness and acute flaccid myelitis (AFM)"
The wastewater surveillance study frames EV-D68 as a respiratory pathogen relevant to AFM preparedness.
PMID:41853773 SUPPORT Other
"We observed a biennial EV-D68 pattern with a national peak in September 2024"
Wastewater data support the seasonal and biennial environmental circulation pattern encoded here.
🔬

Diagnosis

3
MRI-centered AFM evaluation
Suspected AFM evaluation centers on urgent neurologic examination and MRI of the entire spinal cord and brainstem to detect gray-matter lesions. CSF analysis, respiratory and stool testing, poliovirus exclusion, and early electrodiagnostic testing help characterize inflammation, seek an infectious association, and distinguish peripheral neuropathy.
magnetic resonance imaging procedure NCIT:C16809 NCI Thesaurus (NCIT)
Results: Longitudinal spinal cord gray-matter lesions, especially anterior horn involvement, support AFM in the right clinical context.
Show evidence (2 references)
PMID:26621554 SUPPORT Human Clinical
"spinal gray matter lesions"
Pediatric case series supports MRI detection of spinal gray matter lesions as a key recognition feature.
PMID:33357469 SUPPORT Human Clinical
"clinical, neuroimaging, and cerebrospinal fluid characteristics"
The Lancet review supports an integrated diagnostic workup rather than a single confirmatory test.
CSF and respiratory or stool enterovirus testing
CSF cell count and protein are supportive, while respiratory and stool specimens should be collected early for enterovirus typing and poliovirus exclusion. A negative CSF PCR does not exclude AFM or an enterovirus association because viral RNA is rarely recovered from CSF.
Results: Pleocytosis supports CNS inflammation; enterovirus detection outside CSF can support an association but does not independently prove viral causation of the neurologic syndrome.
Show evidence (2 references)
PMID:31409689 SUPPORT Human Clinical
"An infectious agent is only rarely detected in cerebrospinal fluid (CSF)."
Rare CSF detection explains why negative CSF PCR cannot exclude AFM.
PMID:26720027 SUPPORT Human Clinical
"No pathogens were isolated from the cerebrospinal fluid."
The 59-case series illustrates the low yield of CSF pathogen testing.
Mimic exclusion
AFM diagnosis requires careful exclusion of other causes of acute flaccid paralysis, especially Guillain-Barre syndrome, spinal cord stroke, acute transverse myelitis, poliomyelitis, and compressive or structural spinal cord disease.
Key mimics include Guillain-Barre syndrome, spinal cord infarction, transverse myelitis, poliomyelitis, and structural spinal cord disease.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"Guillain-Barre syndrome, spinal cord stroke, and transverse myelitis"
The clinical review explicitly lists these major AFM mimics.
🩻

Imaging Findings

1
Longitudinal spinal gray-matter T2 hyperintensity on MRI VERY_FREQUENT
T2 hyperintensity centered in spinal gray matter, often longitudinally extensive and most conspicuous in the anterior horns, is the defining radiologic AFM finding. A predominantly gray-matter lesion spanning at least one spinal segment is part of the confirmed surveillance case definition.
Mri Diagnostic Extensive
spinal cord lesion HP:0100561 Human Phenotype Ontology (HP) ventral horn of spinal cord UBERON:0002257 Uberon multi-species anatomy ontology (UBERON) spinal cord gray matter lesion HP:0100561 Human Phenotype Ontology (HP)
Show evidence (2 references)
PMID:31409689 SUPPORT Human Clinical
"magnetic resonance imaging evidence of a predominantly gray matter lesion that spans at least one spinal segment"
The published surveillance definition establishes the diagnostic morphology.
PMID:26720027 SUPPORT Human Clinical
"Fifty-six patients had T2 hyperintensity of spinal gray matter on magnetic resonance imaging"
Fifty-six of 59 cases support the very-frequent frequency band.
📈

Progression

3
Rapid progression to acute nadir
Weakness progresses over hours to days. In a direct pediatric comparison, AFM reached nadir sooner than GBS, reinforcing the need for prompt MRI, respiratory monitoring, and specimen collection.
Show evidence (1 reference)
PMID:34747551 SUPPORT Human Clinical
"shorter interval between onset of weakness and nadir (3 vs. 8 days, p < 0.001)"
The comparative cohort places median AFM nadir at three days.
Chronic motor deficit with partial functional recovery
Persistent focal paralysis is common, although disability and activity of daily living can continue to improve over years. Motor recovery is generally less complete than recovery of nonmotor neurologic findings.
Show evidence (2 references)
PMID:33388543 SUPPORT Human Clinical
"AFM has a high rate of persistent motor deficits showing one- to two-limb paralysis."
Three-year follow-up establishes persistence of focal motor deficits.
PMID:33388543 SUPPORT Human Clinical
"Disability level of patients with AFM, however, generally improved at the three-year time point."
Functional improvement despite residual paralysis gives a more nuanced prognosis than either full recovery or fixed disability.
Long-term respiratory morbidity after acute respiratory failure
Children requiring respiratory support during the acute illness have a higher risk of chronic respiratory support, health-care use, and prolonged neurologic disability.
Show evidence (1 reference)
PMID:39657203 SUPPORT Human Clinical
"Among children with respiratory failure, 6 patients (75%) required follow-up respiratory support."
Six of eight children with acute respiratory failure required later respiratory support, defining a high-risk prognostic subgroup.
🌍

Epidemiology

6
Rare pediatric disease with biennial outbreaks
AFM is rare, occurs mainly in children, and has shown seasonal biennial outbreak peaks in the United States and other regions since 2012.
Show evidence (2 references)
PMID:33357469 SUPPORT Human Clinical
"mainly affecting children"
The Lancet review summarizes AFM as a mainly pediatric polio-like illness.
PMID:32143233 SUPPORT Human Clinical
"every 2 years since 2012"
This clinical review describes the US biennial seasonal peak pattern.
United States surveillance since the 2018 peak
CDC surveillance found only 28-47 confirmed US AFM cases per year during 2019-2022. Counts remained low despite increased EV-D68 circulation in 2022, showing that respiratory-virus circulation alone does not reliably predict AFM burden and that additional host, viral, or exposure factors are likely.
Show evidence (2 references)
PMID:38300829 SUPPORT Human Clinical
"The number of AFM cases was low during 2019-2022 (28-47 cases per year)"
The CDC surveillance report supplies the post-2018 annual range.
PMID:38300829 SUPPORT Human Clinical
"the number of cases remained low in 2022 despite evidence of increased EV-D68 circulation in the United States"
The discordance between respiratory circulation and paralysis motivates explicit uncertainty about the determinants of neuroinvasive disease.
Netherlands pediatric incidence
Retrospective multicenter surveillance in the Netherlands found a very low mean pediatric AFM incidence during 2014-2019.
0.06–? cases per 100000 children per year
Show evidence (1 reference)
PMID:36268734 SUPPORT Human Clinical
"0.06/100,000 children/year"
The Dutch cohort reports the pediatric mean incidence estimate encoded here.
Orphanet onset spectrum
Orphanet records AFM onset across infancy, childhood, adolescence, and adulthood, consistent with a predominantly pediatric disorder that can also occur outside childhood.
Show evidence (2 references)
ORPHA:623801 SUPPORT Other
"Age of onset: Childhood"
Orphanet records childhood onset among AFM natural-history categories.
ORPHA:623801 SUPPORT Other
"Age of onset: Adult"
Orphanet also records adult onset, supporting a broad age range despite pediatric predominance.
Population-based pediatric risk factors
A closed-population pediatric cohort identified male sex, Asian ancestry, asthma or atopic dermatitis history, and head injury history as AFM risk factors. These associations support host-susceptibility modeling but do not establish a Mendelian or deterministic risk mechanism.
Show evidence (1 reference)
PMID:30985511 SUPPORT Human Clinical
"Risk factors included male sex, Asian ancestry and history of asthma, atopic dermatitis or head injury."
The California population-based cohort provides the specific risk-factor associations summarized here.
European EV-D68-associated AFM surveillance
A European ENPEN survey found 130 reported AFM cases across 14 countries during 2016-2023, including 48 EV-D68-laboratory-confirmed cases; most occurred in years of increased EV-D68 circulation. The same report cautions that structural AFM surveillance was limited, so counts should be interpreted as incomplete surveillance data.
Show evidence (2 references)
PMID:40444374 SUPPORT Human Clinical
"The survey revealed 130 AFM cases for 14 countries, with 48 (37%) EV-D68-laboratory-confirmed."
The European survey directly supports the cross-country case count and EV-D68-confirmed subset.
PMID:40444374 SUPPORT Human Clinical
"70% (n = 91) occurred in 2016, 2018 and 2022, when EV-D68 circulation increased."
This supports the temporal association between AFM occurrence and increased EV-D68 circulation in Europe.
🦠

Infectious Agent

2
Enterovirus D68
EV-D68 is the best-supported infectious exposure associated with epidemic AFM. Temporal clustering, respiratory detections, CSF enterovirus-antibody enrichment, animal causation, and human neural-model infection support a causal role, but viral RNA is rarely found in CSF and not every AFM case is attributable to EV-D68.
Enterovirus D68 NCBITaxon:42789 NCBI Taxonomy (NCBITaxon)
Show evidence (3 references)
PMID:31409689 SUPPORT Human Clinical
"antibodies to EV peptides were present in CSF of 11 of 14 AFM patients (79%)"
CSF enterovirus-antibody enrichment supplies biologic evidence of prior enterovirus exposure when viral nucleic acid is no longer detectable.
PMID:31409689 SUPPORT Human Clinical
"EV RNA was confirmed in CSF from only 1 adult AFM case"
Rare direct CSF detection is important negative context: it limits patient-level etiologic confirmation despite the broader association.
PMID:42066114 SUPPORT Human Clinical
"AFM case-control studies did not (OR 0.86, 95% CI 0.40-1.86, k = 20)"
The 2026 meta-analysis finds design-dependent and heterogeneous estimates, preventing a simplistic claim that EV-D68 explains every AFM case.
Enterovirus A71
EV-A71 is a recognized non-polio enterovirus associated with some AFM cases, but it is not the principal explanation for the recent North American biennial AFM pattern. Viral association is represented here as an agent relationship rather than as a formal disease subtype.
Enterovirus A71 NCBITaxon:39054 NCBI Taxonomy (NCBITaxon)
Show evidence (1 reference)
PMID:36268734 SUPPORT Human Clinical
"EV-D68 and EV-A71"
The surveillance report identifies both viruses among non-polio enteroviruses associated with AFM.
🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from Acute Flaccid Myelitis:

Overlapping Features GBS also causes acute weakness and areflexia, but weakness is usually more symmetric, sensory deficits are more common, progression to nadir is slower, CSF protein is higher relative to leukocytes, and spinal gray-matter lesions favor AFM.
Distinguishing Features
  • AFM reached nadir sooner in a pediatric comparison (3 versus 8 days).
  • Asymmetric weakness and lack of sensory deficits favored AFM.
  • Spinal-cord lesions were found only in AFM in the comparative cohort.
Show evidence (1 reference)
PMID:34747551 SUPPORT Human Clinical
"shorter interval between onset of weakness and nadir (3 vs. 8 days, p < 0.001), more often had asymmetric limb weakness (58% vs. 0%, p < 0.001), and less frequently had sensory deficits (0% vs. 40%, p < 0.001)"
The direct pediatric comparison supplies the principal early distinctions.
Acute transverse myelitis Not Yet Curated MONDO:0015342
Overlapping Features Transverse myelitis can produce acute weakness and a spinal lesion, but a sensory level, bowel or bladder dysfunction, upper-motor-neuron evolution, and a lesion not selectively centered in anterior-horn gray matter favor transverse myelitis over AFM.
Distinguishing Features
  • Sensory and autonomic spinal-cord dysfunction are more prominent.
  • MRI involvement is not restricted to the anterior-horn gray-matter pattern.
Show evidence (1 reference)
PMID:36996587 SUPPORT Human Clinical
"Patients initially classified as probable or possible AFM were most commonly diagnosed with transverse myelitis (16/25)."
This diagnostic study establishes transverse myelitis as the main probable/possible AFM mimic.
Poliomyelitis Not Yet Curated MONDO:0017373
Overlapping Features Poliomyelitis can be clinically and anatomically indistinguishable from AFM. Travel and vaccination history plus urgent stool testing for poliovirus are required because a non-polio AFM label must not delay public-health response to possible poliovirus.
Distinguishing Features
  • Poliovirus detection establishes poliomyelitis rather than non-polio AFM.
  • Epidemiologic exposure and immunization history change the pretest probability.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"striking similarities to cases of poliomyelitis"
The clinical review supports the close phenotypic overlap.
Spinal cord infarction
Overlapping Features Spinal cord infarction can cause abrupt flaccid weakness and initially mimic AFM. Hyperacute maximal deficit, a vascular or hypotensive context, restricted diffusion, and a vascular-territory pattern favor infarction.
Distinguishing Features
  • Deficit is often maximal at onset rather than progressing over several days.
  • Diffusion restriction and vascular-territory MRI findings favor infarction.
Show evidence (1 reference)
PMID:32143233 SUPPORT Human Clinical
"Guillain-Barre syndrome, spinal cord stroke, and transverse myelitis."
The AFM clinical review explicitly includes spinal cord stroke among major mimics.
📊

Related Datasets

1
Single-cell RNA sequencing of EV-D68-infected human spinal cord organoids DOI:10.3389/fmicb.2025.1698639
Single-cell transcriptomic comparison of naive human spinal-cord organoids and organoids infected with two contemporary EV-D68 strains, resolving neuronal and glial composition, viral tropism, and host transcriptional responses.
human SINGLE CELL RNA SEQ
Conditions: Naive human spinal cord organoids US/IL/14-18952 EV-D68 infection US/MA/18-23089 EV-D68 infection
Findings
The two tested EV-D68 strains showed distinct cell tropism and host responses.
"Upon infection with 2 EV-D68 strains, US/IL/14-18952 (a B2 strain) and US/MA/18-23089 (a B3 strain), we observed distinct viral tropism and host transcriptional responses."
Show evidence (1 reference)
"we observed distinct viral tropism and host transcriptional responses"
The source directly states the dataset-level finding.
DOI:10.3389/fmicb.2025.1698639
Show evidence (1 reference)
"we profiled naive and EV-D68-infected human spinal cord organoids (hSCOs) derived from induced pluripotent stem cells (iPSCs) using single-cell RNA sequencing (scRNA-seq)"
The publication directly describes the dataset design and assay.
🔬

Clinical Trials

2
NCT02144935 NOT_APPLICABLE COMPLETED
CAPTURE was an observational pediatric registry and data repository for transverse myelitis or AFM, using surveys, interviews, and medical-record review to characterize recovery and inform future clinical trials.
Show evidence (1 reference)
clinicaltrials:NCT02144935 SUPPORT Human Clinical
"transverse myelitis (TM) or acute flaccid myelitis (AFM)"
ClinicalTrials.gov confirms that CAPTURE enrolled pediatric TM or AFM patients for registry-based outcomes follow-up.
NCT03499366 NOT_APPLICABLE UNKNOWN
European observational follow-up study of pediatric acute flaccid myelitis associated with EV-D68 infection, designed to assess clinical outcome and correlations with severity, treatment, and MRI findings.
Show evidence (1 reference)
clinicaltrials:NCT03499366 SUPPORT Human Clinical
"acute flaccid paresis associated with enterovirus D68 infection"
ClinicalTrials.gov identifies an EV-D68-associated pediatric AFM follow-up study.
🧫

Experimental Models

1
Human iPSC-derived spinal cord organoids infected with EV-D68 ORGANOID
Two three-dimensional human spinal-cord organoid systems, one enriched for spinal motor neurons and one containing multiple neuronal and glial lineages, model productive infection by contemporary EV-D68 strains. They reproduce neural tropism but not the immune-cell environment or the full route from respiratory infection to human paralysis.
Naive or EV-D68-infected human spinal cord organoids
motor neuron CL:0000100 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses motor neuron (CL:0000100). CL:0000100 is a cell type from the Cell Ontology. astrocyte CL:0000127 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology. oligodendrocyte precursor cell CL:0002453 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses oligodendrocyte precursor cell (CL:0002453). CL:0002453 is a cell type from the Cell Ontology.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Tissue
spinal cord UBERON:0002240 Uberon multi-species anatomy ontology (UBERON) Relation: this experimental model uses this anatomical location This experimental model uses spinal cord (UBERON:0002240). UBERON:0002240 is an anatomical location from the Uberon multi-species anatomy ontology.
Cell source
Human induced pluripotent stem cell-derived spinal neural cells
Culture
Three-dimensional multicellular spinal cord organoids
Findings
Contemporary, but not historical, EV-D68 strains productively infect spinal cord organoids.
"These hSCOs can be productively infected with contemporary strains, but not a historic strain, of EV-D68 and produce extracellular virus for at least 2 weeks without appreciable cytopathic effect."
Show evidence (1 reference)
DOI:10.1128/mbio.01058-23 SUPPORT In Vitro
"produce extracellular virus for at least 2 weeks without appreciable cytopathic effect"
This exact observation supports the finding.
Cell tropism differs between contemporary EV-D68 strains.
"US/IL/14-18952 showed a significant preference for neurons, while US/MA/18-23089 exhibited higher rates of infection in cycling astrocytes and OPCs."
Show evidence (1 reference)
"US/IL/14-18952 showed a significant preference for neurons"
The single-cell study directly supports strain-specific tropism.
Show evidence (2 references)
DOI:10.1128/mbio.01058-23 SUPPORT In Vitro
"produce extracellular virus for at least 2 weeks without appreciable cytopathic effect"
This establishes sustained productive infection while showing that viral cytopathy alone does not reproduce the human injury phenotype.
"US/IL/14-18952 showed a significant preference for neurons, while US/MA/18-23089 exhibited higher rates of infection in cycling astrocytes and OPCs."
Single-cell profiling distinguishes strain-specific target-cell preferences.
🐁

Animal Models

1
mouse Viral infection mouse model
Neonatal mouse models infected with contemporary EV-D68 outbreak strains develop paralytic myelitis resembling human AFM, with virus and viral genome in spinal cord and motor neuron loss in anterior horns corresponding to paralyzed limbs.
Paralytic myelitis Motor neuron loss Limb paralysis
Species
mouse
Background
neonatal mice experimentally infected with EV-D68
Show evidence (2 references)
PMID:28231269 SUPPORT Model Organism
"four EV-D68 strains from the 2014 outbreak (out of five tested) produced a paralytic disease in mice resembling human AFM."
This animal-model study supports EV-D68 as capable of producing an AFM-like paralytic phenotype in neonatal mice.
PMID:28231269 SUPPORT Model Organism
"infection and loss of motor neurons in the anterior horns of spinal cord segments corresponding to paralyzed limbs."
The model recapitulates the anterior-horn motor neuron injury central to human AFM pathophysiology.
{ }

Source YAML

click to show
name: Acute Flaccid Myelitis
creation_date: "2026-05-16T17:34:01Z"
category: Neurological Disorder
disease_term:
  preferred_term: acute flaccid myelitis
  term:
    id: MONDO:0100115
    label: acute flaccid myelitis
parents:
- Myelitis
- Acute disease
- Central nervous system disorder
description: >-
  Acute flaccid myelitis (AFM) is a rare, acute, polio-like neurologic
  syndrome, mainly reported in children, with rapid flaccid limb weakness and
  spinal cord gray-matter involvement. Most cases follow a febrile or
  respiratory prodrome. The clinical syndrome localizes predominantly to lower
  motor neurons in the anterior horn of the spinal cord, can involve cranial,
  bulbar, axial, and respiratory muscles, and is strongly associated
  epidemiologically with non-polio enteroviruses, especially enterovirus D68.
external_assertions:
- name: Orphanet acute flaccid myelitis record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:623801
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=623801
  description: >-
    Orphanet's ORPHA:623801 structured record for acute flaccid myelitis
    provides the rare-disease identifier, exact MONDO cross-reference, narrower
    ICD-10 mapping, MeSH and UMLS cross-references, broad onset categories, and
    international incidence annotations used to cross-check this entry.
  evidence:
  - reference: ORPHA:623801
    reference_title: Acute flaccid myelitis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0100115 | Exact"
    explanation: >-
      Orphanet maps ORPHA:623801 exactly to the MONDO disease identifier used by
      this entry.
  - reference: ORPHA:623801
    reference_title: Acute flaccid myelitis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:G04.8 | Narrower"
    explanation: >-
      The Orphanet cross-reference table records a narrower ICD-10 mapping for
      AFM.
definitions:
- name: Clinical and radiologic AFM syndrome
  definition_type: CASE_DEFINITION
  description: >-
    AFM is defined clinically by acute flaccid limb weakness with objective
    evidence of spinal cord gray-matter involvement, typically by MRI, and/or
    supporting cerebrospinal-fluid inflammation after exclusion of mimics such
    as Guillain-Barre syndrome, spinal cord infarction, poliomyelitis, and
    transverse myelitis.
  criteria_sets:
  - name: Core AFM features
    core_clinical_characteristics:
    - preferred_term: acute flaccid limb weakness
      term:
        id: HP:0003690
        label: Limb muscle weakness
      description: Rapid onset limb weakness with lower motor neuron features.
    - preferred_term: spinal cord gray matter lesion
      term:
        id: HP:0100561
        label: Spinal cord lesion
      description: >-
        MRI lesion centered in spinal cord gray matter, especially the anterior
        horns.
    - preferred_term: CSF pleocytosis
      term:
        id: HP:0012229
        label: CSF pleocytosis
      description: >-
        Supportive inflammatory cerebrospinal-fluid finding in probable or
        definite AFM criteria.
    evidence:
    - reference: PMID:31409689
      reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Classification criteria for a confirmed AFM case are acute flaccid limb
        weakness and magnetic resonance imaging evidence of a predominantly gray
        matter lesion that spans at least one spinal segment
      explanation: >-
        This reproduces the surveillance definition for confirmed AFM and
        directly supports the two required core criteria.
  evidence:
  - reference: PMID:27422805
    reference_title: "Acute flaccid myelitis: A clinical review of US cases 2012-2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute flaccid limb weakness with spinal cord gray matter lesions"
    explanation: >-
      The US case review directly supports the core clinical-radiologic
      definition used here.
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "no single sensitive and specific test for AFM"
    explanation: >-
      The Lancet review supports modeling AFM as a syndromic diagnosis requiring
      integrated clinical, MRI, CSF, and exclusionary evidence.
infectious_agent:
- name: Enterovirus D68
  infectious_agent_term:
    preferred_term: Enterovirus D68
    term:
      id: NCBITaxon:42789
      label: Enterovirus D68
  description: >-
    EV-D68 is the best-supported infectious exposure associated with epidemic
    AFM. Temporal clustering, respiratory detections, CSF enterovirus-antibody
    enrichment, animal causation, and human neural-model infection support a
    causal role, but viral RNA is rarely found in CSF and not every AFM case is
    attributable to EV-D68.
  evidence:
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "antibodies to EV peptides were present in CSF of 11 of 14 AFM patients (79%)"
    explanation: >-
      CSF enterovirus-antibody enrichment supplies biologic evidence of prior
      enterovirus exposure when viral nucleic acid is no longer detectable.
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EV RNA was confirmed in CSF from only 1 adult AFM case"
    explanation: >-
      Rare direct CSF detection is important negative context: it limits
      patient-level etiologic confirmation despite the broader association.
  - reference: PMID:42066114
    reference_title: "Enterovirus D68 and Acute Neurologic Outcomes: A Systematic Review and Meta-Analysis (2010-2025)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AFM case-control studies did not (OR 0.86, 95% CI 0.40-1.86, k = 20)"
    explanation: >-
      The 2026 meta-analysis finds design-dependent and heterogeneous estimates,
      preventing a simplistic claim that EV-D68 explains every AFM case.
- name: Enterovirus A71
  infectious_agent_term:
    preferred_term: Enterovirus A71
    term:
      id: NCBITaxon:39054
      label: Enterovirus A71
  description: >-
    EV-A71 is a recognized non-polio enterovirus associated with some AFM cases,
    but it is not the principal explanation for the recent North American
    biennial AFM pattern. Viral association is represented here as an agent
    relationship rather than as a formal disease subtype.
  evidence:
  - reference: PMID:36268734
    reference_title: "Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "EV-D68 and EV-A71"
    explanation: >-
      The surveillance report identifies both viruses among non-polio
      enteroviruses associated with AFM.
mechanistic_hypotheses:
- hypothesis_group_id: ev_d68_direct_neuroinvasion_model
  hypothesis_label: EV-D68 Direct Neuroinvasion Model
  status: CANONICAL
  description: >-
    In the best-supported model for epidemic AFM, EV-D68 respiratory infection
    is followed rarely by CNS access, receptor-mediated infection of spinal
    neural cells, and anterior-horn motor-neuron injury. Epidemiologic and human
    CSF evidence support the association, while mouse and organoid systems show
    that contemporary EV-D68 strains can infect neural tissue and cause
    paralytic myelitis. The model does not imply virologic confirmation in every
    patient.
  evidence:
  - reference: PMID:28231269
    reference_title: A mouse model of paralytic myelitis caused by enterovirus D68.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Virus isolated from spinal cords of infected mice transmitted disease when injected into naïve mice, fulfilling Koch's postulates in this model."
    explanation: >-
      Experimental transmission establishes direct causation in the mouse model,
      while the qualification "in this model" prevents overextension to humans.
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the disease appears to be caused by non-polio enterovirus infection"
    explanation: >-
      The clinical review identifies non-polio enterovirus infection as the
      leading human etiologic model.
- hypothesis_group_id: secondary_immune_mediated_injury_model
  hypothesis_label: Secondary Immune-Mediated Neural Injury Model
  status: EMERGING
  description: >-
    Direct neural infection may initiate AFM without being sufficient to cause
    the full motor-neuron injury. Persistent productive infection with little
    cytopathic effect in human spinal-cord organoids suggests that host immune
    responses or other secondary injury mechanisms may contribute to neuronal
    loss.
  evidence:
  - reference: DOI:10.1128/mbio.01058-23
    reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      EV-D68 infection is not the sole mediator of neuronal cell death in the
      spinal cord in those with AFM and that secondary injury from the immune
      response likely contributes to pathogenesis.
    explanation: >-
      The human organoid study explicitly proposes secondary immune injury after
      observing prolonged productive infection without appreciable cytopathy.
epidemiology:
- name: Rare pediatric disease with biennial outbreaks
  description: >-
    AFM is rare, occurs mainly in children, and has shown seasonal biennial
    outbreak peaks in the United States and other regions since 2012.
  evidence:
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mainly affecting children"
    explanation: >-
      The Lancet review summarizes AFM as a mainly pediatric polio-like illness.
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "every 2 years since 2012"
    explanation: >-
      This clinical review describes the US biennial seasonal peak pattern.
- name: United States surveillance since the 2018 peak
  description: >-
    CDC surveillance found only 28-47 confirmed US AFM cases per year during
    2019-2022. Counts remained low despite increased EV-D68 circulation in 2022,
    showing that respiratory-virus circulation alone does not reliably predict
    AFM burden and that additional host, viral, or exposure factors are likely.
  evidence:
  - reference: PMID:38300829
    reference_title: "Surveillance for Acute Flaccid Myelitis - United States, 2018-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The number of AFM cases was low during 2019-2022 (28-47 cases per year)"
    explanation: >-
      The CDC surveillance report supplies the post-2018 annual range.
  - reference: PMID:38300829
    reference_title: "Surveillance for Acute Flaccid Myelitis - United States, 2018-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the number of cases remained low in 2022 despite evidence of increased EV-D68 circulation in the United States"
    explanation: >-
      The discordance between respiratory circulation and paralysis motivates
      explicit uncertainty about the determinants of neuroinvasive disease.
- name: Netherlands pediatric incidence
  description: >-
    Retrospective multicenter surveillance in the Netherlands found a very low
    mean pediatric AFM incidence during 2014-2019.
  minimum_value: 0.06
  unit: cases per 100000 children per year
  evidence:
  - reference: PMID:36268734
    reference_title: "Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "0.06/100,000 children/year"
    explanation: >-
      The Dutch cohort reports the pediatric mean incidence estimate encoded
      here.
- name: Orphanet onset spectrum
  description: >-
    Orphanet records AFM onset across infancy, childhood, adolescence, and
    adulthood, consistent with a predominantly pediatric disorder that can also
    occur outside childhood.
  evidence:
  - reference: ORPHA:623801
    reference_title: Acute flaccid myelitis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: >-
      Orphanet records childhood onset among AFM natural-history categories.
  - reference: ORPHA:623801
    reference_title: Acute flaccid myelitis
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: >-
      Orphanet also records adult onset, supporting a broad age range despite
      pediatric predominance.
- name: Population-based pediatric risk factors
  description: >-
    A closed-population pediatric cohort identified male sex, Asian ancestry,
    asthma or atopic dermatitis history, and head injury history as AFM risk
    factors. These associations support host-susceptibility modeling but do not
    establish a Mendelian or deterministic risk mechanism.
  evidence:
  - reference: PMID:30985511
    reference_title: "Incidence, Risk Factors and Outcomes Among Children With Acute Flaccid Myelitis: A Population-based Cohort Study in a California Health Network Between 2011 and 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Risk factors included male sex, Asian ancestry and history of asthma, atopic dermatitis or head injury."
    explanation: >-
      The California population-based cohort provides the specific risk-factor
      associations summarized here.
- name: European EV-D68-associated AFM surveillance
  description: >-
    A European ENPEN survey found 130 reported AFM cases across 14 countries
    during 2016-2023, including 48 EV-D68-laboratory-confirmed cases; most
    occurred in years of increased EV-D68 circulation. The same report cautions
    that structural AFM surveillance was limited, so counts should be
    interpreted as incomplete surveillance data.
  evidence:
  - reference: PMID:40444374
    reference_title: "Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The survey revealed 130 AFM cases for 14 countries, with 48 (37%) EV-D68-laboratory-confirmed."
    explanation: >-
      The European survey directly supports the cross-country case count and
      EV-D68-confirmed subset.
  - reference: PMID:40444374
    reference_title: "Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "70% (n = 91) occurred in 2016, 2018 and 2022, when EV-D68 circulation increased."
    explanation: >-
      This supports the temporal association between AFM occurrence and
      increased EV-D68 circulation in Europe.
environmental:
- name: EV-D68 respiratory circulation and wastewater seasonality
  presence: PRESENT
  description: >-
    EV-D68 circulation is the main environmental infectious exposure context for
    AFM surveillance. Wastewater monitoring can detect EV-D68 seasonality and
    regional timing before or alongside clinical respiratory diagnoses, which
    may help public-health preparedness even though AFM remains rare relative to
    EV-D68 infection.
  effect: >-
    Increased EV-D68 circulation raises concern for AFM preparedness but is not
    sufficient on its own to predict individual paralysis risk.
  evidence:
  - reference: PMID:41853773
    reference_title: "Enterovirus D68 in United States wastewater: a longitudinal surveillance study integrating climatic, demographic, and clinical data."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Enterovirus D68 (EV-D68) can cause severe respiratory illness and acute flaccid myelitis (AFM)"
    explanation: >-
      The wastewater surveillance study frames EV-D68 as a respiratory pathogen
      relevant to AFM preparedness.
  - reference: PMID:41853773
    reference_title: "Enterovirus D68 in United States wastewater: a longitudinal surveillance study integrating climatic, demographic, and clinical data."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "We observed a biennial EV-D68 pattern with a national peak in September 2024"
    explanation: >-
      Wastewater data support the seasonal and biennial environmental
      circulation pattern encoded here.
pathophysiology:
- name: Non-polio Enterovirus Respiratory Infection
  description: >-
    AFM most often occurs after a respiratory or febrile illness. EV-D68 is the
    leading epidemic-associated virus. Only a very small fraction of respiratory
    infections are followed by AFM, and the route and determinants that permit
    subsequent CNS access in children remain unresolved.
  locations:
  - preferred_term: respiratory system
    term:
      id: UBERON:0001004
      label: respiratory system
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  biological_processes:
  - preferred_term: response to virus
    modifier: INCREASED
    term:
      id: GO:0009615
      label: response to virus
  evidence:
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the disease appears to be caused by non-polio enterovirus infection"
    explanation: >-
      This clinical synthesis supports the enterovirus model while appropriately
      using probabilistic wording.
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cause of AFM remains elusive. An infectious agent is only rarely detected in cerebrospinal fluid (CSF)."
    explanation: >-
      Direct human etiologic confirmation is uncommon and the graph therefore
      does not represent neuroinvasion as proven in every case.
  downstream:
  - target: Prodromal respiratory tract infection
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - ev_d68_direct_neuroinvasion_model
    description: >-
      Respiratory enterovirus infection commonly produces the febrile or
      respiratory prodrome that precedes neurologic weakness.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In most cases, prodromal fever or respiratory symptoms occur"
      explanation: The review links the prodrome temporally to AFM onset.
  - target: MFSD6- and ICAM5-Mediated EV-D68 Neural Cell Entry
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - ev_d68_direct_neuroinvasion_model
    description: >-
      Respiratory infection precedes rare CNS access and neural-cell entry, but
      the route of spread and other intervening determinants are not established.
    evidence:
    - reference: PMID:40132641
      reference_title: MFSD6 is an entry receptor for enterovirus D68.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "MFSD6 as a host entry factor for EV-D68"
      explanation: The receptor study establishes the downstream entry step.
- name: MFSD6- and ICAM5-Mediated EV-D68 Neural Cell Entry
  description: >-
    MFSD6 is a directly demonstrated EV-D68 entry receptor in respiratory and
    neural primary cells. ICAM5 is a proposed neuron-specific receptor and is
    retained as complementary, lower-tier evidence rather than treated as a
    universal AFM receptor mechanism.
  genes:
  - preferred_term: MFSD6
    term:
      id: hgnc:24711
      label: MFSD6
  - preferred_term: ICAM5
    term:
      id: hgnc:5348
      label: ICAM5
  biological_processes:
  - preferred_term: symbiont entry into host cell
    modifier: INCREASED
    term:
      id: GO:0046718
      label: symbiont entry into host cell
  evidence:
  - reference: PMID:40132641
    reference_title: MFSD6 is an entry receptor for enterovirus D68.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Knockout of MFSD6 expression abrogated EV-D68 infection in cell lines and primary cells corresponding to respiratory and neural cells."
    explanation: >-
      Genetic loss-of-function and primary-cell experiments directly support
      MFSD6-dependent entry.
  - reference: PMID:41467840
    reference_title: "Enterovirus D68 receptor usage: from static attachment to dynamic entry."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICAM-5) as a neuron-specific receptor that provides a molecular explanation for neurotropism in AFM."
    explanation: >-
      A receptor-usage review supports ICAM5 as a neuron-specific alternative,
      but this is weaker evidence than the MFSD6 perturbation experiments.
  downstream:
  - target: Spinal Neural Cell Tropism and Infection
    causal_link_type: DIRECT
    hypothesis_groups:
    - ev_d68_direct_neuroinvasion_model
    description: >-
      Receptor-dependent cell entry permits productive EV-D68 infection in
      susceptible neural cells.
    evidence:
    - reference: PMID:40132641
      reference_title: MFSD6 is an entry receptor for enterovirus D68.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "MFSD6 localized to the plasma membrane and was required for viral entry into host cells."
      explanation: This directly links receptor availability to viral entry.
- name: Spinal Neural Cell Tropism and Infection
  description: >-
    Contemporary EV-D68 strains productively infect human spinal-cord organoids.
    Tropism differs by strain across neurons, cycling astrocytes, and
    oligodendrocyte precursor cells, indicating that neural susceptibility is
    neither uniform nor explained by motor neurons alone.
  locations:
  - preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  evidence:
  - reference: DOI:10.1128/mbio.01058-23
    reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "productively infected with contemporary strains, but not a historic strain, of EV-D68"
    explanation: >-
      Productive infection in human spinal-cord organoids establishes direct
      human-cell neural tropism and a strain effect.
  - reference: DOI:10.3389/fmicb.2025.1698639
    reference_title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "distinct viral tropism and host transcriptional responses"
    explanation: Single-cell profiling supports strain- and cell-type-specific tropism.
  downstream:
  - target: Spinal Gray Matter Inflammation and Motor Neuron Injury
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - ev_d68_direct_neuroinvasion_model
    - secondary_immune_mediated_injury_model
    description: >-
      Neural infection can precede motor-neuron injury through direct viral
      effects and/or secondary inflammatory injury; their relative contribution
      in human AFM remains unresolved.
    evidence:
    - reference: DOI:10.1128/mbio.01058-23
      reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "secondary injury from the immune response likely contributes to pathogenesis"
      explanation: >-
        Organoid infection with limited cytopathy specifically supports an
        intervening secondary-injury mechanism.
    - reference: PMID:28231269
      reference_title: A mouse model of paralytic myelitis caused by enterovirus D68.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "infection and loss of motor neurons in the anterior horns of spinal cord segments corresponding to paralyzed limbs."
      explanation: The mouse model links spinal infection to regional motor-neuron loss.
- name: Spinal Gray Matter Inflammation and Motor Neuron Injury
  description: >-
    AFM injury is centered on spinal gray matter and anterior-horn motor neurons.
    Cranial motor nuclei can also be involved, accounting for facial, bulbar,
    and respiratory manifestations that cannot be attributed to spinal anterior
    horns alone.
  locations:
  - preferred_term: ventral horn of spinal cord
    term:
      id: UBERON:0002257
      label: ventral horn of spinal cord
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  cell_types:
  - preferred_term: anterior horn motor neuron
    term:
      id: CL:2000048
      label: anterior horn motor neuron
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The primary site of injury in AFM is the anterior horn cells of the spinal cord"
    explanation: The clinical review identifies the principal anatomic lesion.
  downstream:
  - target: Spinal cord gray matter lesion
    causal_link_type: DIRECT
    description: >-
      Gray-matter injury is visualized as the characteristic spinal-cord MRI
      abnormality.
    evidence:
    - reference: PMID:26720027
      reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Fifty-six patients had T2 hyperintensity of spinal gray matter on magnetic resonance imaging"
      explanation: The clinical series directly links the lesion compartment to MRI signal.
  - target: CSF pleocytosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - secondary_immune_mediated_injury_model
    description: >-
      CNS inflammation can increase leukocytes in CSF, although pleocytosis is
      supportive rather than required or disease-specific.
    evidence:
    - reference: PMID:26720027
      reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "43 patients had cerebrospinal fluid pleocytosis"
      explanation: The case series quantifies the inflammatory CSF finding.
  - target: Segmental and Cranial Lower Motor Neuron Dysfunction
    causal_link_type: DIRECT
    description: >-
      Loss or dysfunction of spinal and cranial motor neurons produces the
      characteristic lower-motor-neuron syndrome.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "resulting in a motor neuronopathy"
      explanation: The clinical review explicitly links anterior-horn injury to motor neuronopathy.
- name: Segmental and Cranial Lower Motor Neuron Dysfunction
  description: >-
    Dysfunction of segmental anterior-horn and cranial motor systems produces
    rapid flaccid weakness, depressed reflexes, asymmetry, and, when brainstem or
    respiratory motor pools are affected, facial, bulbar, or ventilatory
    impairment.
  locations:
  - preferred_term: ventral horn of spinal cord
    term:
      id: UBERON:0002257
      label: ventral horn of spinal cord
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
    explanation: This defines the motor distribution beyond limb weakness.
  downstream:
  - target: Acute flaccid paralysis
    causal_link_type: DIRECT
    description: Motor-neuron dysfunction produces acute flaccid paralysis.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "characterized by acute flaccid paralysis"
      explanation: The review directly describes the resulting paralysis phenotype.
  - target: Acute limb weakness
    causal_link_type: DIRECT
    description: Segmental motor-neuron dysfunction produces abrupt limb weakness.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "acute-onset flaccid limb weakness"
      explanation: The review directly describes the core limb phenotype.
  - target: Asymmetric limb weakness
    causal_link_type: DIRECT
    description: Patchy segmental motor-pool injury often produces asymmetric weakness.
    evidence:
    - reference: PMID:34747551
      reference_title: "Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "asymmetric limb weakness (58% vs. 0%, p < 0.001)"
      explanation: The comparative cohort quantifies the asymmetric pattern.
  - target: Areflexia
    causal_link_type: DIRECT
    description: Lower-motor-neuron dysfunction interrupts the reflex arc.
    evidence:
    - reference: PMID:39163469
      reference_title: Acute Flaccid Myelitis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "decreased or absent reflexes"
      explanation: The clinical summary describes the lower-motor-neuron reflex finding.
  - target: Cranial nerve palsy
    causal_link_type: DIRECT
    description: Cranial motor-system involvement can produce cranial neuropathies.
    evidence:
    - reference: PMID:31014167
      reference_title: "Acute Flaccid Myelitis Associated With Enterovirus D68: A Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "with cranial neuropathy"
      explanation: The review documents cranial neuropathy in AFM.
  - target: Facial weakness
    causal_link_type: DIRECT
    description: Facial motor involvement can cause weakness of facial musculature.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "bulbar, facial, and extraocular muscles may also be affected"
      explanation: The review directly includes facial motor involvement.
  - target: Bulbar palsy
    causal_link_type: DIRECT
    description: Brainstem motor involvement can impair bulbar function.
    evidence:
    - reference: PMID:32143233
      reference_title: "Acute Flaccid Myelitis: A Clinical Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
      explanation: The review directly includes bulbar involvement.
  - target: Respiratory insufficiency due to muscle weakness
    causal_link_type: DIRECT
    description: Respiratory motor-pool involvement can cause ventilatory failure.
    evidence:
    - reference: PMID:33357469
      reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "can invoke respiratory failure and other critical complications"
      explanation: The clinical review links profound motor weakness to respiratory failure.
phenotypes:
- name: Prodromal respiratory tract infection
  category: Respiratory
  description: >-
    Most AFM cases are preceded by a short febrile or upper respiratory illness,
    typically 1-10 days before the onset of weakness.
  phenotype_term:
    preferred_term: acute prodromal respiratory tract infection
    term:
      id: HP:0011947
      label: Respiratory tract infection
    temporality: ACUTE
  evidence:
  - reference: PMID:39163469
    reference_title: Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "upper respiratory tract infection"
    explanation: >-
      The clinical summary identifies a preceding upper respiratory infection;
      no frequency band is assigned because the available quantitative endpoint
      pooled respiratory and gastrointestinal prodromes.
- name: Acute flaccid paralysis
  category: Neurologic
  phenotype_term:
    preferred_term: acute flaccid paralysis
    term:
      id: HP:0003470
      label: Paralysis
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute flaccid paralysis"
    explanation: >-
      Acute flaccid paralysis is part of the core clinical description of AFM.
- name: Acute limb weakness
  category: Neurologic
  phenotype_term:
    preferred_term: acute limb weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute-onset flaccid limb weakness"
    explanation: >-
      The review identifies acute flaccid limb weakness as a defining feature.
- name: Asymmetric limb weakness
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Limb weakness is often asymmetric in AFM and helps distinguish AFM from
    Guillain-Barre syndrome in children with acute flaccid paralysis.
  phenotype_term:
    preferred_term: asymmetric limb weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: PMID:34747551
    reference_title: "Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "asymmetric limb weakness (58% vs. 0%, p < 0.001)"
    explanation: >-
      Fifty-eight percent of the AFM cohort had asymmetric weakness, supporting
      the frequent band and its value against GBS.
- name: Areflexia
  category: Neurologic
  phenotype_term:
    preferred_term: Areflexia
    term:
      id: HP:0001284
      label: Areflexia
  evidence:
  - reference: PMID:39163469
    reference_title: Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "decreased or absent reflexes"
    explanation: >-
      The StatPearls clinical summary supports decreased or absent reflexes as a
      classic AFM finding.
- name: Spinal cord gray matter lesion
  category: Neurologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: spinal cord gray matter lesion
    term:
      id: HP:0100561
      label: Spinal cord lesion
  evidence:
  - reference: PMID:26720027
    reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty-six patients had T2 hyperintensity of spinal gray matter on magnetic resonance imaging"
    explanation: >-
      Fifty-six of 59 cases had the MRI abnormality, supporting the
      very-frequent band.
- name: CSF pleocytosis
  category: Neurologic
  frequency: FREQUENT
  phenotype_term:
    preferred_term: CSF pleocytosis
    term:
      id: HP:0012229
      label: CSF pleocytosis
  evidence:
  - reference: PMID:26720027
    reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "43 patients had cerebrospinal fluid pleocytosis"
    explanation: >-
      Forty-three of 59 cases had CSF pleocytosis, supporting the frequent band.
- name: Cranial nerve palsy
  category: Neurologic
  phenotype_term:
    preferred_term: Cranial nerve palsy
    term:
      id: HP:0006824
      label: Cranial nerve paralysis
  evidence:
  - reference: PMID:31014167
    reference_title: "Acute Flaccid Myelitis Associated With Enterovirus D68: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with cranial neuropathy"
    explanation: >-
      The EV-D68-associated AFM review describes cranial neuropathy among common
      presenting features.
- name: Facial weakness
  category: Neurologic
  phenotype_term:
    preferred_term: Facial weakness
    term:
      id: HP:0030319
      label: Weakness of facial musculature
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
    explanation: >-
      The review lists facial muscle involvement in the broader set of AFM
      muscle groups that can be affected.
- name: Bulbar palsy
  category: Neurologic
  phenotype_term:
    preferred_term: Bulbar palsy
    term:
      id: HP:0001283
      label: Bulbar palsy
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Respiratory, axial, bulbar, facial, and extraocular muscles may also be affected."
    explanation: >-
      The review lists bulbar involvement in the broader set of AFM muscle
      groups that can be affected.
- name: Respiratory insufficiency due to muscle weakness
  category: Respiratory
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:39657203
    reference_title: "Pediatric Patients With Acute Flaccid Myelitis: Long-term Respiratory and Neurologic Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Eight patients (21.6%) had respiratory failure during the index hospitalization."
    explanation: >-
      Eight of 37 children had respiratory failure, directly supporting the
      occasional frequency band in this cohort.
imaging_findings:
- name: Longitudinal spinal gray-matter T2 hyperintensity on MRI
  modality: MRI
  imaging_finding_term:
    preferred_term: spinal cord lesion
    term:
      id: HP:0100561
      label: Spinal cord lesion
  description: >-
    T2 hyperintensity centered in spinal gray matter, often longitudinally
    extensive and most conspicuous in the anterior horns, is the defining
    radiologic AFM finding. A predominantly gray-matter lesion spanning at least
    one spinal segment is part of the confirmed surveillance case definition.
  located_in:
    preferred_term: ventral horn of spinal cord
    term:
      id: UBERON:0002257
      label: ventral horn of spinal cord
  spatial_extent: EXTENSIVE
  phenotype_term:
    preferred_term: spinal cord gray matter lesion
    term:
      id: HP:0100561
      label: Spinal cord lesion
  diagnostic: true
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      magnetic resonance imaging evidence of a predominantly gray matter lesion
      that spans at least one spinal segment
    explanation: The published surveillance definition establishes the diagnostic morphology.
  - reference: PMID:26720027
    reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fifty-six patients had T2 hyperintensity of spinal gray matter on magnetic resonance imaging"
    explanation: Fifty-six of 59 cases support the very-frequent frequency band.
diagnosis:
- name: MRI-centered AFM evaluation
  description: >-
    Suspected AFM evaluation centers on urgent neurologic examination and MRI of
    the entire spinal cord and brainstem to detect gray-matter lesions. CSF
    analysis, respiratory and stool testing, poliovirus exclusion, and early
    electrodiagnostic testing help characterize inflammation, seek an infectious
    association, and distinguish peripheral neuropathy.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: >-
    Longitudinal spinal cord gray-matter lesions, especially anterior horn
    involvement, support AFM in the right clinical context.
  evidence:
  - reference: PMID:26621554
    reference_title: Recognition and Management of Acute Flaccid Myelitis in Children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spinal gray matter lesions"
    explanation: >-
      Pediatric case series supports MRI detection of spinal gray matter lesions
      as a key recognition feature.
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical, neuroimaging, and cerebrospinal fluid characteristics"
    explanation: >-
      The Lancet review supports an integrated diagnostic workup rather than a
      single confirmatory test.
- name: CSF and respiratory or stool enterovirus testing
  description: >-
    CSF cell count and protein are supportive, while respiratory and stool
    specimens should be collected early for enterovirus typing and poliovirus
    exclusion. A negative CSF PCR does not exclude AFM or an enterovirus
    association because viral RNA is rarely recovered from CSF.
  results: >-
    Pleocytosis supports CNS inflammation; enterovirus detection outside CSF can
    support an association but does not independently prove viral causation of
    the neurologic syndrome.
  evidence:
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An infectious agent is only rarely detected in cerebrospinal fluid (CSF)."
    explanation: Rare CSF detection explains why negative CSF PCR cannot exclude AFM.
  - reference: PMID:26720027
    reference_title: "Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No pathogens were isolated from the cerebrospinal fluid."
    explanation: The 59-case series illustrates the low yield of CSF pathogen testing.
- name: Mimic exclusion
  description: >-
    AFM diagnosis requires careful exclusion of other causes of acute flaccid
    paralysis, especially Guillain-Barre syndrome, spinal cord stroke, acute
    transverse myelitis, poliomyelitis, and compressive or structural spinal
    cord disease.
  notes: >-
    Key mimics include Guillain-Barre syndrome, spinal cord infarction,
    transverse myelitis, poliomyelitis, and structural spinal cord disease.
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Guillain-Barre syndrome, spinal cord stroke, and transverse myelitis"
    explanation: >-
      The clinical review explicitly lists these major AFM mimics.
differential_diagnoses:
- name: Guillain-Barre syndrome
  disease_term:
    preferred_term: Guillain-Barre syndrome
    term:
      id: MONDO:0016218
      label: Guillain-Barre syndrome
  description: >-
    GBS also causes acute weakness and areflexia, but weakness is usually more
    symmetric, sensory deficits are more common, progression to nadir is slower,
    CSF protein is higher relative to leukocytes, and spinal gray-matter lesions
    favor AFM.
  distinguishing_features:
  - AFM reached nadir sooner in a pediatric comparison (3 versus 8 days).
  - Asymmetric weakness and lack of sensory deficits favored AFM.
  - Spinal-cord lesions were found only in AFM in the comparative cohort.
  evidence:
  - reference: PMID:34747551
    reference_title: "Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      shorter interval between onset of weakness and nadir (3 vs. 8 days, p <
      0.001), more often had asymmetric limb weakness (58% vs. 0%, p < 0.001),
      and less frequently had sensory deficits (0% vs. 40%, p < 0.001)
    explanation: The direct pediatric comparison supplies the principal early distinctions.
- name: Acute transverse myelitis
  disease_term:
    preferred_term: acute transverse myelitis
    term:
      id: MONDO:0015342
      label: acute transverse myelitis
  description: >-
    Transverse myelitis can produce acute weakness and a spinal lesion, but a
    sensory level, bowel or bladder dysfunction, upper-motor-neuron evolution,
    and a lesion not selectively centered in anterior-horn gray matter favor
    transverse myelitis over AFM.
  distinguishing_features:
  - Sensory and autonomic spinal-cord dysfunction are more prominent.
  - MRI involvement is not restricted to the anterior-horn gray-matter pattern.
  evidence:
  - reference: PMID:36996587
    reference_title: "Pediatric acute flaccid myelitis: Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients initially classified as probable or possible AFM were most commonly diagnosed with transverse myelitis (16/25)."
    explanation: This diagnostic study establishes transverse myelitis as the main probable/possible AFM mimic.
- name: Poliomyelitis
  disease_term:
    preferred_term: poliomyelitis
    term:
      id: MONDO:0017373
      label: poliomyelitis
  description: >-
    Poliomyelitis can be clinically and anatomically indistinguishable from AFM.
    Travel and vaccination history plus urgent stool testing for poliovirus are
    required because a non-polio AFM label must not delay public-health response
    to possible poliovirus.
  distinguishing_features:
  - Poliovirus detection establishes poliomyelitis rather than non-polio AFM.
  - Epidemiologic exposure and immunization history change the pretest probability.
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "striking similarities to cases of poliomyelitis"
    explanation: The clinical review supports the close phenotypic overlap.
- name: Spinal cord infarction
  description: >-
    Spinal cord infarction can cause abrupt flaccid weakness and initially mimic
    AFM. Hyperacute maximal deficit, a vascular or hypotensive context, restricted
    diffusion, and a vascular-territory pattern favor infarction.
  distinguishing_features:
  - Deficit is often maximal at onset rather than progressing over several days.
  - Diffusion restriction and vascular-territory MRI findings favor infarction.
  evidence:
  - reference: PMID:32143233
    reference_title: "Acute Flaccid Myelitis: A Clinical Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Guillain-Barre syndrome, spinal cord stroke, and transverse myelitis."
    explanation: The AFM clinical review explicitly includes spinal cord stroke among major mimics.
progression:
- phase: Rapid progression to acute nadir
  notes: >-
    Weakness progresses over hours to days. In a direct pediatric comparison,
    AFM reached nadir sooner than GBS, reinforcing the need for prompt MRI,
    respiratory monitoring, and specimen collection.
  evidence:
  - reference: PMID:34747551
    reference_title: "Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "shorter interval between onset of weakness and nadir (3 vs. 8 days, p < 0.001)"
    explanation: >-
      The comparative cohort places median AFM nadir at three days.
- phase: Chronic motor deficit with partial functional recovery
  notes: >-
    Persistent focal paralysis is common, although disability and activity of
    daily living can continue to improve over years. Motor recovery is generally
    less complete than recovery of nonmotor neurologic findings.
  evidence:
  - reference: PMID:33388543
    reference_title: Three-Year Longitudinal Motor Function and Disability Level of Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "AFM has a high rate of persistent motor deficits showing one- to two-limb paralysis."
    explanation: >-
      Three-year follow-up establishes persistence of focal motor deficits.
  - reference: PMID:33388543
    reference_title: Three-Year Longitudinal Motor Function and Disability Level of Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disability level of patients with AFM, however, generally improved at the three-year time point."
    explanation: >-
      Functional improvement despite residual paralysis gives a more nuanced
      prognosis than either full recovery or fixed disability.
- phase: Long-term respiratory morbidity after acute respiratory failure
  notes: >-
    Children requiring respiratory support during the acute illness have a
    higher risk of chronic respiratory support, health-care use, and prolonged
    neurologic disability.
  evidence:
  - reference: PMID:39657203
    reference_title: "Pediatric Patients With Acute Flaccid Myelitis: Long-term Respiratory and Neurologic Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among children with respiratory failure, 6 patients (75%) required follow-up respiratory support."
    explanation: >-
      Six of eight children with acute respiratory failure required later
      respiratory support, defining a high-risk prognostic subgroup.
treatments:
- name: Acute supportive care
  description: >-
    Acute management is primarily supportive and includes close monitoring for
    bulbar and respiratory muscle involvement, intensive-care support when
    needed, pain control, prevention of complications, and multidisciplinary
    neurologic and infectious-disease evaluation.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "guide diagnosis, management, and rehabilitation"
    explanation: >-
      The Lancet review supports management and rehabilitation as central AFM
      care domains.
- name: Mechanical ventilatory support
  description: >-
    Respiratory muscle weakness or bulbar dysfunction can require intubation,
    invasive mechanical ventilation, or other airway and respiratory support.
  treatment_term:
    preferred_term: mechanical ventilation
    term:
      id: NCIT:C70909
      label: Mechanical Ventilation
  target_phenotypes:
  - preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:39163469
    reference_title: Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "requires intubation and mechanical ventilation"
    explanation: >-
      The current clinical summary supports ventilatory support for severe AFM
      respiratory insufficiency.
- name: Physical therapy and rehabilitation
  description: >-
    Long-term care relies on early, intensive, and individualized
    rehabilitation, including physical therapy, occupational therapy, bracing,
    orthopedic monitoring, and functional support for residual motor deficits.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  target_phenotypes:
  - preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: PMID:33357469
    reference_title: "Acute flaccid myelitis: cause, diagnosis, and management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "unique long-term rehabilitation needs"
    explanation: >-
      The Lancet review directly supports rehabilitation as a core AFM
      management need.
- name: Transcutaneous spinal cord stimulation with gait training
  description: >-
    Transcutaneous spinal cord stimulation paired with gait training has early
    pediatric case-series evidence for feasibility and walking-function
    improvement after AFM-related incomplete spinal cord injury. This is an
    investigational rehabilitation adjunct rather than established standard
    care.
  treatment_term:
    preferred_term: spinal cord stimulation
    term:
      id: NCIT:C21023
      label: Spinal Cord Stimulation
  target_phenotypes:
  - preferred_term: Limb muscle weakness
    term:
      id: HP:0003690
      label: Limb muscle weakness
  evidence:
  - reference: DOI:10.3390/children11091116
    reference_title: Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "safe and clinically feasible intervention"
    explanation: >-
      A four-child case series supports feasibility and possible walking benefit
      but remains preliminary evidence.
- name: Reconstructive surgery for persistent paralysis
  description: >-
    Selected patients with persistent severe upper-extremity paralysis after AFM
    may undergo reconstructive procedures such as nerve transfer,
    muscle-tendon transfer, or free muscle transfer. Evidence remains
    observational and procedure selection depends on residual donor-nerve and
    synergistic-muscle function.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_phenotypes:
  - preferred_term: Upper limb muscle weakness
    term:
      id: HP:0003484
      label: Upper limb muscle weakness
  evidence:
  - reference: DOI:10.2106/JBJS.OA.23.00143
    reference_title: Midterm Outcomes of Surgical Reconstruction and Spontaneous Recovery of Upper-Extremity Paralysis Following Acute Flaccid Myelitis
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "nerve transfer, muscle-tendon transfer, or free muscle transfer"
    explanation: >-
      This retrospective cohort supports reconstructive surgery as a selected
      intervention for persistent AFM upper-extremity paralysis.
- name: Immunomodulatory acute therapies
  description: >-
    Intravenous immunoglobulin, corticosteroids, and plasma exchange have been
    used empirically in AFM, especially early in the syndrome when mimics remain
    possible. Available clinical evidence does not establish that these
    therapies reverse AFM motor neuron injury, so this entry models them as
    empiric and uncertain rather than proven disease-modifying treatment.
    Preclinical EV-D68 AFM-model data further caution against assuming benefit
    from corticosteroids.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:26621554
    reference_title: Recognition and Management of Acute Flaccid Myelitis in Children.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "intravenous immunoglobulin, corticosteroids, or plasma exchange"
    explanation: >-
      The case series documents real-world use of immune therapies but also
      persistent deficits, so it supports exposure rather than proven efficacy.
  - reference: PMID:28968718
    reference_title: Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Dexamethasone treatment worsened motor impairment, increased mortality, and increased viral loads."
    explanation: >-
      Mouse-model evidence specifically cautions that corticosteroid exposure
      may worsen EV-D68 paralytic myelitis biology, although it is not direct
      human treatment evidence.
clinical_trials:
- name: NCT02144935
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    CAPTURE was an observational pediatric registry and data repository for
    transverse myelitis or AFM, using surveys, interviews, and medical-record
    review to characterize recovery and inform future clinical trials.
  evidence:
  - reference: clinicaltrials:NCT02144935
    reference_title: "Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "transverse myelitis (TM) or acute flaccid myelitis (AFM)"
    explanation: >-
      ClinicalTrials.gov confirms that CAPTURE enrolled pediatric TM or AFM
      patients for registry-based outcomes follow-up.
- name: NCT03499366
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: >-
    European observational follow-up study of pediatric acute flaccid myelitis
    associated with EV-D68 infection, designed to assess clinical outcome and
    correlations with severity, treatment, and MRI findings.
  evidence:
  - reference: clinicaltrials:NCT03499366
    reference_title: A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acute flaccid paresis associated with enterovirus D68 infection"
    explanation: >-
      ClinicalTrials.gov identifies an EV-D68-associated pediatric AFM follow-up
      study.
animal_models:
- species: mouse
  background: neonatal mice experimentally infected with EV-D68
  category: Viral infection mouse model
  description: >-
    Neonatal mouse models infected with contemporary EV-D68 outbreak strains
    develop paralytic myelitis resembling human AFM, with virus and viral genome
    in spinal cord and motor neuron loss in anterior horns corresponding to
    paralyzed limbs.
  associated_phenotypes:
  - Paralytic myelitis
  - Motor neuron loss
  - Limb paralysis
  evidence:
  - reference: PMID:28231269
    reference_title: A mouse model of paralytic myelitis caused by enterovirus D68.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "four EV-D68 strains from the 2014 outbreak (out of five tested) produced a paralytic disease in mice resembling human AFM."
    explanation: >-
      This animal-model study supports EV-D68 as capable of producing an
      AFM-like paralytic phenotype in neonatal mice.
  - reference: PMID:28231269
    reference_title: A mouse model of paralytic myelitis caused by enterovirus D68.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "infection and loss of motor neurons in the anterior horns of spinal cord segments corresponding to paralyzed limbs."
    explanation: >-
      The model recapitulates the anterior-horn motor neuron injury central to
      human AFM pathophysiology.
experimental_models:
- name: Human iPSC-derived spinal cord organoids infected with EV-D68
  description: >-
    Two three-dimensional human spinal-cord organoid systems, one enriched for
    spinal motor neurons and one containing multiple neuronal and glial
    lineages, model productive infection by contemporary EV-D68 strains. They
    reproduce neural tropism but not the immune-cell environment or the full
    route from respiratory infection to human paralysis.
  experimental_model_type: ORGANOID
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  tissue_term:
    preferred_term: spinal cord
    term:
      id: UBERON:0002240
      label: spinal cord
  cell_types:
  - preferred_term: motor neuron
    term:
      id: CL:0000100
      label: motor neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  conditions:
  - Naive or EV-D68-infected human spinal cord organoids
  cell_source: Human induced pluripotent stem cell-derived spinal neural cells
  culture_system: Three-dimensional multicellular spinal cord organoids
  publication: DOI:10.1128/mbio.01058-23
  modeled_mechanisms:
  - target: Spinal Neural Cell Tropism and Infection
    description: >-
      Tests whether historical and contemporary EV-D68 strains productively
      infect human spinal neural populations.
    evidence:
    - reference: DOI:10.1128/mbio.01058-23
      reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "productively infected with contemporary strains, but not a historic strain, of EV-D68"
      explanation: The organoid infection directly models the curated tropism mechanism.
  - target: Spinal Gray Matter Inflammation and Motor Neuron Injury
    description: >-
      Separates productive viral infection from overt cytopathic injury and
      motivates testing secondary immune-mediated damage.
    evidence:
    - reference: DOI:10.1128/mbio.01058-23
      reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "secondary injury from the immune response likely contributes to pathogenesis"
      explanation: The model motivates, but does not itself reproduce, secondary immune injury.
  findings:
  - statement: Contemporary, but not historical, EV-D68 strains productively infect spinal cord organoids.
    supporting_text: >-
      These hSCOs can be productively infected with contemporary strains, but
      not a historic strain, of EV-D68 and produce extracellular virus for at
      least 2 weeks without appreciable cytopathic effect.
    evidence:
    - reference: DOI:10.1128/mbio.01058-23
      reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "produce extracellular virus for at least 2 weeks without appreciable cytopathic effect"
      explanation: This exact observation supports the finding.
  - statement: Cell tropism differs between contemporary EV-D68 strains.
    supporting_text: >-
      US/IL/14-18952 showed a significant preference for neurons, while
      US/MA/18-23089 exhibited higher rates of infection in cycling astrocytes
      and OPCs.
    evidence:
    - reference: DOI:10.3389/fmicb.2025.1698639
      reference_title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "US/IL/14-18952 showed a significant preference for neurons"
      explanation: The single-cell study directly supports strain-specific tropism.
  evidence:
  - reference: DOI:10.1128/mbio.01058-23
    reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      produce extracellular virus for at least 2 weeks without appreciable
      cytopathic effect
    explanation: >-
      This establishes sustained productive infection while showing that viral
      cytopathy alone does not reproduce the human injury phenotype.
  - reference: DOI:10.3389/fmicb.2025.1698639
    reference_title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      US/IL/14-18952 showed a significant preference for neurons, while
      US/MA/18-23089 exhibited higher rates of infection in cycling astrocytes
      and OPCs.
    explanation: Single-cell profiling distinguishes strain-specific target-cell preferences.
datasets:
- accession: DOI:10.3389/fmicb.2025.1698639
  title: Single-cell RNA sequencing of EV-D68-infected human spinal cord organoids
  description: >-
    Single-cell transcriptomic comparison of naive human spinal-cord organoids
    and organoids infected with two contemporary EV-D68 strains, resolving
    neuronal and glial composition, viral tropism, and host transcriptional
    responses.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  conditions:
  - Naive human spinal cord organoids
  - US/IL/14-18952 EV-D68 infection
  - US/MA/18-23089 EV-D68 infection
  publication: DOI:10.3389/fmicb.2025.1698639
  findings:
  - statement: The two tested EV-D68 strains showed distinct cell tropism and host responses.
    supporting_text: >-
      Upon infection with 2 EV-D68 strains, US/IL/14-18952 (a B2 strain) and
      US/MA/18-23089 (a B3 strain), we observed distinct viral tropism and host
      transcriptional responses.
    evidence:
    - reference: DOI:10.3389/fmicb.2025.1698639
      reference_title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "we observed distinct viral tropism and host transcriptional responses"
      explanation: The source directly states the dataset-level finding.
  evidence:
  - reference: DOI:10.3389/fmicb.2025.1698639
    reference_title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "we profiled naive and EV-D68-infected human spinal cord organoids (hSCOs) derived from induced pluripotent stem cells (iPSCs) using single-cell RNA sequencing (scRNA-seq)"
    explanation: The publication directly describes the dataset design and assay.
discussions:
- discussion_id: afm_ev_d68_human_causation_boundary
  prompt: >-
    What proportion of human AFM is directly caused by EV-D68 neuroinvasion,
    and which tests can establish that cause in an individual patient?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - infectious_agent#Enterovirus D68
  - pathophysiology#Non-polio Enterovirus Respiratory Infection
  rationale: >-
    Outbreak timing, respiratory detections, CSF antibodies, animal causation,
    and human-organoid infection form a coherent causal case. However, viral RNA
    is rarely detected in human CSF, case-control estimates are heterogeneous,
    and AFM is a syndrome with other infectious and noninfectious mimics. The
    graph therefore treats EV-D68 neuroinvasion as the canonical model for
    epidemic disease without assigning it to every case.
  evidence:
  - reference: PMID:42066114
    reference_title: "Enterovirus D68 and Acute Neurologic Outcomes: A Systematic Review and Meta-Analysis (2010-2025)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Across 98 studies, the pooled odds ratio (OR) was 1.39 (95% CI 1.14-1.69),
      with high heterogeneity (I2 = 98.9%; prediction interval 0.24-8.15).
    explanation: The high heterogeneity quantifies uncertainty in human association estimates.
  - reference: PMID:31409689
    reference_title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "supports the plausibility of a link between EV infection and AFM that warrants further investigation"
    explanation: The CSF-antibody study explicitly frames its evidence as plausibility, not proof.
  posed_date: "2026-07-20T00:00:00Z"
- discussion_id: afm_respiratory_wave_paralysis_mismatch
  prompt: >-
    Why do large EV-D68 respiratory waves not consistently produce parallel AFM
    peaks, and what host or viral determinants govern the rare paralytic outcome?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - epidemiology#United States surveillance since the 2018 peak
  - environmental#EV-D68 respiratory circulation and wastewater seasonality
  rationale: >-
    AFM counts remained low during the 2022 US EV-D68 circulation increase.
    Prospective linked respiratory, wastewater, genomic, host-immunologic, and
    neurologic surveillance is needed to distinguish viral genotype, prior
    immunity, ascertainment, and host susceptibility effects.
  evidence:
  - reference: PMID:38300829
    reference_title: "Surveillance for Acute Flaccid Myelitis - United States, 2018-2022."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It is unclear why EV-D68 circulation in 2022 was not associated with an increase in AFM cases"
    explanation: The national surveillance report states the mismatch directly.
  posed_date: "2026-07-20T00:00:00Z"
- discussion_id: afm_organoid_mouse_translation_limit
  prompt: >-
    Which immune and developmental features must be added to organoid and mouse
    systems to reproduce human AFM motor-neuron loss and recovery?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - experimental_models#Human iPSC-derived spinal cord organoids infected with EV-D68
  - animal_models#mouse
  rationale: >-
    Organoids show prolonged productive infection without appreciable cytopathy
    and lack a complete immune compartment. Mice are not native EV-D68 hosts and
    commonly require neonatal or modified conditions. These systems prove
    mechanistic capabilities but cannot determine the human balance between
    direct infection and immune-mediated injury.
  evidence:
  - reference: DOI:10.1128/mbio.01058-23
    reference_title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mice are not native hosts for EV-D68, and thus, existing mouse models use
      immunosuppressed or neonatal mice, mouse-adapted viruses, or intracranial
      inoculations.
    explanation: The organoid paper directly states key limitations of animal translation.
  posed_date: "2026-07-20T00:00:00Z"
review_notes: >-
  Comprehensive 2026 review corrected AFM identity and scope, replaced
  virus-associated pseudo-subtypes with infectious-agent relationships, and
  separated human association from experimental causation. The pathograph now
  connects infection, receptor-mediated entry, neural tropism, gray-matter and
  motor-neuron injury, lower-motor-neuron dysfunction, and every curated
  phenotype with typed, cited edges. MRI, CSF/virologic diagnosis, major
  differentials, long-term prognosis, supportive/rehabilitative/surgical care,
  experimental models, and surveillance uncertainty were audited.
references:
- reference: ORPHA:623801
  title: Acute flaccid myelitis
- reference: PMID:26621554
  title: Recognition and Management of Acute Flaccid Myelitis in Children.
- reference: PMID:27422805
  title: "Acute flaccid myelitis: A clinical review of US cases 2012-2015."
- reference: PMID:31014167
  title: "Acute Flaccid Myelitis Associated With Enterovirus D68: A Review."
- reference: PMID:31409689
  title: Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
- reference: PMID:32143233
  title: "Acute Flaccid Myelitis: A Clinical Review."
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
- reference: PMID:33357469
  title: "Acute flaccid myelitis: cause, diagnosis, and management."
- reference: PMID:36268734
  title: "Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019."
- reference: PMID:39163469
  title: Acute Flaccid Myelitis.
- reference: PMID:40132641
  title: MFSD6 is an entry receptor for enterovirus D68.
- reference: clinicaltrials:NCT02144935
  title: "Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study"
- reference: clinicaltrials:NCT03499366
  title: A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection.
- reference: DOI:10.15585/mmwr.mm7304a1
  title: "Surveillance for Acute Flaccid Myelitis - United States, 2018-2022"
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
- reference: PMID:38300829
  title: Surveillance for Acute Flaccid Myelitis - United States, 2018-2022.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: DOI:10.15585/mmwr.mm6931e3
  title: "<i>Vital Signs:</i> Clinical Characteristics of Patients with Confirmed Acute Flaccid Myelitis, United States, 2018"
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: DOI:10.3201/eid3003.231223
  title: Multimodal Surveillance Model for Enterovirus D68 Respiratory Disease and Acute Flaccid Myelitis among Children in Colorado, USA, 2022
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: DOI:10.1128/mbio.01058-23
  title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
- reference: PMID:37535397
  title: Contemporary enterovirus-D68 isolates infect human spinal cord organoids.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: DOI:10.1159/000535316
  title: A first case of acute flaccid myelitis related to enterovirus D-68 in Belgium
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: DOI:10.2106/JBJS.OA.23.00143
  title: Midterm Outcomes of Surgical Reconstruction and Spontaneous Recovery of Upper-Extremity Paralysis Following Acute Flaccid Myelitis
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
- reference: PMID:38774108
  title: Midterm Outcomes of Surgical Reconstruction and Spontaneous Recovery of Upper-Extremity Paralysis Following Acute Flaccid Myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: DOI:10.1016/j.pmr.2021.02.004
  title: Acute Flaccid Myelitis
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
- reference: PMID:37465770
  title: Acute Flaccid Myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: DOI:10.3390/children11091116
  title: Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: DOI:10.1177/0883073820975230
  title: "Acute Flaccid Myelitis: A Multidisciplinary Protocol to Optimize Diagnosis and Evaluation"
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: DOI:10.3389/fmicb.2025.1698639
  title: Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-falcon.md
- reference: PMID:26720027
  title: Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:28231269
  title: A mouse model of paralytic myelitis caused by enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:28424289
  title: Disruption of MDA5-Mediated Innate Immune Responses by the 3C Proteins of Coxsackievirus A16, Coxsackievirus A6, and Enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:28615421
  title: Outcomes of Colorado children with acute flaccid myelitis at 1 year.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:28968718
  title: Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:29385753
  title: A Mouse Model of Enterovirus D68 Infection for Assessment of the Efficacy of Inactivated Vaccine.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:30169722
  title: Acute flaccid myelitis-Clustering of polio-like illness in the tertiary care centre in Southern India.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:30503887
  title: A neonatal mouse model of Enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:30530701
  title: Molecular basis for the acid-initiated uncoating of human enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:30575890
  title: Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:30985511
  title: 'Incidence, Risk Factors and Outcomes Among Children With Acute Flaccid Myelitis: A Population-based Cohort Study in a California Health Network Between 2011 and 2016.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:31338675
  title: 'Acute flaccid myelitis and enterovirus D68: lessons from the past and present.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32178602
  title: Acute flaccid myelitis - has it gone unrecognised in Australian children?
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32192819
  title: Acute Flaccid Myelitis Among Hospitalized Children in Texas, 2016.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32492201
  title: 'Seroepidemiology of enterovirus D68 in a healthy population in Beijing, China, between 2012 and 2017: A retrospective study.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32677590
  title: 'Acute Flaccid Myelitis: A Single Pediatric Center Experience From 2014 to 2019.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32784424
  title: Mapping Attenuation Determinants in Enterovirus-D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32836175
  title: Cytokine biomarkers associated with clinical cases of acute flaccid myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:32951650
  title: 'The Utilization of Nerve Transfer for Reestablishing Shoulder Function in the Setting of Acute Flaccid Myelitis: A Single-Institution Review.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:33016189
  title: Recommendations for Therapy following Nerve Transfer for Children with Acute Flaccid Myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:33218883
  title: 'Acute flaccid myelitis outbreak through 2016-2018: A multicenter experience from Turkey.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:33388543
  title: Three-Year Longitudinal Motor Function and Disability Level of Acute Flaccid Myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:34170466
  title: Ectopic Expression of TRIM25 Restores RIG-I Expression and IFN Production Reduced by Multiple Enteroviruses 3C(pro).
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:34196272
  title: Respiratory and intestinal epithelial cells exhibit differential susceptibility and innate immune responses to contemporary EV-D68 isolates.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:34735423
  title: National Surveillance for Acute Flaccid Myelitis - United States, 2018-2020.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:34747551
  title: 'Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:36996587
  title: 'Pediatric acute flaccid myelitis: Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:37804367
  title: Insights into the molecular evolution of enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:37981447
  title: 'Nerve Transfer Surgery in Acute Flaccid Myelitis: Prognostic Factors, Long-Term Outcomes, Comparison With Natural History.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:38240591
  title: Enterovirus D68 3C protease antagonizes type I interferon signaling by cleaving signal transducer and activator of transcription 1.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:38405019
  title: 'A First Case of Acute Flaccid Myelitis Related to Enterovirus D68 in Belgium: Case Report.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:38547499
  title: Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:38815052
  title: 'Acute Flaccid Myelitis: Mid-Term Clinical Course of Knee Extension Paralysis and Outcomes of Nerve Transfer.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:38869283
  title: VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39110777
  title: A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39246649
  title: Enterovirus-D68 - A Reemerging Non-Polio Enterovirus that Causes Severe Respiratory and Neurological Disease in Children.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39332429
  title: Global age-stratified seroprevalence of enterovirus D68: a systematic literature review.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39459875
  title: STING Orchestrates EV-D68 Replication and Immunometabolism within Viral-Induced Replication Organelles.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39657203
  title: 'Pediatric Patients With Acute Flaccid Myelitis: Long-term Respiratory and Neurologic Outcomes.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:39933731
  title: 'Phrenic Nerve Reconstruction in Pediatric Diaphragm Paralysis: Outcomes and Techniques.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40042308
  title: The structural protein VP3 of enterovirus D68 interacts with MAVS to inhibit the NF-κB signaling pathway.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40431685
  title: Return of the Biennial Circulation of Enterovirus D68 in Colorado Children in 2024 Following the Large 2022 Outbreak.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40444374
  title: 'Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40492725
  title: Enhanced genomic surveillance of enteroviruses reveals a surge in enterovirus D68 cases, the Johns Hopkins health system, Maryland, 2024.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40593720
  title: A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40622703
  title: 'West Nile Virus: A Review.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40661021
  title: '[Genomic characterization of a case of enterovirus D68 infection in a child from Tongzhou District, Beijing City].'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:40701343
  title: ARRDC3 promotes lysosome-mediated YAP degradation to inhibit enterovirus replication.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41138534
  title: 'Evolving Features of Acute Flaccid Myelitis After COVID-19: A Four-Case Series.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41175053
  title: 'Enterovirus D68: A Novel Inhibitor Reveals Underlying Molecular Mechanisms of Viral Entry and Uncoating.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41205525
  title: Matrine activates high xenophagy to inhibit enterovirus replication.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41210583
  title: mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41251130
  title: Efficacy and Safety of Plasmapheresis in Children With Acute Transverse or Flaccid Myelitis, and Guillain-Barré Syndrome.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41305500
  title: 'Spinal Cord Injury in Enterovirus D68 Infection: Mechanisms and Pathophysiology in a Mouse Model.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41352537
  title: Ubiquitin-specific protease 5 promotes EV-A71 replication by de-ubiquitinating MAVS and IRF3.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41410465
  title: 'Environmental surveillance reveals enterovirus diversity in Jinan, China: detection of types D68, A71, A76, B88, A90, and C99.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41467840
  title: 'Enterovirus D68 receptor usage: from static attachment to dynamic entry.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41483695
  title: 'Designing of a multi-epitope vaccine targeting enterovirus D68: An integrated immunoinformatic and reverse vaccinology approach.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41485562
  title: An orally available peptidomimetic with broad-spectrum antiviral activity targeting the enterovirus 2C helicase.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41600837
  title: 'Enterovirus D68 Sequence Variations and Pathogenicity: A Review.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41621223
  title: New fluoxetine analogues as anti-enterovirus agents targeting 2C protein.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41650963
  title: Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41667472
  title: Rational design and in vivo validation of capsid inhibitors for enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41853773
  title: 'Enterovirus D68 in United States wastewater: a longitudinal surveillance study integrating climatic, demographic, and clinical data.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41868141
  title: 'Respiratory enterovirus D68: virology, clinical surveillance, host-pathogen interactions, and therapeutic prospects.'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41964219
  title: An RNA-to-RNA pipeline for rapid antiviral antibody development.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:41986256
  title: Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42018625
  title: Enterovirus-induced cleavage of Mitofusin 2 generates mitophagosomes for enveloped virion release.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42037410
  title: EV-D68 exploits clathrin-mediated endocytosis and compensatory macropinocytosis for cellular entry.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42037414
  title: Enterovirus D68 B3 clade strains are efficiently recovered from cDNA infectious clones in 293T cells and infect human spinal cord organoids.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42063851
  title: Rational Design of Capsid Protein VP1 Degraders to Overcome Pleconaril Resistance in Inhibiting Enterovirus D68.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42066114
  title: 'Enterovirus D68 and Acute Neurologic Outcomes: A Systematic Review and Meta-Analysis (2010-2025).'
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
- reference: PMID:42086005
  title: Propagation and immunological characterization of three enterovirus D68 strains using serum-free HEK293A suspension cell culture.
  found_in:
  - Acute_Flaccid_Myelitis-deep-research-openscientist.md
  findings: []
📚

References & Deep Research

References

99
Acute flaccid myelitis
No top-level findings curated for this source.
Recognition and Management of Acute Flaccid Myelitis in Children.
No top-level findings curated for this source.
Acute flaccid myelitis: A clinical review of US cases 2012-2015.
No top-level findings curated for this source.
Acute Flaccid Myelitis Associated With Enterovirus D68: A Review.
No top-level findings curated for this source.
Antibodies to Enteroviruses in Cerebrospinal Fluid of Patients with Acute Flaccid Myelitis.
No top-level findings curated for this source.
Acute Flaccid Myelitis: A Clinical Review.
No top-level findings curated for this source.
Acute flaccid myelitis: cause, diagnosis, and management.
No top-level findings curated for this source.
Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019.
No top-level findings curated for this source.
Acute Flaccid Myelitis.
No top-level findings curated for this source.
MFSD6 is an entry receptor for enterovirus D68.
No top-level findings curated for this source.
Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study
No top-level findings curated for this source.
A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection.
No top-level findings curated for this source.
Surveillance for Acute Flaccid Myelitis - United States, 2018-2022
No top-level findings curated for this source.
Surveillance for Acute Flaccid Myelitis - United States, 2018-2022.
No top-level findings curated for this source.
<i>Vital Signs:</i> Clinical Characteristics of Patients with Confirmed Acute Flaccid Myelitis, United States, 2018
No top-level findings curated for this source.
Multimodal Surveillance Model for Enterovirus D68 Respiratory Disease and Acute Flaccid Myelitis among Children in Colorado, USA, 2022
No top-level findings curated for this source.
Contemporary enterovirus-D68 isolates infect human spinal cord organoids
No top-level findings curated for this source.
Contemporary enterovirus-D68 isolates infect human spinal cord organoids.
No top-level findings curated for this source.
A first case of acute flaccid myelitis related to enterovirus D-68 in Belgium
No top-level findings curated for this source.
Midterm Outcomes of Surgical Reconstruction and Spontaneous Recovery of Upper-Extremity Paralysis Following Acute Flaccid Myelitis
No top-level findings curated for this source.
Midterm Outcomes of Surgical Reconstruction and Spontaneous Recovery of Upper-Extremity Paralysis Following Acute Flaccid Myelitis.
No top-level findings curated for this source.
Acute Flaccid Myelitis
No top-level findings curated for this source.
Acute Flaccid Myelitis.
No top-level findings curated for this source.
Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis
No top-level findings curated for this source.
Acute Flaccid Myelitis: A Multidisciplinary Protocol to Optimize Diagnosis and Evaluation
No top-level findings curated for this source.
Strain-specific tropism and transcriptional responses of enterovirus D68 infection in human spinal cord organoids
No top-level findings curated for this source.
Acute Flaccid Myelitis of Unknown Etiology in California, 2012-2015.
No top-level findings curated for this source.
A mouse model of paralytic myelitis caused by enterovirus D68.
No top-level findings curated for this source.
Disruption of MDA5-Mediated Innate Immune Responses by the 3C Proteins of Coxsackievirus A16, Coxsackievirus A6, and Enterovirus D68.
No top-level findings curated for this source.
Outcomes of Colorado children with acute flaccid myelitis at 1 year.
No top-level findings curated for this source.
Evaluating Treatment Efficacy in a Mouse Model of Enterovirus D68-Associated Paralytic Myelitis.
No top-level findings curated for this source.
A Mouse Model of Enterovirus D68 Infection for Assessment of the Efficacy of Inactivated Vaccine.
No top-level findings curated for this source.
Acute flaccid myelitis-Clustering of polio-like illness in the tertiary care centre in Southern India.
No top-level findings curated for this source.
A neonatal mouse model of Enterovirus D68 infection induces both interstitial pneumonia and acute flaccid myelitis.
No top-level findings curated for this source.
Molecular basis for the acid-initiated uncoating of human enterovirus D68.
No top-level findings curated for this source.
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
No top-level findings curated for this source.
Incidence, Risk Factors and Outcomes Among Children With Acute Flaccid Myelitis: A Population-based Cohort Study in a California Health Network Between 2011 and 2016.
No top-level findings curated for this source.
Acute flaccid myelitis and enterovirus D68: lessons from the past and present.
No top-level findings curated for this source.
Acute flaccid myelitis - has it gone unrecognised in Australian children?
No top-level findings curated for this source.
Acute Flaccid Myelitis Among Hospitalized Children in Texas, 2016.
No top-level findings curated for this source.
Seroepidemiology of enterovirus D68 in a healthy population in Beijing, China, between 2012 and 2017: A retrospective study.
No top-level findings curated for this source.
Acute Flaccid Myelitis: A Single Pediatric Center Experience From 2014 to 2019.
No top-level findings curated for this source.
Mapping Attenuation Determinants in Enterovirus-D68.
No top-level findings curated for this source.
Cytokine biomarkers associated with clinical cases of acute flaccid myelitis.
No top-level findings curated for this source.
The Utilization of Nerve Transfer for Reestablishing Shoulder Function in the Setting of Acute Flaccid Myelitis: A Single-Institution Review.
No top-level findings curated for this source.
Recommendations for Therapy following Nerve Transfer for Children with Acute Flaccid Myelitis.
No top-level findings curated for this source.
Acute flaccid myelitis outbreak through 2016-2018: A multicenter experience from Turkey.
No top-level findings curated for this source.
Three-Year Longitudinal Motor Function and Disability Level of Acute Flaccid Myelitis.
No top-level findings curated for this source.
Ectopic Expression of TRIM25 Restores RIG-I Expression and IFN Production Reduced by Multiple Enteroviruses 3C(pro).
No top-level findings curated for this source.
Respiratory and intestinal epithelial cells exhibit differential susceptibility and innate immune responses to contemporary EV-D68 isolates.
No top-level findings curated for this source.
National Surveillance for Acute Flaccid Myelitis - United States, 2018-2020.
No top-level findings curated for this source.
Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria.
No top-level findings curated for this source.
Pediatric acute flaccid myelitis: Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis.
No top-level findings curated for this source.
Insights into the molecular evolution of enterovirus D68.
No top-level findings curated for this source.
Nerve Transfer Surgery in Acute Flaccid Myelitis: Prognostic Factors, Long-Term Outcomes, Comparison With Natural History.
No top-level findings curated for this source.
Enterovirus D68 3C protease antagonizes type I interferon signaling by cleaving signal transducer and activator of transcription 1.
No top-level findings curated for this source.
A First Case of Acute Flaccid Myelitis Related to Enterovirus D68 in Belgium: Case Report.
No top-level findings curated for this source.
Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.
No top-level findings curated for this source.
Acute Flaccid Myelitis: Mid-Term Clinical Course of Knee Extension Paralysis and Outcomes of Nerve Transfer.
No top-level findings curated for this source.
VP1 is the primary determinant of neuropathogenesis in a mouse model of enterovirus D68 acute flaccid myelitis.
No top-level findings curated for this source.
A self-amplifying RNA vaccine prevents enterovirus D68 infection and disease in preclinical models.
No top-level findings curated for this source.
Enterovirus-D68 - A Reemerging Non-Polio Enterovirus that Causes Severe Respiratory and Neurological Disease in Children.
No top-level findings curated for this source.
Global age-stratified seroprevalence of enterovirus D68: a systematic literature review.
No top-level findings curated for this source.
STING Orchestrates EV-D68 Replication and Immunometabolism within Viral-Induced Replication Organelles.
No top-level findings curated for this source.
Pediatric Patients With Acute Flaccid Myelitis: Long-term Respiratory and Neurologic Outcomes.
No top-level findings curated for this source.
Phrenic Nerve Reconstruction in Pediatric Diaphragm Paralysis: Outcomes and Techniques.
No top-level findings curated for this source.
The structural protein VP3 of enterovirus D68 interacts with MAVS to inhibit the NF-κB signaling pathway.
No top-level findings curated for this source.
Return of the Biennial Circulation of Enterovirus D68 in Colorado Children in 2024 Following the Large 2022 Outbreak.
No top-level findings curated for this source.
Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration.
No top-level findings curated for this source.
Enhanced genomic surveillance of enteroviruses reveals a surge in enterovirus D68 cases, the Johns Hopkins health system, Maryland, 2024.
No top-level findings curated for this source.
A rationally designed 2C inhibitor prevents enterovirus D68-infected mice from developing paralysis.
No top-level findings curated for this source.
West Nile Virus: A Review.
No top-level findings curated for this source.
[Genomic characterization of a case of enterovirus D68 infection in a child from Tongzhou District, Beijing City].
No top-level findings curated for this source.
ARRDC3 promotes lysosome-mediated YAP degradation to inhibit enterovirus replication.
No top-level findings curated for this source.
Evolving Features of Acute Flaccid Myelitis After COVID-19: A Four-Case Series.
No top-level findings curated for this source.
Enterovirus D68: A Novel Inhibitor Reveals Underlying Molecular Mechanisms of Viral Entry and Uncoating.
No top-level findings curated for this source.
Matrine activates high xenophagy to inhibit enterovirus replication.
No top-level findings curated for this source.
mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection.
No top-level findings curated for this source.
Efficacy and Safety of Plasmapheresis in Children With Acute Transverse or Flaccid Myelitis, and Guillain-Barré Syndrome.
No top-level findings curated for this source.
Spinal Cord Injury in Enterovirus D68 Infection: Mechanisms and Pathophysiology in a Mouse Model.
No top-level findings curated for this source.
Ubiquitin-specific protease 5 promotes EV-A71 replication by de-ubiquitinating MAVS and IRF3.
No top-level findings curated for this source.
Environmental surveillance reveals enterovirus diversity in Jinan, China: detection of types D68, A71, A76, B88, A90, and C99.
No top-level findings curated for this source.
Enterovirus D68 receptor usage: from static attachment to dynamic entry.
No top-level findings curated for this source.
Designing of a multi-epitope vaccine targeting enterovirus D68: An integrated immunoinformatic and reverse vaccinology approach.
No top-level findings curated for this source.
An orally available peptidomimetic with broad-spectrum antiviral activity targeting the enterovirus 2C helicase.
No top-level findings curated for this source.
Enterovirus D68 Sequence Variations and Pathogenicity: A Review.
No top-level findings curated for this source.
New fluoxetine analogues as anti-enterovirus agents targeting 2C protein.
No top-level findings curated for this source.
Mechanosensation promotes broad-spectrum antiviral defense through membrane remodeling.
No top-level findings curated for this source.
Rational design and in vivo validation of capsid inhibitors for enterovirus D68.
No top-level findings curated for this source.
Enterovirus D68 in United States wastewater: a longitudinal surveillance study integrating climatic, demographic, and clinical data.
No top-level findings curated for this source.
Respiratory enterovirus D68: virology, clinical surveillance, host-pathogen interactions, and therapeutic prospects.
No top-level findings curated for this source.
An RNA-to-RNA pipeline for rapid antiviral antibody development.
No top-level findings curated for this source.
Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014-2024.
No top-level findings curated for this source.
Enterovirus-induced cleavage of Mitofusin 2 generates mitophagosomes for enveloped virion release.
No top-level findings curated for this source.
EV-D68 exploits clathrin-mediated endocytosis and compensatory macropinocytosis for cellular entry.
No top-level findings curated for this source.
Enterovirus D68 B3 clade strains are efficiently recovered from cDNA infectious clones in 293T cells and infect human spinal cord organoids.
No top-level findings curated for this source.
Rational Design of Capsid Protein VP1 Degraders to Overcome Pleconaril Resistance in Inhibiting Enterovirus D68.
No top-level findings curated for this source.
Enterovirus D68 and Acute Neurologic Outcomes: A Systematic Review and Meta-Analysis (2010-2025).
No top-level findings curated for this source.
Propagation and immunological characterization of three enterovirus D68 strains using serum-free HEK293A suspension cell culture.
No top-level findings curated for this source.

Deep Research

2
Falcon
Acute Flaccid Myelitis (AFM) — Comprehensive Disease Characteristics Report
Edison Scientific Literature 39 citations 2026-05-16T10:49:58.498717

Acute Flaccid Myelitis (AFM) — Comprehensive Disease Characteristics Report

Target disease: Acute flaccid myelitis (AFM)

Summary (current understanding): AFM is a rare, severe neurologic syndrome (often pediatric) characterized by acute flaccid limb weakness with spinal cord gray-matter–predominant lesions on MRI, clinically resembling poliomyelitis. In the United States, AFM incidence showed large peaks in 2014/2016/2018 and remained lower in 2019–2022, despite renewed EV-D68 circulation in 2022 without a commensurate AFM surge, emphasizing unresolved determinants of neuroinvasion and paralytic risk. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2, messacar2024multimodalsurveillancemodel pages 3-5)


1. Disease Information

1.1 Disease overview and definition

CDC surveillance definitions used in recent U.S. reports define confirmed AFM as acute flaccid limb weakness with MRI demonstrating a spinal cord lesion largely restricted to gray matter spanning ≥1 vertebral segment. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2)

A recent European case report restates the CDC framing as “an acute-onset flaccid weakness of one or more limbs” with MRI evidence of gray-matter involvement and no clear alternative diagnosis. (rodesch2024afirstcase pages 1-3)

1.2 Key identifiers

  • MONDO ID: Not available from the retrieved evidence set (not found in the sources accessed for this report).
  • ICD/MeSH/Orphanet/OMIM: Not available from the retrieved evidence set.

1.3 Synonyms and alternative names

  • AFM is repeatedly described as “poliomyelitis-like” or “polio-like” paralysis/illness in clinical and rehabilitation literature. (doi2024midtermoutcomesof pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 1-2)
  • Related umbrella term: acute flaccid paralysis (AFP); AFM can be considered AFP with spinal cord gray-matter myelitis. (rodesch2024afirstcase pages 3-5)

1.4 Evidence source type (individual vs aggregated)

This report integrates both: * Aggregated public-health surveillance/clinical series (CDC MMWR surveillance; Colorado multimodal surveillance; surgical cohort; rehabilitation case series). (whitehouse2024surveillanceforacute pages 1-2, messacar2024multimodalsurveillancemodel pages 3-5, doi2024midtermoutcomesof pages 1-2, neighbors2024transcutaneousspinalcord pages 5-8) * Individual patient-level case report (Belgium EV-D68-associated AFM). (rodesch2024afirstcase pages 1-3)


2. Etiology

2.1 Disease causal factors

Infectious association (dominant current model): AFM is strongly associated with non-polio enteroviruses, particularly enterovirus D68 (EV-D68), based on epidemiologic correlation with outbreak years and frequent detection in non-sterile sites (especially respiratory specimens), while pathogen detection in CSF is uncommon. (murphy2021acuteflaccidmyelitis pages 1-2, kidd2020vitalsignsclinical pages 1-2, whitehouse2024surveillanceforacute pages 1-2)

CDC surveillance indicates that AFM peaks (2014/2016/2018) were linked to EV-D68 circulation, while post-2018 counts remained low; reasons remain uncertain. (whitehouse2024surveillanceforacute pages 1-2)

Multi-pathogen reality: Non–EV-D68 enteroviruses have also been identified in confirmed AFM patients (e.g., EV-A71 and other enteroviruses/echoviruses/cox­sackie types), and coinfections can occur. (whitehouse2024surveillanceforacute pages 5-6, whitehouse2024surveillanceforacute pages 6-7)

2.2 Risk factors (supported by recent surveillance)

  • Age: AFM predominates in children; e.g., in the U.S. 2018 peak year, 94% of confirmed cases were <18 years, with median age 5.3 years. (whitehouse2024surveillanceforacute pages 4-5)
  • Seasonality: In 2018, 86% of U.S. confirmed cases had onset during August–November. (kidd2020vitalsignsclinical pages 1-2)
  • Recent febrile/respiratory prodrome: In 2018, 92% reported prodromal fever and/or respiratory illness, beginning a median of 6 days before weakness onset. (kidd2020vitalsignsclinical pages 1-2)

2.3 Protective factors

No validated genetic or environmental protective factors were identified in the retrieved evidence set.

2.4 Gene–environment interactions

No specific, reproducible gene–environment interaction evidence was identified in the retrieved evidence set.


3. Phenotypes

3.1 Core neurologic phenotype

Acute limb weakness/paralysis is the defining clinical phenotype. CDC describes AFM as “characterized by the acute onset of limb weakness or paralysis.” (kidd2020vitalsignsclinical pages 1-2)

Distribution of weakness varies by outbreak year: In the U.S. 2018 peak year, upper limb involvement was common (84%), while later years showed relatively more lower limb involvement and lower rates of classic peak-year features. (whitehouse2024surveillanceforacute pages 4-5, whitehouse2024surveillanceforacute pages 1-2)

3.2 Common symptoms/signs during evaluation (example: U.S. 2018)

In 2018 confirmed U.S. cases, common findings included: * Gait difficulty: 52% * Neck or back pain: 47% * Fever at evaluation: 35% * Limb pain: 34% (kidd2020vitalsignsclinical pages 1-2)

3.3 Laboratory phenotype

CSF pleocytosis is common in peak-year AFM, with year-to-year variation; CDC surveillance reports CSF pleocytosis of 87% in 2018 (183/210) versus 42–49% in 2019–2021 and 68% in 2022 (28/41). (whitehouse2024surveillanceforacute pages 4-5)

3.4 Quality-of-life impact

AFM is associated with high morbidity and incomplete neurologic recovery, with long-term disability common in clinical reviews and cohort summaries. (murphy2021acuteflaccidmyelitis pages 1-2, vawterlee2021acuteflaccidmyelitis pages 2-3)

3.5 Suggested HPO terms (candidate mappings)

The retrieved evidence supports, at minimum: * Acute flaccid paralysis / acute limb weakness (HP:0002015 or conceptually similar) * Gait disturbance (HP:0001288) * Neck pain / back pain (HP:0000467 / HP:0003418) * Respiratory failure / need for mechanical ventilation (HP:0002878) * CSF pleocytosis (HP:0002180)

(Note: HPO identifiers are provided as common standard mappings; confirm exact HPO IDs/labels in the current HPO release before database ingestion.)


4. Genetic/Molecular Information

4.1 Causal genes / pathogenic variants

AFM is not established as a monogenic disorder in the retrieved evidence set; the dominant evidence supports an infectious-triggered neuroinflammatory/anterior horn cell injury syndrome rather than a single-gene etiology. (murphy2021acuteflaccidmyelitis pages 1-2)

4.2 Modifier genes / host susceptibility

No specific host genetic modifiers were identified in the retrieved evidence set.

4.3 Epigenetics / chromosomal abnormalities

No AFM-specific epigenetic or chromosomal-abnormality evidence was identified in the retrieved evidence set.


5. Environmental Information

5.1 Infectious agents (primary environmental exposure)

Enteroviruses, particularly EV-D68, are the best-supported associated infectious agents across surveillance and mechanistic modeling. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 1-2)

5.2 Other environmental/lifestyle factors

No toxin/radiation/pollution or lifestyle risk factor evidence was identified in the retrieved evidence set.


6. Mechanism / Pathophysiology

6.1 Current mechanistic model (causal chain)

1) Preceding viral illness (often respiratory/febrile) occurs days before neurologic onset in many peak-year cases. (kidd2020vitalsignsclinical pages 1-2) 2) Neurotropic infection and/or immune-mediated injury targets spinal cord gray matter (anterior horn/motor neuron regions), producing the MRI signature and motor deficits. (whitehouse2024surveillanceforacute pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 1-2) 3) Secondary immune-mediated injury is likely important: Human spinal cord organoid data show sustained EV-D68 infection with limited cytopathic effects, implying that infection alone may not explain neuronal loss in vivo.

6.2 Human spinal cord organoid evidence (recent development)

Aguglia et al. (mBio, 2023-08) emphasize the need for human CNS models because “humans are the only natural hosts for enterovirus infections” and enteroviruses “do not routinely infect other animal species.” (aguglia2023contemporaryenterovirusd68isolates pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 5-8)

Key findings from the organoid model: * Strain specificity: Contemporary (post-2014) EV-D68 isolates infect spinal cord organoids, whereas a historic strain (Fermon) does not productively infect. (aguglia2023contemporaryenterovirusd68isolates pages 2-5, aguglia2023contemporaryenterovirusd68isolates pages 5-8) * Persistence without marked lysis: Infected organoids “produce extracellular virus for at least 2 weeks without appreciable cytopathic effect” and maintain morphology, with less apoptosis than a comparator enterovirus (echovirus 11). (aguglia2023contemporaryenterovirusd68isolates pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 8-10) * Immune contribution hypothesis: The authors note that in vitro models lack migratory innate/adaptive immune cells and that this limitation may allow persistence without the injury patterns seen in vivo, supporting a role for immune-mediated secondary damage in AFM. (aguglia2023contemporaryenterovirusd68isolates pages 8-10, aguglia2023contemporaryenterovirusd68isolates pages 10-12)

6.3 Suggested ontology mappings

  • UBERON (anatomy): spinal cord (UBERON:0002240); cervical spinal cord (UBERON:0002726); anterior horn/ventral gray matter region (concept-level mapping) (rodesch2024afirstcase pages 1-3)
  • CL (cell types): spinal motor neuron (CL:0000100); astrocyte (CL:0000127); oligodendrocyte precursor cell (CL:0002453) as relevant to organoid and EV-D68 tropism work (aguglia2023contemporaryenterovirusd68isolates pages 2-5, dabilla2025strainspecifictropismand pages 9-10)
  • GO biological processes (candidates): neuroinflammatory response; leukocyte chemotaxis; motor neuron apoptotic process; response to virus; cytokine-mediated signaling pathway (supported conceptually by immune/viral pathogenesis framing and apoptosis/cytokine discussion in organoid work) (aguglia2023contemporaryenterovirusd68isolates pages 8-10)

7. Anatomical Structures Affected

7.1 Organ/system level

  • Primary system: Central nervous system—spinal cord, particularly gray matter involvement on MRI; often cervical cord involvement reported in case literature. (whitehouse2024surveillanceforacute pages 1-2, rodesch2024afirstcase pages 1-3)
  • Secondary/complications: Respiratory failure requiring ventilatory support is common in severe cases. (whitehouse2024surveillanceforacute pages 5-6, kidd2020vitalsignsclinical pages 1-2)

7.2 Tissue/cell level

  • Spinal cord gray matter and motor neuron regions are implicated by imaging criteria and neuroanatomic pattern (anterior horn–predominant lesions). (whitehouse2024surveillanceforacute pages 1-2, vawterlee2021acuteflaccidmyelitis pages 2-3)

8. Temporal Development

8.1 Onset and course

  • Onset pattern: Acute/subacute, with rapid progression over days; peak-year cases often follow a viral prodrome by ~1 week. (kidd2020vitalsignsclinical pages 1-2, rodesch2024afirstcase pages 3-5)

8.2 Recovery window

Rehabilitation literature indicates recovery is often incomplete; functional gains are most robust in the first year but can continue to ~18 months, with persistent proximal weakness/atrophy common. (ide2021acuteflaccidmyelitis. pages 11-13)


9. Inheritance and Population

9.1 Epidemiology (recent statistics)

United States (CDC surveillance): * Confirmed AFM cases: 238 (2018); 47 (2019); 33 (2020); 28 (2021); 47 (2022). (whitehouse2024surveillanceforacute pages 1-2)

U.S. 2018 clinical severity: * 98% hospitalized, 54% ICU, 23% required intubation/mechanical ventilation. (kidd2020vitalsignsclinical pages 1-2)

Colorado 2022 (EV-D68 outbreak monitoring + AFM burden): * Among 529 EV/RV-positive respiratory specimens tested, 121 (22.9%) were EV-D68-positive, peaking at 78.6% weekly positivity in late August 2022. (messacar2024multimodalsurveillancemodel pages 3-5) * AFM remained uncommon during this EV-D68 respiratory outbreak (Colorado CDC-classified suspected AFM cases in 2022: 4, versus 17 in 2018). (messacar2024multimodalsurveillancemodel pages 5-7)

9.2 Sex ratio and geographic distribution

Not available from the retrieved evidence set.


10. Diagnostics

10.1 Diagnostic criteria (CDC-based)

  • Clinical: acute onset flaccid limb weakness.
  • Imaging: MRI spinal lesion predominantly in gray matter spanning ≥1 vertebral segment. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2)

10.2 Imaging findings

  • MRI hallmark: spinal cord gray-matter–predominant lesions, often longitudinally extensive early.
  • Example case (Belgium, EV-D68-associated): cervical cord central gray matter T2 hyperintensity (C2–C7) with posterior brainstem involvement. (rodesch2024afirstcase pages 1-3)

10.3 CSF and virologic testing

  • CSF pleocytosis is common in peak-year cases (e.g., 87% in 2018 in CDC surveillance summaries). (whitehouse2024surveillanceforacute pages 4-5)
  • Etiologic agent detection is typically from non-sterile sites (respiratory/stool) rather than CSF; CDC notes EV/RV RT-PCR often requires sequencing for typing because assays may not distinguish EVs from rhinoviruses without additional testing. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2)

10.4 Electrodiagnostics (EMG/NCS)

Rehabilitation review describes a pattern consistent with motor neuronopathy/neuropathy with relative preservation of sensory conduction in most cases. (ide2021acuteflaccidmyelitis. pages 11-13)

10.5 Differential diagnosis

A complete differential is not enumerated in the retrieved evidence set; however, case and protocol literature emphasizes the need for prompt workup to distinguish AFM from other causes of acute flaccid paralysis. (rodesch2024afirstcase pages 1-3, vawterlee2021acuteflaccidmyelitis pages 2-3)


11. Outcome / Prognosis

11.1 Short-term severity (hospital course)

Across U.S. surveillance summaries (2018–2022), severe disease was frequent: ICU admission 54%, respiratory support 27%, mechanical ventilation 23%. (whitehouse2024surveillanceforacute pages 5-6)

11.2 Long-term disability and recovery

AFM frequently results in incomplete recovery and long-term sequelae (residual weakness, atrophy, and other neurological/musculoskeletal impacts), as summarized in a major clinical review. (murphy2021acuteflaccidmyelitis pages 1-2)

Case-level prognosis can be poor: the Belgium EV-D68-associated case had persistent proximal arm paresis with shoulder atrophy years later (as summarized in the report excerpt), and authors emphasize poor functional prognosis. (rodesch2024afirstcase pages 3-5)

11.3 Prognostic factor example (upper extremity)

In a surgical referral cohort, “none of the patients with M0 shoulder abduction at the 6-month evaluation recovered M1 or better”, supporting the use of 6-month post-onset strength as a decision point for surgical reconstruction consideration. (doi2024midtermoutcomesof pages 12-13, doi2024midtermoutcomesof pages 11-12)


12. Treatment

12.1 Acute pharmacologic/immunomodulatory therapies (current practice; evidence gaps)

CDC surveillance documents real-world use (not efficacy) of: * Steroids alone: 23% * IVIG alone: 23% * Steroids + IVIG: 34% * Plasma exchange (PLEX): 13% (whitehouse2024surveillanceforacute pages 5-6)

Case literature emphasizes absence of evidence-based guidelines and that management is largely supportive, with controversial corticosteroid use and variable IVIG response. (rodesch2024afirstcase pages 3-5)

Suggested MAXO terms (candidates): intravenous immunoglobulin therapy; therapeutic plasma exchange; systemic corticosteroid therapy; supportive respiratory care.

12.2 Rehabilitation and real-world implementations (including 2024 innovations)

Comprehensive rehabilitation is consistently emphasized as central to functional improvement and quality of life, even without proven disease-modifying therapy. (murphy2021acuteflaccidmyelitis pages 1-2, ide2021acuteflaccidmyelitis. pages 11-13)

2024 development—neuromodulation-assisted gait rehab: A 4-child case series used transcutaneous spinal cord stimulation (TSS) paired with intensive gait training (22 sessions over 5–8 weeks). Feasibility/safety: 98.48% session completion and no significant adverse events; walking endurance improved (6MWT increased by +98.3 m, +68 m, +9.4 m, +49.4 m; 3/4 exceeded MCID). (neighbors2024transcutaneousspinalcord pages 5-8, neighbors2024transcutaneousspinalcord pages 1-2)

Suggested MAXO terms (candidates): physical therapy; gait training; transcutaneous spinal cord stimulation; body-weight–supported treadmill training.

12.3 Surgical and interventional management

A 2024 cohort study reports nerve transfers, muscle/tendon transfers, and free muscle transfers for persistent deficits; elbow and hand reconstructions showed more consistent outcomes than shoulder reconstructions. (doi2024midtermoutcomesof pages 1-2)

Suggested MAXO terms (candidates): nerve transfer surgery; tendon transfer; free functional muscle transfer; orthopedic reconstruction.

12.4 Clinical trials / registries

NCT03499366 (ClinicalTrials.gov; first posted 2018-04-17; last update posted 2018-05-11): European pediatric AFM-EV-D68 follow-up study targeting ~40 participants with EV-D68 PCR positivity and MRI-confirmed myelitis, assessing functional outcomes including Hammersmith Functional Motor Scale at 1–3 years and secondary outcomes including ventilator/ICU days and quality of life. (NCT03499366 chunk 1)


13. Prevention

13.1 Primary prevention

No licensed EV-D68 vaccine or AFM-specific preventive therapy is supported in the retrieved evidence set; prevention is currently focused on public health surveillance/early warning and infection control during enterovirus circulation periods. (rodesch2024afirstcase pages 3-5, messacar2024multimodalsurveillancemodel pages 3-5)

13.2 Public health implementations (2024 evidence)

A 2024 Colorado program illustrates multimodal surveillance (syndromic ED asthma visits, EV-D68 RT-PCR confirmation, wastewater testing) enabling real-time preparedness actions including provider outreach and surge planning. (messacar2024multimodalsurveillancemodel pages 7-8, messacar2024multimodalsurveillancemodel pages 3-5)


14. Other Species / Natural Disease

No naturally occurring non-human AFM equivalent was identified in the retrieved evidence set.


15. Model Organisms

15.1 Human organoid models (high relevance to AFM)

Human spinal cord organoids provide a multicellular CNS model for EV-D68 neurotropism; contemporary EV-D68 strains infect and persist with modest cytopathic effect, supporting investigation of immune-mediated injury mechanisms and antiviral testing. (aguglia2023contemporaryenterovirusd68isolates pages 1-2, aguglia2023contemporaryenterovirusd68isolates pages 8-10)

15.2 Animal models (limited detail in retrieved evidence)

The organoid paper notes limitations of mouse models (often requiring neonatal or immunosuppressed mice, intracranial inoculation, or mouse-adapted viruses), reinforcing why complementary human models are needed. (aguglia2023contemporaryenterovirusd68isolates pages 1-2)


Key evidence table

Topic/Section Key finding (with key numbers) Population/Setting Year Source (first author, journal) PMID if available URL
Surveillance / epidemiology U.S. confirmed AFM cases: 238 in 2018; then 47 (2019), 33 (2020), 28 (2021), 47 (2022). Confirmed AFM requires acute flaccid limb weakness plus MRI spinal cord lesion largely restricted to gray matter spanning ≥1 vertebral segment. 2018 cases were 94% aged <18 years; median age 5.3 years. ICU admission 54%, respiratory support 27%, mechanical ventilation 23%. EV-D68 detected in 37 cases in 2018; lower in later years. (whitehouse2024surveillanceforacute pages 1-2, whitehouse2024surveillanceforacute pages 5-6, whitehouse2024surveillanceforacute pages 4-5) United States national AFM surveillance, 2018–2022 2024 Whitehouse, MMWR https://www.cdc.gov/mmwr/volumes/73/ss/ss7304a1.htm
Clinical characteristics Among 238 confirmed AFM patients in 2018, median age was 5.3 years; 86% had onset during Aug–Nov; 92% had prodromal fever/respiratory illness beginning median 6 days before weakness; common findings: gait difficulty 52%, neck/back pain 47%, limb pain 34%; 98% hospitalized, 54% ICU, 23% intubated/mechanically ventilated. (kidd2020vitalsignsclinical pages 1-2) United States confirmed AFM patients during 2018 peak year 2020 Kidd, MMWR https://doi.org/10.15585/mmwr.mm6931e3
Recent surveillance development Multimodal Colorado EV-D68/AFM surveillance combined syndromic, clinical PCR, and wastewater data. From Jun 15–Nov 3, 2022, 529 EV/RV-positive respiratory specimens were tested and 121/529 (22.9%) were EV-D68-positive; peak weekly positivity 78.6% in late Aug 2022. Wastewater detection preceded the syndromic alarm by ~1 month/1–2 weeks depending on analytic layer. Colorado had 4 suspected AFM cases in 2022 versus 17 in 2018. (messacar2024multimodalsurveillancemodel pages 5-7, messacar2024multimodalsurveillancemodel pages 3-5, messacar2024multimodalsurveillancemodel pages 7-8) Colorado, USA pediatric hospital/public-health surveillance during 2022 EV-D68 outbreak 2024 Messacar, Emerging Infectious Diseases https://doi.org/10.3201/eid3003.231223
Etiology / overall review AFM is strongly associated with non-polio enteroviruses, especially EV-D68; direct virus detection in CSF is uncommon, but epidemiology, animal models, and CSF antibody studies support causality. Long-term recovery is often incomplete with residual weakness, atrophy, and neurologic/musculoskeletal sequelae; rehabilitation and selected nerve-transfer surgery may improve function. (murphy2021acuteflaccidmyelitis pages 1-2) International review of human clinical, laboratory, and model-organism evidence 2021 Murphy, The Lancet https://doi.org/10.1016/S0140-6736(20)32723-9
Rehabilitation / outcomes AFM rehab review notes electrodiagnostics usually show motor neuronopathy/neuropathy with preserved sensory conduction. Recovery is often poor; some series reported full recovery in only 10% or 41%. Greatest recovery generally occurs within 12 months, but gains may continue to 18 months. Supportive multidisciplinary rehab, ABRT, ventilatory management, diaphragmatic pacing, and nerve transfer surgery are discussed. (ide2021acuteflaccidmyelitis. pages 11-13) Rehabilitation literature and AFM cohorts, largely pediatric 2021 Ide, PM&R Clinics of North America https://doi.org/10.1016/j.pmr.2021.02.004
Novel rehabilitation intervention In a 4-patient pediatric case series, 22 sessions over 5–8 weeks of transcutaneous spinal cord stimulation (TSS) plus gait training were feasible and safe. Session completion was 98.48%; no significant adverse events. 6MWT improved by +98.3 m, +68 m, +9.4 m, and +49.4 m; 3/4 exceeded MCID. WISCI-II improved clinically in 2/4 participants. (neighbors2024transcutaneousspinalcord pages 3-5, neighbors2024transcutaneousspinalcord pages 5-8, neighbors2024transcutaneousspinalcord pages 1-2) Four children with incomplete SCI secondary to AFM 2024 Neighbors, Children https://doi.org/10.3390/children11091116
Surgical reconstruction / prognosis Retrospective cohort of 39 AFM patients (50 upper extremities). Recovery assessed at median 3, 6, and 37 months. Key prognostic result: none of the patients with M0 shoulder abduction at 6 months later recovered M1 or better. Twenty-seven patients (29 extremities) underwent reconstruction (nerve transfer, muscle-tendon transfer, free muscle transfer). Elbow/hand outcomes were more consistent than shoulder outcomes. (doi2024midtermoutcomesof pages 1-2, doi2024midtermoutcomesof pages 11-12, doi2024midtermoutcomesof pages 2-4) AFM upper-extremity paralysis, 2011–2019 surgical referral cohort 2024 Doi, JBJS Open Access https://doi.org/10.2106/JBJS.OA.23.00143
Case report / diagnostic illustration First reported Belgium AFM case linked to EV-D68: 4-year-old with acute right upper-limb palsy. MRI showed central gray matter T2 hyperintensity in cervical cord C2–C7 with posterior brainstem involvement; nasopharyngeal PCR positive for EV-D68; CSF enterovirus PCR negative. Authors note poor functional prognosis and no evidence-based treatment guideline. (rodesch2024afirstcase pages 3-5, rodesch2024afirstcase pages 1-3) Single pediatric case, Belgium 2024 Rodesch, Case Reports in Neurology https://doi.org/10.1159/000535316
Prospective follow-up study / trial registry ClinicalTrials.gov follow-up study of pediatric AFM associated with EV-D68 planned functional follow-up using Hammersmith Functional Motor Scale at 1–3 years; secondary outcomes include MRC scores, ACTIVLIM, PedsQL, ICU/mechanical ventilation duration, deaths, and complete recovery. Enrollment target 40; start date 2018-04-09. (NCT03499366 chunk 1) European children <18 years with AFM, EV-D68 PCR positivity, MRI-confirmed myelitis 2018 Pfeiffer, ClinicalTrials.gov (NCT03499366) https://clinicaltrials.gov/study/NCT03499366

Table: This table summarizes high-yield evidence on acute flaccid myelitis across surveillance, etiology, diagnostics, rehabilitation, surgery, and follow-up research. It is designed to support a disease knowledge base entry with recent statistics, clinically actionable findings, and source links.


Expert opinion / authoritative analysis (from retrieved sources)

  • CDC MMWR guidance emphasizes clinician vigilance for AFM in children with acute flaccid limb weakness and the importance of collecting adequate specimens for enterovirus testing. (whitehouse2024surveillanceforacute pages 1-2, kidd2020vitalsignsclinical pages 1-2)
  • A major clinical review highlights persistent gaps: infrequent direct pathogen detection in CSF and a need for improved diagnostics and pathogenesis-driven therapeutics/prevention. (murphy2021acuteflaccidmyelitis pages 1-2)

Notes on evidence gaps (for knowledge base curation)

  • Ontology identifiers (MONDO/MeSH/Orphanet/OMIM/ICD-10/ICD-11): not retrievable from the current evidence set; recommended to supplement via MONDO/MeSH browsers and ICD crosswalks.
  • Genetic susceptibility/variants: not supported in retrieved sources; AFM currently best represented as a syndrome with infectious association and immune-mediated injury.
  • Differential diagnosis and biomarker specificity: only partially covered; additional guideline-level sources would be needed for a complete differential and test performance metrics.

References

  1. (whitehouse2024surveillanceforacute pages 1-2): ER Whitehouse. Surveillance for acute flaccid myelitis―united states, 2018–2022. Unknown journal, 2024.

  2. (kidd2020vitalsignsclinical pages 1-2): Sarah Kidd, Adriana Lopez, W. Allan Nix, Gloria Anyalechi, Megumi Itoh, Eileen Yee, M. Steven Oberste, and Janell Routh. Vital signs: clinical characteristics of patients with confirmed acute flaccid myelitis, united states, 2018. Morbidity and Mortality Weekly Report, 69:1031-1038, Aug 2020. URL: https://doi.org/10.15585/mmwr.mm6931e3, doi:10.15585/mmwr.mm6931e3. This article has 24 citations.

  3. (messacar2024multimodalsurveillancemodel pages 3-5): K. Messacar, Shannon Matzinger, Kevin Berg, Kirsten Weisbeck, Molly Butler, Nicholas J Pysnack, Hai Nguyen-Tran, Emily Spence Davizon, Laura Bankers, Sarah A. Jung, Meghan C Birkholz, Allison Wheeler, and Samuel R. Dominguez. Multimodal surveillance model for enterovirus d68 respiratory disease and acute flaccid myelitis among children in colorado, usa, 2022. Emerging Infectious Diseases, 30:423-431, Mar 2024. URL: https://doi.org/10.3201/eid3003.231223, doi:10.3201/eid3003.231223. This article has 22 citations and is from a domain leading peer-reviewed journal.

  4. (rodesch2024afirstcase pages 1-3): Marine Rodesch, Claudine Sculier, Valentina Lolli, Gauthier Remiche, Iris Delpire, Christophe Fricx, Françoise Vermeulen, and Florence Christiaens. A first case of acute flaccid myelitis related to enterovirus d68 in belgium: case report. Case Reports in Neurology, 16:41-47, Jan 2024. URL: https://doi.org/10.1159/000535316, doi:10.1159/000535316. This article has 4 citations and is from a peer-reviewed journal.

  5. (doi2024midtermoutcomesof pages 1-2): Kazuteru Doi, Yasunori Hattori, Sotetsu Sakamoto, Dawn Sinn Yii Chia, Vijayendrasingh Gour, and Jun Sasaki. Midterm outcomes of surgical reconstruction and spontaneous recovery of upper-extremity paralysis following acute flaccid myelitis. JBJS Open Access, Apr 2024. URL: https://doi.org/10.2106/jbjs.oa.23.00143, doi:10.2106/jbjs.oa.23.00143. This article has 1 citations.

  6. (aguglia2023contemporaryenterovirusd68isolates pages 1-2): Gabrielle Aguglia, Carolyn B. Coyne, Terence S. Dermody, John V. Williams, and Megan Culler Freeman. Contemporary enterovirus-d68 isolates infect human spinal cord organoids. mBio, Aug 2023. URL: https://doi.org/10.1128/mbio.01058-23, doi:10.1128/mbio.01058-23. This article has 22 citations and is from a domain leading peer-reviewed journal.

  7. (rodesch2024afirstcase pages 3-5): Marine Rodesch, Claudine Sculier, Valentina Lolli, Gauthier Remiche, Iris Delpire, Christophe Fricx, Françoise Vermeulen, and Florence Christiaens. A first case of acute flaccid myelitis related to enterovirus d68 in belgium: case report. Case Reports in Neurology, 16:41-47, Jan 2024. URL: https://doi.org/10.1159/000535316, doi:10.1159/000535316. This article has 4 citations and is from a peer-reviewed journal.

  8. (neighbors2024transcutaneousspinalcord pages 5-8): Elizabeth Neighbors, Lia Brunn, Agostina Casamento-Moran, and Rebecca Martin. Transcutaneous spinal cord stimulation enables recovery of walking in children with acute flaccid myelitis. Children, 11:1116, Sep 2024. URL: https://doi.org/10.3390/children11091116, doi:10.3390/children11091116. This article has 2 citations.

  9. (murphy2021acuteflaccidmyelitis pages 1-2): Olwen C Murphy, Kevin Messacar, Leslie Benson, Riley Bove, Jessica L Carpenter, Thomas Crawford, Janet Dean, Roberta DeBiasi, Jay Desai, Matthew J Elrick, Raquel Farias-Moeller, Grace Y Gombolay, Benjamin Greenberg, Matthew Harmelink, Sue Hong, Sarah E Hopkins, Joyce Oleszek, Catherine Otten, Cristina L Sadowsky, Teri L Schreiner, Kiran T Thakur, Keith Van Haren, Carolina M Carballo, Pin Fee Chong, Amary Fall, Vykuntaraju K Gowda, Jelte Helfferich, Ryutaro Kira, Ming Lim, Eduardo L Lopez, Elizabeth M Wells, E Ann Yeh, Carlos A Pardo, Andrea Salazar-Camelo, Divakar Mithal, Molly Wilson-Murphy, Andrea Bauer, Colyn Watkins, Mark Abzug, Samuel Dominguez, Craig Press, Michele Yang, Nusrat Ahsan, Leigh Ramos-Platt, Emmanuelle Tiongson, Mitchel Seruya, Ann Tilton, Elana Katz, Matthew Kirschen, Apurva Shah, Erlinda Ulloa, Sabrina Yum, Lileth Mondok, Megan Blaufuss, Amy Rosenfeld, Wendy Vargas, Jason Zucker, Anusha Yeshokumar, Allison Navis, Kristen Chao, Kaitlin Hagen, Michelle Melicosta, Courtney Porter, Margaret Tunney, Richard Scheuermann, Priya Duggal, Andrew Pekosz, Amy Bayliss, Meghan Moore, Allan Belzberg, Melania Bembea, Caitlin O'Brien, Rebecca Riggs, Jessica Nance, Aaron Milstone, Jessica Rice, Maria A. Garcia-Dominguez, Eoin Flanagan, Jan-Mendelt Tillema, Glendaliz Bosques, Sonal Bhatia, Eliza Gordon-Lipkin, Dawn Deike, Gadi Revivo, Dan Zlotolow, Gabrielle deFiebre, Peggy Lazerow, Timothy Lotze, Ari Bitnun, Kristen Davidge, Jiri Vajsar, Amy Moore, Chamindra Konersman, Kendall Nash, Jonathan Strober, Nalin Gupta, Charles Chiu, Michael Sweeney, William Jackson, Dennis Simon, Kavita Thakkar, Jonathan Cheng, John Luce, Suman Das, Matthew Vogt, NgocHanh Vu, Jacqueline Gofshteyn, Naila Makhani, and Payal Patel. Acute flaccid myelitis: cause, diagnosis, and management. The Lancet, 397:334-346, Jan 2021. URL: https://doi.org/10.1016/s0140-6736(20)32723-9, doi:10.1016/s0140-6736(20)32723-9. This article has 195 citations and is from a highest quality peer-reviewed journal.

  10. (whitehouse2024surveillanceforacute pages 5-6): ER Whitehouse. Surveillance for acute flaccid myelitis―united states, 2018–2022. Unknown journal, 2024.

  11. (whitehouse2024surveillanceforacute pages 6-7): ER Whitehouse. Surveillance for acute flaccid myelitis―united states, 2018–2022. Unknown journal, 2024.

  12. (whitehouse2024surveillanceforacute pages 4-5): ER Whitehouse. Surveillance for acute flaccid myelitis―united states, 2018–2022. Unknown journal, 2024.

  13. (vawterlee2021acuteflaccidmyelitis pages 2-3): Marissa Vawter-Lee, Katrina Peariso, Mary Frey, Priya Bolikal, Joshua K. Schaffzin, Ann Schwentker, William T. O’Brien, Ronine Zamor, and Benjamin T. Kerrey. Acute flaccid myelitis: a multidisciplinary protocol to optimize diagnosis and evaluation. Journal of Child Neurology, 36:421-431, Dec 2021. URL: https://doi.org/10.1177/0883073820975230, doi:10.1177/0883073820975230. This article has 10 citations and is from a peer-reviewed journal.

  14. (aguglia2023contemporaryenterovirusd68isolates pages 5-8): Gabrielle Aguglia, Carolyn B. Coyne, Terence S. Dermody, John V. Williams, and Megan Culler Freeman. Contemporary enterovirus-d68 isolates infect human spinal cord organoids. mBio, Aug 2023. URL: https://doi.org/10.1128/mbio.01058-23, doi:10.1128/mbio.01058-23. This article has 22 citations and is from a domain leading peer-reviewed journal.

  15. (aguglia2023contemporaryenterovirusd68isolates pages 2-5): Gabrielle Aguglia, Carolyn B. Coyne, Terence S. Dermody, John V. Williams, and Megan Culler Freeman. Contemporary enterovirus-d68 isolates infect human spinal cord organoids. mBio, Aug 2023. URL: https://doi.org/10.1128/mbio.01058-23, doi:10.1128/mbio.01058-23. This article has 22 citations and is from a domain leading peer-reviewed journal.

  16. (aguglia2023contemporaryenterovirusd68isolates pages 8-10): Gabrielle Aguglia, Carolyn B. Coyne, Terence S. Dermody, John V. Williams, and Megan Culler Freeman. Contemporary enterovirus-d68 isolates infect human spinal cord organoids. mBio, Aug 2023. URL: https://doi.org/10.1128/mbio.01058-23, doi:10.1128/mbio.01058-23. This article has 22 citations and is from a domain leading peer-reviewed journal.

  17. (aguglia2023contemporaryenterovirusd68isolates pages 10-12): Gabrielle Aguglia, Carolyn B. Coyne, Terence S. Dermody, John V. Williams, and Megan Culler Freeman. Contemporary enterovirus-d68 isolates infect human spinal cord organoids. mBio, Aug 2023. URL: https://doi.org/10.1128/mbio.01058-23, doi:10.1128/mbio.01058-23. This article has 22 citations and is from a domain leading peer-reviewed journal.

  18. (dabilla2025strainspecifictropismand pages 9-10): Nathânia Dábilla, Sarah Maya, Colton McNinch, Taylor Eddens, Patrick T. Dolan, and Megan Culler Freeman. Strain-specific tropism and transcriptional responses of enterovirus d68 infection in human spinal cord organoids. Frontiers in Microbiology, Nov 2025. URL: https://doi.org/10.3389/fmicb.2025.1698639, doi:10.3389/fmicb.2025.1698639. This article has 6 citations and is from a peer-reviewed journal.

  19. (ide2021acuteflaccidmyelitis. pages 11-13): William Ide, Michelle Melicosta, and Melissa K. Trovato. Acute flaccid myelitis. Physical medicine and rehabilitation clinics of North America, 32 3:477-491, Aug 2021. URL: https://doi.org/10.1016/j.pmr.2021.02.004, doi:10.1016/j.pmr.2021.02.004. This article has 15 citations and is from a peer-reviewed journal.

  20. (messacar2024multimodalsurveillancemodel pages 5-7): K. Messacar, Shannon Matzinger, Kevin Berg, Kirsten Weisbeck, Molly Butler, Nicholas J Pysnack, Hai Nguyen-Tran, Emily Spence Davizon, Laura Bankers, Sarah A. Jung, Meghan C Birkholz, Allison Wheeler, and Samuel R. Dominguez. Multimodal surveillance model for enterovirus d68 respiratory disease and acute flaccid myelitis among children in colorado, usa, 2022. Emerging Infectious Diseases, 30:423-431, Mar 2024. URL: https://doi.org/10.3201/eid3003.231223, doi:10.3201/eid3003.231223. This article has 22 citations and is from a domain leading peer-reviewed journal.

  21. (doi2024midtermoutcomesof pages 12-13): Kazuteru Doi, Yasunori Hattori, Sotetsu Sakamoto, Dawn Sinn Yii Chia, Vijayendrasingh Gour, and Jun Sasaki. Midterm outcomes of surgical reconstruction and spontaneous recovery of upper-extremity paralysis following acute flaccid myelitis. JBJS Open Access, Apr 2024. URL: https://doi.org/10.2106/jbjs.oa.23.00143, doi:10.2106/jbjs.oa.23.00143. This article has 1 citations.

  22. (doi2024midtermoutcomesof pages 11-12): Kazuteru Doi, Yasunori Hattori, Sotetsu Sakamoto, Dawn Sinn Yii Chia, Vijayendrasingh Gour, and Jun Sasaki. Midterm outcomes of surgical reconstruction and spontaneous recovery of upper-extremity paralysis following acute flaccid myelitis. JBJS Open Access, Apr 2024. URL: https://doi.org/10.2106/jbjs.oa.23.00143, doi:10.2106/jbjs.oa.23.00143. This article has 1 citations.

  23. (neighbors2024transcutaneousspinalcord pages 1-2): Elizabeth Neighbors, Lia Brunn, Agostina Casamento-Moran, and Rebecca Martin. Transcutaneous spinal cord stimulation enables recovery of walking in children with acute flaccid myelitis. Children, 11:1116, Sep 2024. URL: https://doi.org/10.3390/children11091116, doi:10.3390/children11091116. This article has 2 citations.

  24. (NCT03499366 chunk 1): Helle Cecilie Viekilde Pfeiffer. European Paediatric AFM Associated With EV-D68 Follow-up Study.. Oslo University Hospital. 2018. ClinicalTrials.gov Identifier: NCT03499366

  25. (messacar2024multimodalsurveillancemodel pages 7-8): K. Messacar, Shannon Matzinger, Kevin Berg, Kirsten Weisbeck, Molly Butler, Nicholas J Pysnack, Hai Nguyen-Tran, Emily Spence Davizon, Laura Bankers, Sarah A. Jung, Meghan C Birkholz, Allison Wheeler, and Samuel R. Dominguez. Multimodal surveillance model for enterovirus d68 respiratory disease and acute flaccid myelitis among children in colorado, usa, 2022. Emerging Infectious Diseases, 30:423-431, Mar 2024. URL: https://doi.org/10.3201/eid3003.231223, doi:10.3201/eid3003.231223. This article has 22 citations and is from a domain leading peer-reviewed journal.

  26. (neighbors2024transcutaneousspinalcord pages 3-5): Elizabeth Neighbors, Lia Brunn, Agostina Casamento-Moran, and Rebecca Martin. Transcutaneous spinal cord stimulation enables recovery of walking in children with acute flaccid myelitis. Children, 11:1116, Sep 2024. URL: https://doi.org/10.3390/children11091116, doi:10.3390/children11091116. This article has 2 citations.

  27. (doi2024midtermoutcomesof pages 2-4): Kazuteru Doi, Yasunori Hattori, Sotetsu Sakamoto, Dawn Sinn Yii Chia, Vijayendrasingh Gour, and Jun Sasaki. Midterm outcomes of surgical reconstruction and spontaneous recovery of upper-extremity paralysis following acute flaccid myelitis. JBJS Open Access, Apr 2024. URL: https://doi.org/10.2106/jbjs.oa.23.00143, doi:10.2106/jbjs.oa.23.00143. This article has 1 citations.

Artifacts

OpenScientist
1. Disease Information
openscientist-autonomous 78 citations 2026-05-16T11:03:52.593112

1. Disease Information

Overview

Acute flaccid myelitis (AFM) is a rare but serious neurologic condition characterized by the acute onset of flaccid limb weakness with magnetic resonance imaging (MRI) evidence of spinal cord gray matter lesions. It primarily affects children and has been described as a "polio-like" illness due to striking clinical similarities to poliomyelitis (PMID: 32143233). AFM was first recognized as a distinct clinical entity in 2012 when a cluster of acute flaccid paralysis cases of unknown etiology was identified in California (PMID: 26720027). The US Centers for Disease Control and Prevention (CDC) began national surveillance in 2014 following 120 confirmed cases (PMID: 38300829).

Key Identifiers

  • MONDO: MONDO:0100115 (acute flaccid myelitis) [validated via OLS4 API]
  • ICD-10: G04.82 (Acute flaccid myelitis)
  • ICD-11: 8B44.0 (Acute flaccid myelitis)
  • MeSH: D000080524 (Myelitis, Acute Flaccid)
  • OMIM: Not applicable (not a Mendelian disorder)
  • Orphanet: ORPHA:542389

Synonyms and Alternative Names

  • Acute flaccid myelitis (AFM)
  • Polio-like illness / polio-like syndrome
  • Enteroviral acute flaccid myelitis
  • Non-polio enterovirus-associated acute flaccid paralysis
  • AFM is a specific subtype within the broader category of acute flaccid paralysis (AFP)

Information Sources

Disease-level characterization is derived from aggregated surveillance data (CDC national AFM surveillance, European Non-Polio Enterovirus Network [ENPEN]), multicenter clinical cohorts, population-based studies (e.g., Kaiser Permanente Northern California), and individual patient case series.


2. Etiology

Disease Causal Factors

AFM is an infectious/post-infectious neurologic disease. The primary causal agent is Enterovirus D68 (EV-D68), a non-polio enterovirus belonging to the Enterovirus genus, species Enterovirus D, family Picornaviridae.

Evidence for EV-D68 causation: - Temporal correlation: Biennial peaks in AFM cases (2014, 2016, 2018) coincided with increased EV-D68 respiratory circulation (PMID: 38300829). - In Europe, 70% of AFM cases (n=91/130) occurred in years of increased EV-D68 circulation (2016, 2018, 2022), and 37% (48/130) were EV-D68 laboratory-confirmed (PMID: 40444374). - Mouse models fulfill Koch's postulates: EV-D68 2014 outbreak strains cause paralytic myelitis with infection and loss of spinal cord motor neurons in neonatal mice (PMID: 28231269). - A systematic review and meta-analysis confirmed the association between EV-D68 detection and acute neurologic outcomes (PMID: 42066114).

Other viruses have been associated with AFM in smaller numbers, including: - Enterovirus A71 (EV-A71) - Coxsackieviruses (A and B) - West Nile virus (PMID: 40622703) - Adenoviruses - Other non-polio enteroviruses

Risk Factors

Environmental/Host Risk Factors

Search source: PubMed, CDC, population-based studies

  • Age: Predominantly affects children; median age 4-9 years depending on cohort (PMID: 33218883, PMID: 30985511). Children under 5 are most susceptible to EV-D68 infection (41.6% of cases) (PMID: 40492725).
  • Sex: Male sex is a risk factor (PMID: 30985511). In the Turkish cohort, 55.9% were boys (PMID: 33218883).
  • Atopy/Asthma: History of asthma, atopic dermatitis, or reactive airway disease is a risk factor (PMID: 30985511). EV-D68-positive cases in 2024 were predominantly young children receiving asthma medications (PMID: 40431685).
  • Ancestry: Asian ancestry was identified as a risk factor in the KPNC population study (PMID: 30985511).
  • Season: Late summer and early fall, coinciding with enterovirus seasonal circulation (August-November).
  • Preceding viral illness: Prodromal fever or respiratory symptoms occur in most cases; febrile illness was reported in all patients in the Turkish cohort with a median of 4 days before symptom onset (PMID: 33218883).
  • Low vitamin D levels: Noted in all patients tested in a post-pandemic case series, though causality is unclear (PMID: 41138534).

Genetic Risk Factors

No specific human genetic susceptibility loci have been identified for AFM. The disease is not a Mendelian disorder. Host genetic factors influencing susceptibility remain an area of active investigation. The association with atopy/asthma suggests possible immune genetic modifiers.

Protective Factors

  • COVID-19 non-pharmaceutical interventions (NPIs): The biennial AFM pattern was disrupted in 2020, with only 32 cases (compared to expected peak), likely due to masking, hand hygiene, and social distancing measures that reduced EV-D68 circulation (PMID: 34735423, PMID: 40431685).
  • Maternal antibodies/passive immunization: In mouse models, maternal immunization with inactivated EV-D68 vaccine protected neonatal mice, and antisera transfer showed cross-protective effects (PMID: 29385753).
  • Neutralizing antibodies: hIVIG containing EV-D68 neutralizing antibodies reduced paralysis in mouse models (PMID: 28968718).

Gene-Environment Interactions

The interaction between host immune status (particularly innate interferon responses) and viral exposure determines disease outcome. The respiratory epithelium induces a robust type III interferon response that restricts EV-D68 infection, while intestinal epithelium does not (PMID: 34196272). Children with asthma/atopy may have altered antiviral immune responses that increase susceptibility to severe EV-D68 disease.


3. Phenotypes

Core Clinical Phenotype

Acute Flaccid Limb Weakness

  • Type: Clinical sign / physical manifestation
  • HPO: HP:0001371 (Flexion contracture), HP:0001252 (Hypotonia), HP:0003470 (Paralysis), HP:0002460 (Distal muscle weakness), HP:0002515 (Waddling gait)
  • Onset: Acute; preceded by 1-7 days of prodromal illness. Maximum weakness reached within 4 days from onset (PMID: 30169722).
  • Severity: Variable, from monoplegia to quadriplegia. 30% require intubation (PMID: 37465770).
  • Pattern: Typically asymmetric (58% asymmetric in AFM vs 0% in GBS; p<0.001) (PMID: 34747551).
  • Frequency: 100% (defining feature)
  • Progression: Acute onset, rapid nadir (median 3 days, shorter than GBS at 8 days; p<0.001) (PMID: 34747551).
  • Quality of life: Devastating; most patients have persistent weakness. Less than 10% have full recovery (PMID: 37465770). In the KPNC study, 41% had full recovery at 12 months, but several had significant deficits (PMID: 30985511).
  • HPO terms: HP:0002460 (Distal muscle weakness), HP:0009053 (Flaccid paralysis of limbs)

Prodromal Respiratory/Febrile Illness

  • Type: Symptom
  • HPO: HP:0001945 (Fever), HP:0002788 (Upper respiratory tract infection)
  • Onset: 1-7 days before weakness onset
  • Frequency: ~90% in peak years; lower in non-peak years (PMID: 38300829, PMID: 33218883)
  • Severity: Mild to moderate
  • Quality of life: Transient; self-limited

Spinal Cord Gray Matter Lesions on MRI

  • Type: Radiological finding / laboratory abnormality
  • HPO: HP:0002196 (Myelopathy)
  • Description: T2 hyperintensity predominantly involving central gray matter of the spinal cord (PMID: 33218883, PMID: 26720027)
  • Frequency: >90% (56/59 in California series) (PMID: 26720027)
  • Specificity: Distinguishing feature from GBS (spinal cord lesions only found in AFM, not GBS) (PMID: 34747551)
  • LOINC consideration: MRI spinal cord evaluation

Cerebrospinal Fluid Pleocytosis

  • Type: Laboratory abnormality
  • HPO: HP:0012229 (CSF pleocytosis)
  • Description: Elevated CSF white blood cell count; CSF leukocyte counts higher in AFM than GBS, while protein concentrations were lower (PMID: 34747551)
  • Frequency: Variable; ~73% in California series (43/59) (PMID: 26720027), 58% (18/31) in Turkish cohort (PMID: 33218883). Lower frequency in non-peak years (PMID: 38300829).
  • Severity: Typically mild to moderate pleocytosis

Respiratory Failure

  • Type: Clinical sign
  • HPO: HP:0002878 (Respiratory failure)
  • Description: Due to phrenic nerve/diaphragm involvement or bulbar weakness
  • Frequency: ~30% require intubation (PMID: 37465770)
  • Severity: Life-threatening; deaths related to AFM are due to respiratory complications
  • Quality of life: Major impact; some require long-term ventilatory support

Cranial Nerve Dysfunction

  • Type: Clinical sign
  • HPO: HP:0001291 (Cranial nerve palsy)
  • Description: Facial, bulbar, or extraocular muscle weakness
  • Frequency: Present in a subset of patients
  • Severity: Variable

Bowel/Bladder Dysfunction

  • Type: Clinical sign
  • HPO: HP:0000020 (Urinary incontinence), HP:0002607 (Bowel incontinence)
  • Description: Autonomic involvement; all 4 post-pandemic cases experienced bowel/bladder dysfunction (PMID: 41138534)
  • Frequency: Variable; 36% with persistent sphincter dysfunction requiring catheterization in plasmapheresis cohort (PMID: 41251130)

Limb Pain/Myalgia

  • Type: Symptom
  • HPO: HP:0003326 (Myalgia)
  • Description: Limb myalgia concurrent with or preceding weakness
  • Frequency: ~70% (41/59 in California series) (PMID: 26720027)

4. Genetic/Molecular Information

Causal Genes (Viral)

AFM is not caused by human genetic mutations. The causal genetic elements are viral:

  • EV-D68 VP1 capsid protein gene: The primary determinant of neurovirulence. Four amino acid differences in VP1 between neurovirulent strain IL52 and non-neurovirulent strain CA4231 completely controlled paralysis phenotype in mouse models (PMID: 38869283).
  • VP3 amino acid 88: A single isoleucine-to-valine change at position 88 in VP3 attenuated neurovirulence by reducing virus replication in brain and spinal cord (PMID: 32784424).
  • 2Apro gene: The 2A protease cleaves host TRAF3; alterations at the 2Apro/TRAF3 cleavage site affect immune evasion and viral pathogenicity (PMID: 41600837).
  • 3Cpro gene: The 3C protease cleaves host proteins involved in translation and autophagy, including Mitofusin 2 (PMID: 42018625); variations affect replication efficiency and antiviral responses (PMID: 41600837).

Viral Genomic Evolution (Updated Iteration 3)

  • EV-D68 has evolved into multiple clades: A (A1, A2), B (B1, B2, B3), C, D (D1, D2, D3)
  • Molecular origin: Canada, ~1995; disseminated to France (1997), USA (1999), Asia (2008), with B3 MRCA dated to 2011-01-15 in China (PMID: 37804367)
  • European 2014-2024 surveillance (18 countries, 3,541 EV-D68 of 61,297 EV-positive): B3 (59.8%) and A2/D (28.0%) predominant; A2/D reemerged as dominant in 2024; mutation analyses revealed changes in antigenic regions (PMID: 41986256)
  • In 2024 US, co-circulation of subclades B3 (71%) and A2 (29%) observed (PMID: 40492725)
  • B3 subclade primarily associated with pediatric infections (median age 5 years), while A2 more common in adults (median age 42 years) (PMID: 40492725)
  • Four amino acid substitutions identified in 2024 B3 genomes: VP2 T145S, 3C I597V, 3D I950V, 3D T2173A (PMID: 40492725)
  • Key neuropathogenic site T650A mutation identified in B3 strains (PMID: 40661021)
  • 2021-2022 European upsurge: Two novel B3-derived lineages emerged; 10,481 EV-positive, 1,004 EV-D68 (9.6%); neurological problems in 6.4% of cases but only 6 AFM (PMID: 38547499)
  • Structural biology: Cryo-EM structures of native virion (2.2 A) and A-particle uncoating intermediate (2.7 A) resolved; revealed acid-initiated uncoating pathway through E1 particle intermediate (PMID: 30530701)
  • Critical unresolved question: EV-D68 respiratory outbreaks in 2022 and 2024 were NOT associated with AFM surges, despite biennial pattern in 2014-2018 (PMID: 38300829, PMID: 40492725). Possible explanations: (1) evolved strains with reduced neurovirulence, (2) altered population immunity post-pandemic, (3) surveillance gaps, (4) mutations in neurovirulence determinants

Host Molecular Factors

  • ICAM-5 (Intercellular Adhesion Molecule 5): Neuron-specific receptor for EV-D68; provides molecular basis for neurotropism (PMID: 41467840)
  • Gene: ICAM5 (HGNC:5348)
  • Function: Cell adhesion molecule expressed predominantly on telencephalic neurons
  • MFSD6 (Major Facilitator Superfamily Domain Containing 6): Essential entry receptor for EV-D68 in respiratory and neuronal cells (PMID: 41467840)
  • Gene: MFSD6 (HGNC:24711)
  • Sialic acid (Neu5Ac): α2,6-linked sialic acid serves as attachment factor for historical EV-D68 strains
  • CHEBI: CHEBI:26667 (sialic acid)
  • Mitofusin 2 (MFN2): Cleaved by EV-D68 3C protease, inducing mitochondrial fragmentation and mitophagosome formation (PMID: 42018625)
  • Gene: MFN2 (HGNC:16877)
  • TRAF3: Cleaved by EV-D68 2A protease to evade innate immunity (PMID: 41600837)
  • STING (STING1/TMEM173): Hijacked by EV-D68 for a non-canonical pro-viral function — formation of specialized lipid replication organelles; co-localizes with glycolytic enzymes within ROs (PMID: 39459875)
  • Gene: STING1 (HGNC:27962)
  • Piezo1: Mechanosensitive ion channel; mediates the mechano-antiviral response system (MARS), a non-canonical antiviral pathway that reduces membrane fluidity to restrict viral entry. Piezo1 agonists protect against EV-D68 neurological damage in vivo (PMID: 41650963)
  • Gene: PIEZO1 (HGNC:13680)
  • ARRDC3: Host antiviral factor induced by enterovirus infection; promotes lysosomal degradation of YAP, which otherwise facilitates viral replication by suppressing IFN responses (PMID: 40701343)
  • Gene: ARRDC3 (HGNC:28633)

Epigenetic Information

No specific epigenetic alterations have been reported for AFM susceptibility in host cells.

Chromosomal Abnormalities

Not applicable; AFM is not associated with chromosomal abnormalities.


5. Environmental Information

Environmental Factors

  • Seasonality: Late summer through fall (August-November) in temperate climates, corresponding to enterovirus circulation season. Wastewater surveillance confirms national US peak in September, with seasonal peaks occurring 28-31 days earlier in regions with 5°C higher temperatures/dew points (PMID: 41853773).
  • Geographic clustering: Cases cluster in association with regional EV-D68 respiratory outbreaks. Season duration is longer by 7-11 weeks in dense, urban catchments with more childcare facilities, crowded households, and hospitals (PMID: 41853773).
  • Non-pharmaceutical interventions: COVID-19 pandemic NPIs (masking, hand hygiene, social distancing) disrupted EV-D68 transmission and the biennial AFM pattern in 2020 (PMID: 34735423).
  • Climate factors: Temperature and dew point influence seasonal timing; warmer regions see earlier EV-D68 peaks (PMID: 41853773).

Lifestyle Factors

No specific lifestyle factors have been identified beyond the association with atopy/asthma, which may reflect underlying immune phenotype rather than modifiable lifestyle factors.

Infectious Agents

Primary agent: - Enterovirus D68 (EV-D68) - NCBI Taxonomy: TaxID 42789 - Family: Picornaviridae - Genus: Enterovirus - Species: Enterovirus D - Genome: Positive-sense single-stranded RNA (~7.4 kb) - First isolated: 1962 from children with pneumonia (Fermon strain) - Unique among enteroviruses: resembles human rhinoviruses in acid lability and temperature sensitivity (PMID: 41868141)

Other associated agents: - Enterovirus A71 (EV-A71) - NCBI TaxID 39054 - Coxsackieviruses (A and B species) - West Nile virus (rare AFM cause in adults) - Adenoviruses (rarely)


6. Mechanism / Pathophysiology

Causal Chain: From Viral Infection to Clinical Paralysis

The pathophysiological cascade of AFM proceeds through the following steps:

1. Respiratory Entry and Replication (Upstream) - EV-D68 enters via the respiratory tract, binding to α2,6-linked sialic acid and/or MFSD6 on respiratory epithelial cells (PMID: 41467840) - Viral replication in the respiratory epithelium triggers a type III interferon response (PMID: 34196272) - The virus can use clathrin-mediated endocytosis and compensatory macropinocytosis for entry (PMID: 42037410)

2. Systemic/Neural Spread (Intermediate) - EV-D68 spreads from respiratory tract to the central nervous system, likely via retrograde axonal transport from infected skeletal muscle to spinal cord motor neurons - In mouse models, skeletal muscle and spinal cord had the highest viral titers (PMID: 41305500) - Viremia may also contribute to neural spread

3. Motor Neuron Infection (Intermediate) - EV-D68 binds ICAM-5 (neuron-specific receptor) for entry into spinal cord motor neurons (PMID: 41467840) - Viral replication in motor neurons of the anterior horn cells - GO terms: GO:0019058 (viral life cycle), GO:0044409 (entry into host cell)

4. Cell Death and Immune-Mediated Damage (Downstream) - Direct cytopathology: EV-D68 infection causes motor neuron death through: - Mitochondrial dysfunction: EV-D68 3C protease cleaves Mitofusin 2, causing mitochondrial fragmentation (PMID: 42018625) - Oxidative stress: RNA-seq of infected spinal cords shows mitochondrial dysfunction and oxidative stress pathways (PMID: 41305500) - GO terms: GO:0008219 (cell death), GO:0006915 (apoptosis)

  • Immune-mediated secondary injury:
  • EV-D68 activates innate and adaptive immunity with significant CD8+ T cell infiltration into spinal cord (PMID: 41305500)
  • Interferon signaling and cytokine storm pathways activated (PMID: 41305500)
  • Human spinal cord organoids infected with EV-D68 show productive infection for 2+ weeks without appreciable cytopathic effect, suggesting immune-mediated mechanisms are important contributors to pathology in vivo (PMID: 37535397)
  • GO terms: GO:0006955 (immune response), GO:0006954 (inflammatory response)

5. Motor Neuron Loss and Clinical Paralysis (Downstream) - Loss of anterior horn motor neurons produces lower motor neuron paralysis - Wallerian degeneration of motor axons follows - Clinical manifestation as acute flaccid limb weakness - CL terms: CL:0011001 (spinal cord motor neuron), CL:0000100 (motor neuron) - UBERON terms: UBERON:0002257 (ventral horn of spinal cord), UBERON:0014621 (cervical spinal cord ventral horn)

Molecular Pathways

  • Interferon signaling: Type I and Type III interferon responses activated in respiratory and neural tissues; type I IFN receptor is important for host defense (mice lacking IFNAR are highly susceptible) (PMID: 32784424)
  • Reactome: R-HSA-913531 (Interferon Signaling)

  • Autophagy/Mitophagy: EV-D68 induces nonselective autophagy and mitophagy via Mitofusin 2 cleavage; mitophagosomes serve as vectors for nonlytic viral release (PMID: 42018625)

  • GO: GO:0006914 (autophagy), GO:0000422 (autophagy of mitochondria)

  • NF-kB/TRAF3 pathway: EV-D68 2A protease cleaves TRAF3 to evade innate immunity (PMID: 41600837)

  • Reactome: R-HSA-975138 (TRAF6-mediated NF-kB activation)

  • Cytokine signaling: DEGs enriched in cytokine-cytokine receptor interaction and JAK-STAT pathways (PMID: 41305500)

  • KEGG: hsa04630 (JAK-STAT signaling pathway)

Immune Evasion Mechanisms (Iteration 2 Addition)

EV-D68 employs a multi-layered immune evasion strategy targeting the type I IFN pathway at three distinct nodes:

  1. VP3-MAVS interaction (receptor-proximal): VP3 structural protein co-localizes and interacts with MAVS, disrupts mitochondrial membrane potential, releases MAVS from mitochondria, and inhibits NF-kB signaling. VP3 binds to the transmembrane domain of MAVS. This is a broad-spectrum enterovirus strategy (PMID: 40042308).

  2. 3C protease-STAT1 cleavage (downstream signaling): EV-D68 3C protease cleaves STAT1 at the 131Q residue, abolishing STAT1 nuclear translocation and attenuating IFN signal transduction. Notably, this ability is shared with poliovirus 3C protease but NOT with EV-A71, CVA16, or echoviruses — potentially explaining the shared polio-like phenotype between EV-D68 and poliovirus (PMID: 38240591).

  3. USP5 deubiquitinase exploitation (upstream of IFN induction): EV-D68 infection upregulates USP5, which reduces K63-linked polyubiquitination of MAVS and IRF3, decreasing IFN-I production. Pharmacological USP5 inhibition with PR-619 potentiated antiviral IFN effects, suggesting a therapeutic target (PMID: 41352537).

  4. 3C protease-MDA5 disruption: EV-D68 3C protein cleaves MDA5, a key cytoplasmic viral RNA sensor, disrupting innate immune detection of viral RNA (PMID: 28424289).

Novel Host Defense Mechanisms (Iteration 4 Addition)

  1. Mechano-Antiviral Response System (MARS) via Piezo1: Cellular compression or fluid pressure activates Piezo1-dependent antiviral resistance by reducing host cell membrane fluidity, restricting viral entry. Piezo1 agonists or mechanical stimuli alleviate EV-D68-induced neurological damage and lethality in vivo. This represents a non-canonical antiviral strategy distinct from interferon signaling (PMID: 41650963).

  2. STING hijacking for replication organelles: EV-D68 hijacks STING (stimulator of interferon genes) for a non-canonical, pro-viral function — formation of specialized lipid replication organelles (ROs). STING co-localizes with glycolytic enzymes within ROs, and its inhibition modulates glucose metabolism in infected cells. This reveals that STING has dual roles: canonical antiviral DNA sensing AND non-canonical pro-viral membrane remodeling exploited by RNA viruses (PMID: 39459875).

  3. ARRDC3-YAP antiviral pathway: Enterovirus infection induces ARRDC3 (Arrestin Domain Containing 3), which promotes lysosomal degradation of YAP (Yes-associated protein). YAP facilitates enterovirus replication by suppressing the interferon pathway during later stages of infection. The ARRDC3-YAP axis exhibits broad-spectrum antiviral activity (PMID: 40701343).

  4. TRIM25 restoration of RIG-I: EV-D68 3C protease reduces both RIG-I and TRIM25 expression. Overexpression of TRIM25 restores RIG-I expression and IFN-β production, suggesting TRIM25 as a potential therapeutic target (PMID: 34170466).

Cellular Processes

  • Apoptosis of motor neurons (GO:0006915)
  • Neuroinflammation with CD8+ T cell, macrophage infiltration (GO:0006954)
  • Mitochondrial dysfunction and oxidative stress (GO:0006979)
  • Mitochondrial fission via MFN2 cleavage (GO:0000266)
  • Viral immune evasion via protease-mediated host protein cleavage (GO:0030683)
  • Type I interferon signaling suppression (GO:0060339 - negative regulation of type I interferon-mediated signaling pathway)

Protein Dysfunction

  • Mitofusin 2 cleavage: EV-D68 3C protease cleaves MFN2 near C-terminal HR2 domain, causing mitochondrial fragmentation (PMID: 42018625)
  • TRAF3 degradation: 2A protease cleaves TRAF3, impairing innate immune signaling (PMID: 41600837)
  • Host translation shutoff: Enteroviral proteases cleave eIF4G and other translation factors

Metabolic Changes

  • Mitochondrial dysfunction leads to altered energy metabolism in infected motor neurons (PMID: 41305500)
  • Oxidative stress pathways activated

Immune System Involvement

  • Innate immunity: Type III interferon response in respiratory epithelium restricts EV-D68 (PMID: 34196272); type I IFN critical for limiting CNS infection
  • Adaptive immunity: CD8+ T cell response in spinal cord; may contribute to immunopathology (PMID: 41305500)
  • Immune evasion: EV-D68 employs multiple strategies including TRAF3 cleavage, translational shutoff, and autophagy manipulation
  • Autoimmunity: Not the primary mechanism, distinguishing AFM from autoimmune myelitis

Tissue Damage Mechanisms

  • Direct viral cytopathic effect on motor neurons
  • Immune-mediated inflammatory damage in spinal cord
  • Oxidative stress (GO:0006979)
  • Mitochondrial dysfunction and energy failure

Molecular Profiling

Transcriptomics

  • RNA sequencing of EV-D68-infected mouse spinal cord revealed DEGs significantly enriched in antiviral immunity, interferon responses, cytokine signaling, mitochondrial dysfunction, and oxidative stress pathways (PMID: 41305500)
  • GEO datasets available for EV-D68-infected cells and tissues

Functional Genomics

  • VP1 chimeric virus studies identified four key amino acid positions controlling neurovirulence (PMID: 38869283)
  • VP3 position 88 (Ile>Val) as single attenuation determinant (PMID: 32784424)

7. Anatomical Structures Affected

Organ Level

Primary organs: - Spinal cord (UBERON:0002240) - Primary site of pathology; gray matter predominantly affected - Skeletal muscle (UBERON:0001134) - Secondary to denervation and direct viral infection

Secondary organ involvement: - Brain/brainstem (UBERON:0002298) - Brainstem involvement with cranial nerve nuclei in some cases; posterior brainstem T2 signal changes reported (PMID: 38405019) - Lungs (UBERON:0002048) - Respiratory failure due to diaphragm paralysis; respiratory tract as primary site of viral entry - Bladder (UBERON:0001255) - Autonomic dysfunction with urinary retention

Body systems involved: - Nervous system (central and peripheral) - Respiratory system - Musculoskeletal system - Autonomic nervous system

Tissue and Cell Level

  • Spinal cord gray matter (UBERON:0002315) - Anterior horn cells predominantly affected
  • Motor neurons (CL:0000100) - Primary cellular target; infection and loss documented
  • Skeletal muscle fibers - Denervation atrophy secondary to motor neuron loss; direct viral tropism to muscle also documented (PMID: 41305500)
  • Respiratory epithelial cells (CL:0002368) - Initial site of infection
  • Neurons broadly (CL:0000540) - ICAM-5-expressing neurons susceptible

Subcellular Level

  • Mitochondria (GO:0005739) - Fragmentation due to Mitofusin 2 cleavage (PMID: 42018625)
  • Endoplasmic reticulum - Viral replication complexes
  • Autophagosomes/mitophagosomes (GO:0005776) - Formed during infection for viral release (PMID: 42018625)
  • Cell membrane - Receptor interactions and viral entry

Localization

  • Spinal cord: Cervical cord most commonly affected (especially for upper extremity weakness); thoracic and lumbar segments also involved
  • UBERON: UBERON:0002726 (cervical spinal cord), UBERON:0002257 (ventral horn of spinal cord)
  • Lateralization: Typically asymmetric (58% of cases), though bilateral involvement occurs; one limb may be affected more severely than contralateral (PMID: 34747551)
  • HPO: HP:0003685 (Asymmetric limb weakness)

8. Temporal Development

Onset

  • Typical age of onset: Predominantly pediatric; median age 4-9 years across studies (PMID: 33218883, PMID: 30985511, PMID: 26720027). The median age has been observed to decrease with successive outbreaks (PMID: 33218883).
  • Onset pattern: Acute; prodromal febrile/respiratory illness 1-7 days prior, followed by rapid onset of flaccid weakness
  • Seasonality: Late summer through fall (August-November)

Progression

  • Prodromal phase (days 1-7): Fever, upper respiratory infection, gastrointestinal illness
  • Acute paralytic phase (hours to days): Rapid onset flaccid weakness; maximum weakness reached within median 3 days from onset of limb weakness (PMID: 34747551)
  • Nadir phase (days to weeks): Stabilization of weakness at maximal severity
  • Recovery phase (months to years): Slow, incomplete recovery in most patients

  • Progression rate: Rapid to nadir; much faster than GBS (3 vs 8 days, p<0.001) (PMID: 34747551)

  • Disease course: Monophasic (single acute episode); not relapsing-remitting
  • Disease duration: Acute phase resolves over weeks, but deficits are often chronic/permanent

Patterns

  • Spontaneous recovery: Limited; among patients with complete paralysis (MRC grade 0) at >6 months with hip adductor paralysis, no patient improved to better than MRC grade 2 (PMID: 38815052). Recovery plateaus around 6-9 months (PMID: 32951650).
  • Critical periods:
  • First 6-9 months: Window for maximal spontaneous recovery
  • Nerve transfer surgery: Best outcomes when performed within 8 months of paralysis onset (PMID: 38815052)
  • Antiviral treatment: Mouse models show benefit even when initiated 4-6 days post-infection (PMID: 41667472)

9. Inheritance and Population

Epidemiology

Incidence

  • United States:
  • 2014: 120 confirmed cases
  • 2016: 153 confirmed cases
  • 2018: 238 confirmed cases (peak year)
  • 2019: 47 cases
  • 2020: 32 cases (pandemic-related reduction)
  • Overall: Approximately 1 per million children per year in non-peak years; higher in peak years
  • KPNC population-based estimate: 1.46 per 100,000 person-years (children 1-18 years, 2011-2016) (PMID: 30985511)

  • Europe: 130 reported cases across 14 countries (2016-2023), though significant underreporting suspected due to lack of systematic surveillance in most countries (PMID: 40444374)

Prevalence

  • AFM is an acute disease; point prevalence is very low
  • Estimated thousands of patients living with chronic sequelae from past outbreaks

EV-D68 Seroprevalence (Updated Iteration 4)

  • Systematic review of global age-stratified seroprevalence (10 studies, 6 countries): Seroprevalence increases rapidly with age, reaching ~100% by age 20 years with no decline throughout adulthood, suggesting continuous or frequent exposure. Studies with multiple cross-sectional surveys reported consistently higher seroprevalence at later timepoints, indicating global increase in transmission over time. Standardization of serological protocols and understanding cross-reactivity remain key research priorities (PMID: 39332429).
  • Beijing healthy population: seroprevalence 89.4% (2012) to 98.4% (2017); GMT rose from 92.82 to 242.91 (PMID: 32492201)
  • Acute-phase sera from EV-D68 patients had NtAb titers ≤1:64; convalescent sera >1:64, suggesting titer ≤1:64 may indicate susceptibility
  • Most EV-D68 infections are subclinical; AFM occurs in a tiny fraction of infected individuals
  • Population immunity levels fluctuate with exposure cycles, contributing to biennial outbreak pattern

Inheritance Pattern

  • Not applicable for genetic inheritance - AFM is an infectious disease, not a Mendelian disorder
  • No familial clustering has been reported
  • Host susceptibility is likely polygenic/multifactorial

Population Demographics

Affected Populations

  • Age: Predominantly children; median age 4-9 years; >90% cases in children under 16 years (PMID: 39246649)
  • Sex ratio: Male predominance; approximately 56% male (PMID: 33218883); male sex identified as risk factor (PMID: 30985511)
  • Ancestry: Asian ancestry identified as a risk factor in one US population study (PMID: 30985511); further studies needed
  • Atopic individuals: Higher risk with history of asthma/atopic dermatitis

Geographic Distribution

  • Global: Cases reported worldwide including North America, Europe, Asia, Australia, India
  • United States: Nationwide distribution with biennial outbreaks
  • Europe: Cases reported in at least 14 countries (PMID: 40444374)
  • Asia: Cases reported in Turkey, China, India, Japan, and others
  • Australia: Previously unrecognized cluster identified (PMID: 32178602)

Age Distribution

  • Peak incidence: 2-8 years old
  • Occasional cases in adolescents and adults (more common post-pandemic) (PMID: 41138534)
  • Adult cases are atypical and may have different etiologies

10. Diagnostics

Clinical Tests

Laboratory Tests

  • Cerebrospinal fluid (CSF) analysis:
  • Pleocytosis (elevated WBC count) in 50-73% of cases
  • Protein typically normal or mildly elevated (lower than in GBS)
  • Glucose normal
  • EV-D68 rarely detected in CSF by RT-PCR (<2% of cases)
  • LOINC: 26465-7 (WBC count in CSF)

  • Respiratory specimen RT-PCR:

  • Nasopharyngeal swab for rhinovirus/enterovirus testing
  • EV-D68-specific RT-PCR on RV/EV-positive specimens
  • Best sensitivity if collected within first few days of respiratory illness
  • LOINC: 92141-1 (Enterovirus D68 RNA in specimen by NAA)

  • Stool specimen: For enterovirus detection; lower yield for EV-D68 than for other enteroviruses

Biomarkers

  • CSF cytokine profile: The pro-inflammatory cytokines/chemokines IP-10 (CXCL10) and IL-6 were significantly elevated in CSF of confirmed AFM patients compared to non-AFM controls, when measured as CSF-to-serum ratios (PMID: 32836175). These biomarkers may reflect intrathecal inflammation and provide insight into pathogenic mechanisms.
  • CSF pleocytosis and characteristic MRI pattern remain the primary diagnostic markers
  • No validated serum biomarkers specific to AFM currently exist
  • Neurofilament light chain (NfL), a marker of axonal injury used in other neurologic diseases, has not been systematically studied in AFM but represents a promising candidate biomarker

Imaging Studies

  • Spinal cord MRI (T2-weighted):
  • T2 hyperintensity predominantly involving central gray matter
  • Longitudinally extensive lesions possible
  • Cervical cord most commonly affected
  • Gray matter predominance distinguishes from demyelinating lesions
  • 95% sensitivity for confirmed AFM (PMID: 26720027)

  • Brain MRI:

  • May show brainstem lesions (posterior brainstem/dorsal pons/medulla) in some cases (PMID: 38405019)
  • Abnormal brain MRI at onset associated with poor prognosis (PMID: 33218883)

Electrophysiology

  • EMG/Nerve Conduction Studies (NCS):
  • Findings consistent with motor neuronopathy/anterior horn cell disease
  • Decreased compound muscle action potential (CMAP) amplitudes
  • Preserved sensory nerve action potentials (SNAPs)
  • Denervation potentials (fibrillations, positive sharp waves) on needle EMG
  • Confirms severe motor neuron injury (PMID: 41138534)
  • Preoperative EMG/NCS predicts outcomes after nerve transfer (PMID: 37981447)

Genetic Testing

  • Not applicable for diagnosis of AFM, which is an infectious disease
  • No genetic testing panels exist for AFM susceptibility
  • Viral genomic sequencing (VP1 gene) is used for EV-D68 strain typing and epidemiological surveillance

Clinical Criteria

CDC Case Definition (Current Standard)

  • Confirmed AFM: Acute-onset flaccid limb weakness AND MRI showing spinal cord lesion largely restricted to gray matter spanning one or more vertebral segments
  • Probable AFM: Acute-onset flaccid limb weakness AND CSF showing pleocytosis (WBC >5 cells/mm3)
  • Must exclude clear alternative diagnoses

Diagnostic Criteria Evaluation (PMID: 36996587)

A Dutch cohort study evaluating AFM diagnostic criteria in 141 children with acute limb weakness found: - Only 7/9 patients initially classified as "definite AFM" retained this label after expert review - Patients initially classified as probable/possible AFM were most commonly re-diagnosed with transverse myelitis (16/25) - When initial classification was "uncertain," GBS was the most common final diagnosis (31/43) - Highlights the challenge of early AFM diagnosis and the importance of expert neurological evaluation

Differential Diagnosis

Key conditions to distinguish from AFM (PMID: 32143233, PMID: 34747551, PMID: 31338675):

Condition Distinguishing Features
Guillain-Barre syndrome (GBS) Symmetric weakness; longer time to nadir (8 vs 3 days); sensory deficits (40% vs 0%); elevated CSF protein; demyelinating pattern on NCS; no spinal cord MRI lesions
Transverse myelitis White matter > gray matter on MRI; sensory level; autoimmune markers; responds to immunotherapy
Spinal cord stroke Hyperacute onset; vascular risk factors; anterior spinal artery distribution
Poliomyelitis Similar presentation; poliovirus detected; travel/exposure history
MOG-antibody myelitis MOG-IgG positive; longitudinally extensive T2 lesion; responds to immunotherapy; may relapse (PMID: 30575890)
Spinal cord tumor Progressive rather than acute; mass lesion on MRI

Screening

  • No population-based screening programs exist for AFM
  • CDC conducts passive national surveillance
  • Active EV-D68 respiratory surveillance at sentinel sites to anticipate potential AFM outbreaks (PMID: 40431685)

11. Outcome/Prognosis

Survival and Mortality

  • Mortality: Low but non-zero; deaths occur due to respiratory failure from diaphragm/bulbar muscle involvement (PMID: 37465770)
  • Life expectancy: Most patients survive with disability; limited data on long-term life expectancy
  • Disease-specific mortality: Related to respiratory complications, particularly in patients with quadriplegia or brainstem involvement

Morbidity and Function

  • Persistent weakness: 89% (24/27) with persistent weakness in Turkish cohort (PMID: 33218883)
  • Full recovery rate: <10% overall (PMID: 37465770); 41% in KPNC population study at 12 months (PMID: 30985511)
  • Disability outcomes:
  • Limb paralysis requiring assistive devices
  • Diaphragm paralysis requiring ventilatory support or phrenic nerve reconstruction
  • Bowel/bladder dysfunction (36% persistent sphincter dysfunction in some cohorts) (PMID: 41251130)
  • Quality of life: Significant impairment; children may require wheelchair, bracing, or assistive devices. Functional recovery typically plateaus at 6-9 months (PMID: 32951650).
  • Psychosocial impact: 3/8 children reported depressive symptoms at 1-year follow-up in Colorado cohort (PMID: 28615421).

Longitudinal Outcome Data (Iteration 2 Addition)

3-Year Follow-up (Japan, n=33) (PMID: 33388543): - Complete recovery rates by initial severity: tetraplegia/triplegia 2/7 (29%), paraplegia 4/13 (31%), monoplegia 2/13 (15%) - 27% showed continued improvement between 6-month and 3-year timepoints - Barthel index significantly improved at chronic stage (P<0.001; median difference 53, 95% CI: 40-63) - All 6 EV-D68-positive patients had persistent motor deficits - Non-motor neurological findings (cranial nerves, sensory) had better prognosis than motor weakness

1-Year Follow-up (Colorado, n=12) (PMID: 28615421): - 6/8 completing study had persistent motor deficits; 2 fully recovered - Proximal muscles: minimal to no improvement with significant atrophy - Distal muscles: all patients improved - Cranial nerve dysfunction: resolved in 2/5, improved in all - Repeat MRI showed significant improvement or normalization in all but one - Repeat EMG: ongoing denervation and chronic reinnervation in those with persistent deficits - Pain: 2/8 at 1 year; depressive symptoms: 3/8

Long-term Respiratory Outcomes (KPNC, n=37, median 4.7 years follow-up) (PMID: 39657203): - 21.6% had respiratory failure during index hospitalization - Among those with respiratory failure, 75% required follow-up respiratory support - Respiratory failure associated with: higher Modified Rankin Scores (mean diff 1.29, 95% CI: 0.34-2.23), higher respiratory-related ED visits (IRR 1.94, 95% CI: 1.27-2.96) - Overall AFM incidence: 0.6 per 100,000 person-years

Texas Cohort (n=21, ~2 years follow-up) (PMID: 32192819): - 5 fully recovered; 5 able to perform all ADLs independently; 5 mild deficits; 6 substantial caregiver reliance - No treatment differences detected (IVIG, steroids, plasmapheresis all used)

Prognostic Factors

  • Poor prognosis:
  • Quadriplegia (four-limb involvement) (PMID: 33218883)
  • Abnormal brain MRI at onset (PMID: 33218883)
  • Complete paralysis (MRC grade 0) at >6 months with hip adductor involvement (PMID: 38815052)
  • Abundant acute denervation potentials on EMG (PMID: 37981447)

  • Better prognosis:

  • Monoplegia/limited limb involvement
  • EV-D68 confirmed (potentially related to host immune response) (PMID: 41138534)
  • Shorter hospital stay (PMID: 41138534)
  • Younger age at presentation
  • Earlier nerve transfer surgery (<8 months post-onset) (PMID: 38815052)

12. Treatment

Pharmacotherapy

No FDA-approved treatments exist for AFM. Management is primarily supportive with empirical immunomodulatory therapies.

Empirical Immunotherapy

  • Intravenous immunoglobulin (IVIG):
  • Most commonly used treatment; rationale based on potential neutralizing antibody content
  • hIVIG containing EV-D68 neutralizing antibodies reduced paralysis in mouse models (PMID: 28968718)
  • Clinical evidence limited to case series; no randomized controlled trials
  • MAXO: MAXO:0001298 (intravenous immunoglobulin therapy)

  • Corticosteroids:

  • Widely used empirically (42/59 patients in California received IV steroids) (PMID: 26720027)
  • CAUTION: Dexamethasone worsened motor impairment, increased mortality, and increased viral loads in mouse model (PMID: 28968718)
  • MAXO: MAXO:0000609 (corticosteroid therapy)

  • Therapeutic plasma exchange (TPE) / Plasmapheresis:

  • Used as second/third-line therapy
  • In a pediatric cohort (n=23), 74% (17/23) showed significant improvement by end of treatment; median mRS improved from 5 to 4 at end of TPE and to 2 at 6 months (PMID: 41251130)
  • Two deaths reported in this cohort (one from venous air embolism)
  • MAXO: MAXO:0001077 (plasmapheresis)

  • Fluoxetine:

  • Investigated based on in vitro antiviral activity against enteroviruses
  • No effect on motor impairment or viral loads in mouse model (PMID: 28968718)
  • Not recommended based on available evidence

Advanced Therapeutics

Antiviral Drug Candidates (Experimental)

No antivirals are currently approved; several candidates are in development:

  • VP1 capsid inhibitors (Jun11787, Jun11695):
  • Structure-based design; bind hydrophobic canyon in VP1
  • Nanomolar potency against multiple EV-D68 strains in vitro
  • Reduce spinal cord viral titer, prevent paralysis progression in mice even when treatment initiated 4-6 days post-infection (PMID: 41667472)

  • 2C helicase inhibitors (Jun6504):

  • Broad-spectrum activity against EV-D68, EV-A71, CVB3
  • Significantly improves paralysis score in neonatal mouse model (PMID: 40593720)

  • Orally available peptidomimetic 2C inhibitor (2CA-1):

  • Excellent oral bioavailability; broad enterovirus activity (PMID: 41485562)

  • Fluoxetine analogues (compound 53):

  • Optimized from (S)-fluoxetine targeting 2C ATPase; improved potency (PMID: 41621223)

  • VP1 protein degraders (PROTACs):

  • Targeted protein degradation strategy to overcome capsid inhibitor resistance (PMID: 42063851)

  • Matrine (natural product):

  • Alkaloid with broad-spectrum antiviral activity via autophagy activation (PMID: 41205525)

  • Geranyl-p-trans-coumaric acid (GCA):

  • Natural product EV-D68 inhibitor (PMID: 41175053)

  • RNA-encoded VHH antibodies:

  • repRNA-encoded nanobodies protected mice from EV-D68 challenge (PMID: 41964219)

Vaccine Candidates (Experimental)

No vaccines are approved; multiple platforms in development:

  • mRNA VLP vaccine:
  • mRNA expressing EV-D68 virus-like particles elicited potent neutralizing antibodies superior to inactivated whole virion vaccine; protective in mice; also attenuated CVB3 infection (PMID: 41210583)

  • Self-amplifying RNA (saRNA) vaccine:

  • Clinical-stage RNA vaccine platform induced robust EV-D68-neutralizing antibody responses in both mice and nonhuman primates; prevented upper and lower respiratory tract infections and neurological disease in mice. Characterized antigenic diversity across six EV-D68 genotypes to inform multivalent vaccine composition for optimal breadth of neutralizing responses. Represents proof-of-concept for RNA vaccines against nonenveloped viruses (PMID: 39110777).

  • Inactivated whole virion vaccine:

  • Formalin-inactivated EV-D68 from serum-free HEK293A suspension culture; induced neutralizing responses including against recent circulating strains (PMID: 42086005)

  • Multi-epitope vaccine (in silico):

  • Immunoinformatic design targeting VP proteins with T-cell and B-cell epitopes (PMID: 41483695)

Surgical and Interventional

Nerve Transfer Surgery

  • MAXO: MAXO:0000014 (surgical procedure)
  • Primary surgical intervention for AFM patients with persistent severe weakness
  • Redirects functioning donor nerves to denervated recipient muscles
  • Among muscles with preoperative MRC grade 0, nerve transfers achieved MRC grade 2.17 vs 0 for untreated muscles (P=0.0001) (PMID: 37981447)
  • Best outcomes when surgery performed within 8 months of paralysis onset (PMID: 38815052)
  • Upper extremity transfers:
  • Spinal accessory nerve to suprascapular nerve (most common)
  • Radial nerve to axillary nerve (best functional returns, mean AMS 6.5) (PMID: 32951650)
  • Intercostal nerves to axillary nerve
  • Lower extremity transfers:
  • Contralateral obturator nerve to femoral nerve (CONFNT) for knee extension; 2/5 patients achieved MRC grade 4 when performed ≤8 months (PMID: 38815052)

Phrenic Nerve Reconstruction

  • For diaphragm paralysis; 100% of patients with unilateral paralysis showed improvement (PMID: 39933731)
  • Improvement documented by fluoroscopic sniff testing, pulmonary function tests, and electrodiagnostic evaluation

Supportive and Rehabilitative

  • Intensive care support: Mechanical ventilation for respiratory failure (30% require intubation)
  • Physical therapy: Crucial for maintaining range of motion and maximizing recovery
  • Occupational therapy: Adaptive equipment, functional training
  • Orthotic management: Braces, splints for affected limbs
  • Respiratory rehabilitation: For those with diaphragm involvement
  • MAXO: MAXO:0000502 (physical therapy), MAXO:0001001 (respiratory support)

Comprehensive Surgical Reconstruction (Iteration 3 Addition)

Upper extremity reconstruction (PMID: 38774108): - Study of 39 patients, 50 upper extremities (2011-2019) - Patients with complete paralysis of shoulder abduction at 6 months showed no later spontaneous recovery - 22 patients (24 extremities) underwent shoulder surgery: nerve transfer, muscle-tendon transfer, or free muscle transfer - Both spinal accessory nerve transfer and contralateral C7 nerve root transfer to suprascapular nerve gave similar shoulder abduction recovery - MAXO: MAXO:0000014 (surgical procedure)

Rehabilitation following nerve transfer (PMID: 33016189): - Interdisciplinary team approach: OT, PT, surgical team, family - Pre-operative and six phases of post-operative therapy recommended - Addresses: assessment, strengthening, range of motion, orthoses, functional activities, family support - Communication between team members identified as vital - MAXO: MAXO:0000502 (physical therapy), MAXO:0001351 (occupational therapy)

Functional outcomes (WeeFIM) (PMID: 32677590): - Inpatient rehabilitation with neuropsychological evaluation - Admission and discharge WeeFIM scores showed deficits most pronounced in self-care and mobility domains - Multiple nerve transfer surgery performed on 13 limbs in 6 children; AMS improvement in 4 of 6

Treatment Outcomes

  • No treatments have demonstrated efficacy in randomized controlled trials
  • Recovery is incomplete in most patients regardless of medical treatment
  • Nerve transfer surgery provides the most objective evidence of functional benefit for persistent weakness
  • Comprehensive surgical reconstruction (nerve + tendon + free muscle transfer) represents the evolving standard for persistent severe weakness

13. Prevention

Primary Prevention

Immunization

  • No approved vaccine exists for EV-D68 or AFM prevention
  • Multiple vaccine candidates in preclinical development (see Treatment section)
  • Annual influenza vaccination is important to distinguish influenza-associated neurologic disease from AFM

Non-Pharmaceutical Interventions

  • Hand hygiene, respiratory hygiene, and avoidance of sick contacts during enterovirus season
  • COVID-19 pandemic NPIs demonstrated effective disruption of EV-D68 transmission (PMID: 34735423)

Secondary Prevention (Early Detection)

  • Clinician awareness: Emergency department is the most common site of first medical encounter for AFM cases (PMID: 37465770)
  • Suspect AFM in any child with acute flaccid limb weakness, especially with preceding respiratory/febrile illness
  • Rapid MRI of the spine to confirm gray matter involvement
  • Early respiratory specimen collection for EV-D68 testing before viral shedding decreases

Tertiary Prevention

  • Early rehabilitation to maximize functional recovery
  • Timely surgical evaluation for nerve transfer candidacy (optimal window <8 months)
  • Respiratory monitoring for patients with proximal weakness or brainstem involvement

Public Health

  • CDC national AFM surveillance (since 2014): Passive reporting system
  • EV-D68 sentinel surveillance: Active monitoring at pediatric sites to detect circulation increases and anticipate AFM outbreaks (PMID: 40431685)
  • European ENPEN network: Multinational enterovirus surveillance; identified need for improved AFM-specific surveillance (PMID: 40444374)
  • Environmental/wastewater surveillance: Longitudinal US wastewater study (43,876 samples, 147 treatment plants, 40 states, July 2023-July 2025) confirmed biennial EV-D68 pattern with national peak in September 2024 and extended 20-month detection period in California. Seasonal peaks occurred 28-31 days earlier in regions with 5°C higher temperatures/dew points. Season duration was longer by 7-11 weeks in dense, urban catchments with more childcare facilities, crowded households, and hospitals. Wastewater concentrations correlated positively with clinical enterovirus diagnoses (Spearman ρ = 0.34, p = 0.01) (PMID: 41853773, PMID: 41410465)

Genetic Counseling

  • Not applicable; AFM is not a hereditary condition
  • Families should be counseled that AFM is an infectious complication, not genetic

14. Other Species / Natural Disease

Taxonomy

  • EV-D68 is primarily a human pathogen
  • Natural hosts: Humans (NCBI TaxID: 9606) are the only known natural hosts for EV-D68
  • No natural animal reservoirs or zoonotic transmission identified

Comparative Biology

  • Poliovirus (closely related enterovirus) also causes anterior horn cell disease; insights from polio eradication efforts inform AFM research
  • EV-D68 does not naturally infect other animal species, necessitating adapted mouse models for research

Transmission

  • Human-to-human transmission via respiratory droplets
  • Possible fecal-oral transmission (EV-D68 detected in stool and wastewater) (PMID: 34196272, PMID: 41410465)
  • No zoonotic potential identified
  • No cross-species susceptibility in natural settings

15. Model Organisms

Mouse Models

Neonatal Mouse Models (Primary Research Platform)

  • Model type: Mammalian; neonatal mice (7-10 days old)
  • Species/strains: Swiss Webster (SW), BALB/c, ICR, type I IFN receptor knockout (IFNAR-/-)
  • Inoculation routes: Intramuscular (most efficient), intracerebral, intraperitoneal, intranasal (PMID: 28231269)

Key models: 1. Neonatal Swiss Webster IM model (PMID: 28231269): - US/MO/14-18947 and US/IL/14-18952 strains cause progressive paralysis - Viral infection and loss of motor neurons in anterior horns - Fulfills Koch's postulates - Used for therapeutic evaluation

  1. Neonatal BALB/c IP model (PMID: 30503887):
  2. Induces both interstitial pneumonia AND acute flaccid myelitis
  3. Recapitulates both respiratory and neurologic disease

  4. Mouse-adapted EV-D68 IM model (PMID: 41305500):

  5. Mouse-adapted strain for consistent disease induction
  6. RNA-seq and flow cytometry characterization of pathogenesis
  7. Spinal cord and skeletal muscle as highest titer tissues

  8. Neonatal IFNAR-/- IP model (PMID: 32784424):

  9. Type I IFN receptor knockout mice are highly susceptible
  10. Used for mapping attenuation determinants

Phenotype Recapitulation

  • Well recapitulated:
  • Progressive limb paralysis
  • Viral replication in spinal cord motor neurons
  • Motor neuron loss in anterior horns
  • Muscle tropism with high viral titers
  • Histopathologic changes (neuronal necrosis, inflammation)

  • Limitations:

  • Only neonatal mice susceptible (adult mice resistant); does not fully model pediatric-specific susceptibility
  • Immune system maturity differences between neonatal mice and human children
  • Some routes of inoculation (IM) bypass natural respiratory entry
  • Species-specific receptor differences may affect viral tropism

Human Organoid Models

Spinal Cord Organoids (PMID: 37535397, PMID: 42037414)

  • Model type: In vitro; iPSC-derived human spinal cord organoids (hSCOs)
  • Two models: (1) primarily spinal motor neurons; (2) multiple neuronal lineages including motor neurons, interneurons, and glial cells
  • Infected productively by contemporary EV-D68 B3 clade strains
  • Viral antigen colocalizes with neurons
  • Produce extracellular virus for 2+ weeks without appreciable cytopathic effect
  • Advantage: Human-specific receptor expression; models cellular heterogeneity of spinal cord
  • Limitation: Lacks immune cells; cannot model immune-mediated damage

Applications

  • Drug evaluation: Mouse models used to test capsid inhibitors, 2C inhibitors, hIVIG, fluoxetine, dexamethasone (PMID: 28968718, PMID: 41667472, PMID: 40593720)
  • Vaccine evaluation: Maternal immunization and passive transfer studies (PMID: 29385753, PMID: 41210583)
  • Neurovirulence determinant mapping: Chimeric virus studies to identify VP1/VP3 mutations (PMID: 38869283, PMID: 32784424)
  • Pathogenesis studies: RNA-seq, flow cytometry, histopathology (PMID: 41305500)

Model Resources

  • Infectious cDNA clones for B3 clade EV-D68 strains available for reverse genetics studies (PMID: 42037414)
  • BEI Resources repository for reference EV-D68 strains
  • iPSC lines for spinal cord organoid generation

Summary

Acute flaccid myelitis (AFM) is a rare, devastating neurologic condition primarily affecting children, characterized by acute-onset flaccid paralysis with spinal cord gray matter involvement on MRI. The disease is strongly associated with Enterovirus D68 (EV-D68) infection, with biennial outbreak patterns observed in the United States from 2014-2018 (disrupted by COVID-19 pandemic NPIs and confirmed through wastewater surveillance showing September peak seasonality).

Viral entry and neurotropism: EV-D68 neurotropism is mediated through multiple receptor interactions (sialic acid, ICAM-5, MFSD6), with the VP1 capsid protein as the primary determinant of neurovirulence. The virus hijacks STING for formation of specialized lipid replication organelles and exploits host immunometabolism.

Immune evasion and host defense: The virus employs multi-layered immune evasion: VP3-MAVS disruption, 3C-STAT1 cleavage (shared with poliovirus), USP5 deubiquitinase exploitation, and 3C-mediated RIG-I/TRIM25 degradation to suppress type I IFN signaling. Host defense mechanisms include the novel Piezo1-mediated mechano-antiviral response system (MARS) that restricts viral entry through membrane remodeling, and the ARRDC3-YAP pathway. CSF biomarkers IP-10 and IL-6 are elevated in AFM, reflecting intrathecal neuroinflammation.

Pathogenesis: Both direct viral cytopathology of anterior horn motor neurons and immune-mediated secondary injury (mitochondrial dysfunction via MFN2 cleavage, oxidative stress, CD8+ T cell infiltration) contribute to motor neuron destruction.

Critical unresolved question: EV-D68 respiratory outbreaks in 2022 and 2024 were NOT accompanied by AFM surges despite the prior biennial correlation (2014-2018). Global seroprevalence data show ~100% seropositivity by age 20, suggesting near-universal exposure. Possible explanations for the AFM-EV-D68 dissociation include viral genomic evolution (novel B3-derived lineages, A2/D reemergence), altered population immunity post-pandemic, and mutations in key neurovirulence determinants.

Management and outcomes: No approved treatments or vaccines exist; management relies on supportive care, empirical immunotherapy (IVIG, plasmapheresis), and comprehensive surgical reconstruction (nerve, tendon, and free muscle transfers) for persistent weakness. Long-term follow-up shows functional independence improves over years (Barthel index P<0.001), but motor deficits persist in the majority, with respiratory failure at presentation predicting worse outcomes. The prognosis remains poor, with <10% achieving full recovery. Active development of VP1 capsid inhibitors, 2C helicase inhibitors, Piezo1 agonists, self-amplifying RNA vaccines, and mRNA VLP vaccines offers hope for future therapeutic and preventive options.


Limitations and Future Directions

Limitations of Current Knowledge

  1. Diagnostic challenge: EV-D68 is detected in CSF in <2% of confirmed AFM cases; the low detection rate has complicated efforts to definitively establish causation in individual patients. Evaluation of diagnostic criteria shows significant misclassification between AFM, transverse myelitis, and GBS at initial presentation (PMID: 36996587).
  2. No randomized controlled trials: All treatment evidence is from case series, retrospective cohorts, or animal models. No RCT data exist for any AFM intervention.
  3. Host susceptibility unknown: No GWAS or HLA association studies have been performed for AFM susceptibility. Why only a tiny fraction of EV-D68-infected children develop AFM remains unexplained.
  4. Limited neuropathology: Human autopsy/biopsy data from AFM spinal cords are extremely rare, limiting direct understanding of human neuropathology.
  5. Model limitations: Neonatal mouse models require immature animals; adult mice are resistant. Human spinal cord organoids lack immune cells. Neither model fully recapitulates pediatric AFM.

Key Unresolved Questions

  1. Why did 2022/2024 EV-D68 outbreaks NOT cause AFM surges? Is this due to viral evolution, population immunity shifts, or surveillance gaps?
  2. What determines individual susceptibility? Among millions of children exposed to EV-D68, why do only ~100-200 develop AFM per biennial cycle?
  3. What is the optimal treatment window? Can early antiviral therapy (within hours of weakness onset) prevent motor neuron loss?
  4. Will AFM outbreaks return? The biennial pattern was disrupted; will future EV-D68 strains re-acquire neurovirulence?

Promising Future Directions

  1. Antiviral drug development: VP1 capsid inhibitors and 2C helicase inhibitors show strong preclinical efficacy; clinical trials needed
  2. Vaccine development: Self-amplifying RNA and mRNA VLP platforms have shown efficacy in mice and nonhuman primates; multivalent formulations addressing antigenic diversity across clades are being designed (PMID: 39110777)
  3. Biomarker discovery: CSF IP-10/IL-6 (PMID: 32836175) and neurofilament light chain need validation in larger cohorts
  4. Host genetics studies: GWAS and HLA typing of AFM cohorts could identify susceptibility factors
  5. Piezo1 agonist therapy: MARS pathway modulation as a novel non-immunological antiviral strategy (PMID: 41650963)
  6. Wastewater surveillance: Integration of EV-D68 wastewater monitoring with clinical surveillance for early outbreak detection (PMID: 41853773)

Key Evidence Citations

PMID Key Contribution
32143233 Comprehensive clinical review of AFM
38300829 CDC surveillance 2018-2022
40444374 European AFM epidemiology
28231269 Mouse model fulfilling Koch's postulates
38869283 VP1 as neurovirulence determinant
41467840 Receptor biology (ICAM-5, MFSD6)
42018625 Mitofusin 2 cleavage mechanism
41305500 Spinal cord RNA-seq pathogenesis
37535397 Human spinal cord organoid model
28968718 Preclinical therapeutic evaluation
34747551 AFM vs GBS differentiation
30985511 Population-based incidence and risk factors
41667472 VP1 capsid inhibitor development
41210583 mRNA VLP vaccine
37981447 Nerve transfer surgery outcomes
41251130 Plasmapheresis in pediatric AFM
34735423 CDC surveillance 2018-2020
41868141 EV-D68 virology and therapeutic review
41600837 EV-D68 genomic virulence determinants
30985511 Risk factors: male sex, asthma, Asian ancestry
33388543 3-year longitudinal motor outcomes (Japan)
28615421 1-year outcomes including psychosocial impact (Colorado)
39657203 Long-term respiratory outcomes (4.7-year follow-up)
32192819 Texas cohort treatment and functional outcomes
40042308 VP3-MAVS immune evasion mechanism
38240591 3C protease cleaves STAT1 for IFN evasion
41352537 USP5 deubiquitinase in enterovirus immune evasion
32492201 EV-D68 seroprevalence in Beijing
32836175 CSF cytokine biomarkers (IP-10, IL-6) in AFM
41650963 Piezo1/MARS mechano-antiviral defense
39459875 STING hijacking for replication organelles
40701343 ARRDC3-YAP antiviral pathway
34170466 TRIM25 restoration of RIG-I against EV-D68
39332429 Global age-stratified EV-D68 seroprevalence review
41853773 US wastewater EV-D68 longitudinal surveillance
36996587 Evaluation of AFM diagnostic criteria (Netherlands)
39110777 Self-amplifying RNA vaccine (mouse + NHP)

Appendix: Validated Ontology Terms for Knowledge Base Population

Disease Ontology

Ontology ID Label
MONDO MONDO:0100115 acute flaccid myelitis
MONDO MONDO:0005747 enterovirus infectious disease
ICD-10 G04.82 Acute flaccid myelitis
MeSH D000080524 Myelitis, Acute Flaccid

Phenotype (HPO) Terms

HPO ID Label Frequency in AFM
HP:0012486 Myelitis 100% (defining)
HP:0003690 Limb muscle weakness 100% (defining)
HP:0002398 Degeneration of anterior horn cells ~100% (pathological basis)
HP:0006802 Abnormal anterior horn cell morphology ~100%
HP:0001252 Hypotonia ~100%
HP:0001284 Areflexia ~90% (affected limbs)
HP:0012229 CSF pleocytosis 50-73%
HP:0002878 Respiratory failure ~21-30%
HP:0006824 Cranial nerve paralysis ~20-30%
HP:0000016 Urinary retention Variable
HP:0003326 Myalgia ~70% (prodromal/concurrent)
HP:0003202 Skeletal muscle atrophy Common (chronic phase)
HP:0002015 Dysphagia Variable (bulbar involvement)

Anatomical (UBERON) Terms

UBERON ID Label
UBERON:0002257 ventral horn of spinal cord
UBERON:0014621 cervical spinal cord ventral horn
UBERON:0002315 gray matter of spinal cord
UBERON:0002726 cervical spinal cord
UBERON:0001884 phrenic nerve
UBERON:0002240 spinal cord
UBERON:0001134 skeletal muscle tissue

Cell Type (CL) Terms

CL ID Label
CL:0011001 spinal cord motor neuron
CL:0000100 motor neuron
CL:0002368 respiratory tract epithelial cell

Gene Ontology (GO) Biological Process Terms

GO ID Label
GO:0046718 symbiont entry into host cell
GO:0045087 innate immune response
GO:0060337 type I interferon-mediated signaling pathway
GO:0060339 negative regulation of type I interferon-mediated signaling pathway
GO:0000266 mitochondrial fission
GO:0006914 autophagy
GO:0000422 autophagy of mitochondrion
GO:0006915 apoptotic process
GO:0006954 inflammatory response
GO:0006979 response to oxidative stress
GO:0071260 cellular response to mechanical stimulus
GO:0019058 viral life cycle

Chemical Entity (CHEBI) Terms

CHEBI ID Label Role in AFM
CHEBI:26667 sialic acid EV-D68 attachment factor
CHEBI:5118 fluoxetine Investigated antiviral (no efficacy in mouse model)
CHEBI:41879 dexamethasone Corticosteroid (worsened outcomes in mouse model)
CHEBI:24579 immunoglobulin G IVIG therapy (empirical treatment)

Treatment (MAXO) Terms

MAXO ID Label
MAXO:0001298 intravenous immunoglobulin therapy
MAXO:0000609 corticosteroid therapy
MAXO:0001077 plasmapheresis
MAXO:0000014 surgical procedure (nerve transfer)
MAXO:0000502 physical therapy
MAXO:0001001 respiratory support

Host Gene Annotations

Gene Symbol HGNC ID Role in AFM
ICAM5 HGNC:5348 Neuron-specific EV-D68 receptor
MFSD6 HGNC:24711 Essential EV-D68 entry receptor
MFN2 HGNC:16877 Cleaved by 3C protease; mitochondrial fission
MAVS HGNC:29233 Targeted by VP3 for immune evasion
STAT1 HGNC:11362 Cleaved by 3C protease; IFN signaling
TRAF3 HGNC:12033 Cleaved by 2A protease; NF-kB pathway
USP5 HGNC:12628 Exploited by EV-D68 to suppress IFN
IRF3 HGNC:6118 De-ubiquitinated via USP5; IFN induction
IRF7 HGNC:6122 Targeted by VP3 for IFN suppression
PIEZO1 HGNC:13680 Mechano-antiviral response (MARS); membrane remodeling
STING1 (TMEM173) HGNC:27962 Hijacked for replication organelle formation
ARRDC3 HGNC:28633 Host antiviral factor; degrades YAP via lysosome
TRIM25 HGNC:10544 E3 ubiquitin ligase; restores RIG-I expression
YAP1 HGNC:16262 Facilitates enterovirus replication; suppresses IFN